The	O
anesthetic	O
and	O
intoxicating	O
effects	O
of	O
ether	other-medical
have	O
made	O
it	O
a	O
recreational	O
drug	O
.	O

The	O
binding	O
affinity	O
(	O
K	O
)	O
and	O
inhibitory	O
potency	O
(	O
i.e.	O
,	O
the	O
half	O
maximal	O
inhibitory	O
concentration	O
or	O
IC	O
)	O
of	O
bupropion	other-medical
at	O
the	O
human	O
dopamine	O
transporter	O
are	O
526	O
nanomolar	O
(	O
nM	O
)	O
and	O
443	O
nM	O
,	O
respectively	O
.	O

Diphtheria	other-medical
toxin	other-medical
is	O
a	O
single	O
polypeptide	O
chain	O
of	O
535	O
amino	O
acids	O
consisting	O
of	O
two	O
subunits	O
linked	O
by	O
disulfide	O
bridges	O
,	O
known	O
as	O
an	O
A-B	O
toxin	O
.	O

Hemorrhage	other-medical
is	O
rare	O
,	O
but	O
the	O
most	O
likely	O
cause	O
of	O
fatality	O
after	O
a	O
tracheostomy	other-medical
.	O

Diabetic	O
ketoacidosis	O
may	O
be	O
diagnosed	O
when	O
the	O
combination	O
of	O
hyperglycemia	other-medical
(	O
high	other-medical
blood	other-medical
sugars	other-medical
)	O
,	O
ketones	O
in	O
the	O
blood	O
or	O
on	O
urinalysis	O
and	O
acidosis	other-medical
are	O
demonstrated	O
.	O

Heparin	other-medical
should	O
be	O
avoided	O
because	O
it	O
can	O
lead	O
to	O
hemorrhage	O
into	O
the	O
pericardial	O
sac	O
,	O
leading	O
to	O
tamponade	O
.	O

Data	O
has	O
also	O
shown	O
that	O
the	O
heroin	other-medical
shortage	O
of	O
2001	O
has	O
also	O
changed	O
who	O
in	O
Australia	O
is	O
using	O
heroin	other-medical
,	O
with	O
a	O
decline	O
in	O
younger	O
first-time	O
heroin	other-medical
users	O
injecting	O
the	O
drug	O
,	O
which	O
is	O
consistent	O
with	O
studies	O
that	O
show	O
that	O
the	O
use	O
of	O
heroin	other-medical
amongst	O
the	O
general	O
population	O
is	O
low	O
and	O
has	O
plateaued	O
since	O
2001	O
.	O

Miglustat	other-medical
is	O
indicated	O
to	O
treat	O
adults	O
with	O
mild	O
to	O
moderate	O
type	O
I	O
Gaucher	O
disease	O
for	O
whom	O
enzyme	O
replacement	O
therapy	O
is	O
unsuitable	O
.	O

If	O
symptoms	O
are	O
detected	O
early	O
enough	O
and	O
the	O
patient	O
is	O
injected	O
with	O
this	O
compound	O
,	O
levels	O
of	O
severe	O
mental	O
retardation	O
can	O
be	O
slightly	O
lessened	O
,	O
but	O
brain	other-medical
damage	other-medical
is	O
irreversible	O
.	O

Israel	O
has	O
the	O
highest	O
rate	O
of	O
IVF	other-medical
in	O
the	O
world	O
,	O
with	O
1657	O
procedures	O
performed	O
per	O
million	O
people	O
per	O
year	O
.	O

Sometimes	O
prednisone	other-medical
will	O
be	O
prescribed	O
to	O
prevent	O
a	O
possible	O
late	O
phase	O
Type	O
I	O
hypersensitivity	O
reaction	O
.	O

The	O
most	O
common	O
adverse	O
effects	O
include	O
:	O
hepatotoxicity	O
(	O
liver	O
damage	O
)	O
,	O
ulcerative	O
stomatitis	O
,	O
leukopenia	O
and	O
thus	O
predisposition	O
to	O
infection	other-medical
,	O
nausea	other-medical
,	O
abdominal	other-medical
pain	other-medical
,	O
fatigue	other-medical
,	O
fever	other-medical
,	O
dizziness	other-medical
,	O
acute	O
pneumonitis	O
,	O
rarely	O
pulmonary	O
fibrosis	O
,	O
and	O
kidney	other-medical
failure	other-medical
.	O

Hyoscine	other-medical
butylbromide	other-medical
,	O
also	O
known	O
as	O
scopolamine	other-medical
butylbromide	other-medical
and	O
sold	O
under	O
the	O
brandname	O
Buscopan	O
among	O
others	O
,	O
is	O
an	O
anticholinergic	O
medication	O
used	O
to	O
treat	O
crampy	O
abdominal	O
pain	O
,	O
esophageal	O
spasms	O
,	O
renal	O
colic	O
,	O
and	O
bladder	O
spasms	O
.	O

The	O
Knee	O
Surgery	O
,	O
Sports	O
Traumatology	O
,	O
Arthroscopy	O
is	O
a	O
monthly	O
peer-reviewed	O
medical	O
journal	O
published	O
in	O
English	O
covering	O
orthopaedic	O
surgery	O
,	O
especially	O
related	O
to	O
sports	O
trauma	O
and	O
surgeries	O
,	O
in	O
particular	O
arthroscopies	other-medical
.	O

If	O
the	O
person	O
presents	O
symptoms	O
of	O
hyperthyroidism	other-medical
,	O
doctors	O
are	O
more	O
likely	O
to	O
test	O
for	O
Thyroid	O
stimulating	O
hormone	O
receptor	O
Antibodies	O
(	O
TRAb	O
)	O
,	O
and	O
monitor	O
the	O
effects	O
of	O
anti-thyroid	other-medical
therapy	O
,	O
also	O
associated	O
with	O
Graves	O
'	O
disease	O
.	O

Three	O
years	O
later	O
Merck	O
pulled	O
Vioxx	other-medical
from	O
the	O
market	O
when	O
additional	O
studies	O
confirmed	O
that	O
daily	O
,	O
long-term	O
use	O
of	O
the	O
drug	O
could	O
increase	O
the	O
risk	O
of	O
heart	O
attacks	O
and	O
strokes	O
.	O

Because	O
of	O
the	O
limited	O
amount	O
of	O
acetylcholine	O
receptors	O
that	O
are	O
available	O
for	O
binding	O
,	O
symptomatic	O
treatment	O
consists	O
of	O
using	O
an	O
acetylcholinesterase	other-medical
inhibitor	other-medical
to	O
reduce	O
the	O
breakdown	O
of	O
acetylcholine	O
in	O
the	O
neuromuscular	O
junction	O
,	O
so	O
that	O
enough	O
acetylcholine	O
will	O
be	O
present	O
for	O
the	O
small	O
number	O
of	O
unblocked	O
receptors	O
.	O

Chronic	O
use	O
of	O
benzodiazepines	other-medical
can	O
lead	O
to	O
the	O
development	O
of	O
tolerance	O
with	O
a	O
decrease	O
of	O
benzodiazepine	other-medical
binding	O
sites	O
.	O

Liraglutide	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Victoza	O
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
diabetes	O
mellitus	O
type	O
2	O
and	O
obesity	O
.	O

In	O
the	O
UK	O
,	O
Gardasil	other-medical
replaced	O
Cervarix	other-medical
in	O
September	O
2012	O
for	O
reasons	O
unrelated	O
to	O
safety	O
.	O

Metronidazole	other-medical
is	O
less	O
effective	O
,	O
but	O
is	O
available	O
in	O
a	O
gel	O
and	O
can	O
be	O
applied	O
twice	O
daily	O
.	O

Amesergide	other-medical
(	O
,	O
;	O
developmental	O
code	O
name	O
LY-237733	O
)	O
is	O
a	O
serotonin	O
receptor	O
antagonist	O
of	O
the	O
ergoline	O
and	O
lysergamide	O
families	O
related	O
to	O
methysergide	O
which	O
was	O
under	O
development	O
by	O
Eli	O
Lilly	O
and	O
Company	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
including	O
depression	O
,	O
anxiety	O
,	O
schizophrenia	O
,	O
male	O
sexual	O
dysfunction	O
,	O
migraine	O
,	O
and	O
thrombosis	O
but	O
was	O
never	O
marketed	O
.	O

Since	O
serotonin	other-medical
deficiency	other-medical
has	O
been	O
recognized	O
as	O
a	O
possible	O
cause	O
of	O
depression	O
,	O
it	O
has	O
been	O
suggested	O
that	O
consumption	O
of	O
tryptophan	O
or	O
5-HTP	O
may	O
therefore	O
improve	O
depression	O
symptoms	O
by	O
increasing	O
the	O
level	O
of	O
serotonin	O
in	O
the	O
brain	O
.	O

Ro15-4513	other-medical
was	O
somewhat	O
less	O
effective	O
than	O
flumazenil	other-medical
at	O
blocking	O
the	O
effects	O
of	O
benzodiazepines	other-medical
,	O
but	O
instead	O
selectively	O
blocked	O
the	O
effects	O
of	O
ethanol	O
.	O

Propranolol	other-medical
is	O
a	O
blocker	O
for	O
the	O
beta-adrenergic	O
receptors	O
in	O
the	O
amygdala	O
which	O
usually	O
are	O
bound	O
to	O
by	O
stress	O
hormones	O
released	O
by	O
the	O
adrenal	O
gland-	O
epinephrine	O
and	O
norepinephrine	O
.	O

Chemotherapy	other-medical
is	O
the	O
initial	O
treatment	O
of	O
choice	O
,	O
and	O
most	O
people	O
with	O
ALL	O
receive	O
a	O
combination	O
of	O
medications	O
.	O

Between	O
1930	O
and	O
1960	O
synthetic	O
analeptics	O
such	O
as	O
nikethamide	other-medical
,	O
pentylenetetrazol	other-medical
,	O
bemegride	other-medical
,	O
amphetamine	other-medical
,	O
and	O
methylphenidate	other-medical
replaced	O
the	O
naturally	O
occurring	O
compounds	O
in	O
treating	O
barbiturate	other-medical
overdose	O
.	O

Strontium	other-medical
ranelate	other-medical
also	O
stimulates	O
osteoblasts	O
to	O
secrete	O
osteoprotegerin	O
in	O
inhibiting	O
osteoclasts	O
formed	O
from	O
pre-osteoclasts	O
in	O
relation	O
to	O
the	O
RANKL	O
system	O
,	O
which	O
leads	O
to	O
the	O
decrease	O
of	O
bone	O
resorption	O
.	O

Disseminated	O
intravascular	other-medical
coagulation	other-medical
occurs	O
as	O
the	O
toxin	O
interacts	O
with	O
the	O
victim	O
's	O
body	O
.	O

According	O
to	O
the	O
American	O
Cancer	O
Society	O
and	O
the	O
Memorial	O
Sloan-Kettering	O
Cancer	O
Center	O
,	O
there	O
is	O
no	O
evidence	O
that	O
Ukrain	other-medical
is	O
an	O
effective	O
cancer	O
treatment	O
.	O

with	O
a	O
Marfanoid	other-medical
Habitus	other-medical
.	O

San	O
Antonio	O
's	O
South	O
Texas	O
Medical	O
Center	O
facilities	O
rank	O
sixth	O
in	O
clinical	other-medical
medicine	other-medical
research	other-medical
impact	O
in	O
the	O
United	O
States	O
.	O

Cauterization	other-medical
methods	O
include	O
burning	O
the	O
affected	O
area	O
with	O
acid	O
,	O
hot	O
metal	O
,	O
or	O
lasers	O
.	O

Fanapanel	other-medical
(	O
INN	other-medical
,	O
code	O
name	O
ZK-200775	O
)	O
,	O
also	O
known	O
as	O
MPQX	other-medical
,	O
is	O
a	O
quinoxalinedione	O
derivative	O
drug	O
which	O
acts	O
as	O
a	O
competitive	O
antagonist	O
of	O
the	O
AMPA	O
receptor	O
.	O

First-generation	O
antihistamines	other-medical
include	O
diphenhydramine	other-medical
(	O
Benadryl	other-medical
)	O
,	O
carbinoxamine	other-medical
(	O
Clistin	other-medical
)	O
,	O
clemastine	other-medical
(	O
Tavist	other-medical
)	O
,	O
chlorpheniramine	other-medical
(	O
Chlor-Trimeton	other-medical
)	O
,	O
and	O

In	O
the	O
Nigro	O
protocol	O
,	O
the	O
patient	O
receives	O
30	O
Gy	O
(	O
3000	O
rads	O
)	O
of	O
radiation	O
over	O
a	O
three-week	O
period	O
,	O
as	O
well	O
as	O
continuous	O
administration	O
of	O
fluorouracil	other-medical
for	O
the	O
first	O
four	O
days	O
and	O
on	O
days	O
20–31	O
,	O
with	O
bolus	other-medical
mitomycin	other-medical
on	O
day	O
1	O
.	O

A	O
major	O
use	O
of	O
systemic	O
radioisotope	other-medical
therapy	other-medical
is	O
in	O
the	O
treatment	O
of	O
bone	O
metastasis	O
from	O
cancer	O
.	O

Pentobarbital	other-medical
-induced	O
coma	O
has	O
been	O
advocated	O
in	O
patients	O
with	O
acute	O
liver	O
failure	O
refractory	O
to	O
mannitol	other-medical
.	O

The	O
MHA-TP	other-medical
test	O
is	O
rarely	O
used	O
any	O
more	O
.	O

In	O
arm	O
fractures	O
in	O
children	O
,	O
ibuprofen	other-medical
has	O
been	O
found	O
to	O
be	O
as	O
effective	O
as	O
a	O
combination	O
of	O
paracetamol	other-medical
and	O
codeine	other-medical
.	O

Henry	O
Wellcome	O
's	O
interest	O
was	O
the	O
history	O
of	O
medicine	O
in	O
a	O
broad	O
sense	O
and	O
included	O
subjects	O
such	O
as	O
alchemy	O
or	O
witchcraft	O
,	O
but	O
also	O
anthropology	other-medical
and	O
ethnography	other-medical
.	O

A	O
possible	O
response	O
to	O
this	O
drawback	O
is	O
a	O
venous	other-medical
fat	other-medical
hemorrhage	other-medical
,	O
in	O
which	O
small	O
and	O
medium-chain	O
fatty	O
acids	O
are	O
given	O
by	O
diet	O
,	O
and	O
long-chain	O
fatty	O
acids	O
are	O
given	O
intravenously	O
.	O

The	O
(	O
+	O
)	O
-isomer	O
is	O
predominantly	O
active	O
as	O
an	O
opiate	other-medical
with	O
a	O
higher	O
affinity	O
for	O
the	O
µ-opiate	other-medical
receptor	O
(	O
20	O
times	O
higher	O
affinity	O
than	O
the	O
(	O
-	O
)	O
-isomer	O
)	O
.	O

Sinus	O
node	O
blocker	O
Ivabradine	other-medical
can	O
successfully	O
restrain	O
heart	O
rate	O
in	O
POTS	O
without	O
affecting	O
blood	O
pressure	O
,	O
demonstrated	O
in	O
approximately	O
60	O
%	O
of	O
people	O
with	O
POTS	O
treated	O
in	O
an	O
open-label	O
trial	O
of	O
ivabradine	other-medical
experienced	O
symptom	O
improvement	O
.	O

Amiodarone	other-medical
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
ventricular	O
tachycardia	O
in	O
certain	O
instances	O
.	O

His	O
reports	O
concluded	O
that	O
Penicillin	other-medical
in	O
this	O
context	O
,	O
should	O
be	O
used	O
early	O
in	O
the	O
treatment	O
of	O
infected	O
wound	O
rather	O
than	O
at	O
the	O
later	O
stage	O
of	O
chronic	O
suppuration	O
.	O

Using	O
caffeine	other-medical
and	O
naps	O
before	O
night	O
shifts	O
can	O
decrease	O
sleepiness	O
.	O

Birth	O
defects	O
have	O
been	O
associated	O
with	O
use	O
of	O
lisinopril	other-medical
in	O
any	O
trimester	O
.	O

Loratadine	other-medical
,	O
another	O
non-sedating	O
antihistamine	O
,	O
is	O
the	O
prodrug	O
of	O
desloratadine	other-medical
,	O
which	O
is	O
largely	O
responsible	O
for	O
the	O
antihistaminergic	O
effects	O
of	O
the	O
parent	O
compound	O
.	O

The	O
European	O
Medicines	O
Agency	O
,	O
also	O
in	O
2008	O
,	O
had	O
recommended	O
restricting	O
the	O
use	O
of	O
oral	other-medical
norfloxacin	other-medical
to	O
treat	O
urinary	O
infections	O
.	O

Chemotherapy	other-medical
for	O
ALL	O
consists	O
of	O
three	O
phases	O
:	O
remission	O
induction	O
,	O
intensification	O
,	O
and	O
maintenance	O
therapy	O
.	O

In	O
the	O
second	O
trial	O
,	O
62	O
%	O
of	O
fluoxetine	other-medical
treated	O
patients	O
were	O
free	O
of	O
panic	O
attacks	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
vs.	O
44	O
%	O
in	O
the	O
placebo	other-medical
arm	O
.	O

Salgia	O
is	O
the	O
Arthur	O
&	O
amp	O
;	O
Rosalie	O
Kaplan	O
Endowed	O
Chair	O
of	O
Medical	other-medical
Oncology	other-medical
at	O
City	O
of	O
Hope	O
National	O
Medical	O
Center	O
in	O
Duarte	O
,	O
California	O
.	O

Dexbrompheniramine/pseudoephedrine	other-medical
(	O
trade	O
name	O
Drixoral	other-medical
)	O
is	O
a	O
combination	O
medication	O
that	O
contains	O
the	O
antihistamine	O
dexbrompheniramine	other-medical
maleate	other-medical
and	O
the	O
decongestant	O
pseudoephedrine	other-medical
sulfate	other-medical
.	O

Prazosin	other-medical
is	O
commonly	O
used	O
as	O
an	O
anti-hypertensive	other-medical
,	O
but	O
because	O
alpha-1	other-medical
adrenergic	other-medical
activity	O
has	O
been	O
connected	O
to	O
fear	O
and	O
startle	O
responses	O
,	O
it	O
sees	O
use	O
as	O
a	O
PTSD	O
treatment	O
.	O

Flu	O
drugs	O
Tamiflu	other-medical
and	O
Relenza	other-medical
work	O
by	O
inhibiting	O
some	O
strains	O
of	O
neuraminidase	O
.	O

Hsp90	other-medical
inhibitors	other-medical
are	O
another	O
possible	O
treatment	O
for	O
autoimmunity	O
,	O
because	O
hsp90	other-medical
is	O
necessary	O
for	O
proper	O
folding	O
of	O
many	O
pro-inflammatory	O
proteins	O
(	O
components	O
of	O
PI3K	O
,	O
MAPK	O
and	O
NF-kB	O
cascades	O
)	O
.	O

Telmisartan	other-medical
was	O
patented	O
in	O
1991	O
and	O
came	O
into	O
medical	O
use	O
in	O
1999	O
.	O

Tadalafil	other-medical
is	O
structurally	O
different	O
from	O
both	O
sildenafil	other-medical
and	O
vardenafil	other-medical
.	O

Metronidazole	other-medical
began	O
to	O
be	O
commercially	O
used	O
in	O
1960	O
in	O
France	O
.	O

Propofol	other-medical
is	O
only	O
to	O
be	O
used	O
in	O
a	O
hospital	O
,	O
``	O
not	O
just	O
any	O
hospital	O
room	O
,	O
but	O
only	O
in	O
an	O
intensive	O
care	O
unit	O
or	O
procedure	O
room	O
,	O
by	O
specialist	O
personnel	O
''	O
(	O
an	O
anesthesiologist	O
present	O
throughout	O
its	O
use	O
)	O
.	O

When	O
compared	O
with	O
just	O
5-fluorouracil	other-medical
and	O
folinic	other-medical
acid	other-medical
administered	O
according	O
to	O
the	O
de	other-medical
Gramont	other-medical
regimen	other-medical
,	O
a	O
FOLFOX4	other-medical
regime	other-medical
produced	O
no	O
significant	O
increase	O
in	O
overall	O
survival	O
,	O
but	O
did	O
produce	O
an	O
improvement	O
in	O
progression-free	O
survival	O
,	O
the	O
primary	O
end-point	O
of	O
the	O
phase	O
III	O
randomized	O
trial	O
.	O

If	O
your	O
headache	O
would	O
remain	O
without	O
aspirin	O
but	O
disappear	O
if	O
you	O
took	O
aspirin	other-medical
,	O
then	O
the	O
causal	O
effect	O
of	O
taking	O
aspirin	other-medical
is	O
headache	O
relief	O
.	O

If	O
the	O
perioral	O
dermatitis	O
was	O
triggered	O
by	O
a	O
topical	O
steroid	O
then	O
pimecrolimus	other-medical
cream	O
has	O
been	O
suggested	O
as	O
effective	O
in	O
improving	O
symptoms	O
.	O

Isotopes	other-medical
commonly	O
used	O
in	O
the	O
treatment	O
of	O
bone	O
metastasis	O
are	O
radium-223	O
,	O
strontium-89	O
and	O
samarium	O
(	O
153Sm	O
)	O
lexidronam	O
.	O

Subsequent	O
analysis	O
demonstrated	O
that	O
patients	O
treated	O
with	O
Ribociclib	other-medical
and	O
letrozole	other-medical
showed	O
a	O
median	O
progression-free	O
survival	O
of	O
25.3	O
months	O
.	O

The	O
FDA	O
has	O
warned	O
that	O
Prozac	other-medical
and	O
similar	O
antidepressants	O
could	O
cause	O
agitation	O
,	O
panic	O
attacks	O
and	O
aggression	O
.	O

The	O
MicroMed	other-medical
DeBakey	other-medical
VAD	other-medical
is	O
an	O
axial-flow	O
ventricular	O
assist	O
device	O
and	O
is	O
known	O
as	O
a	O
second-generation	O
LVAD	other-medical
.	O

Anthelmintics	other-medical
should	O
generally	O
be	O
paired	O
with	O
corticosteroids	O
in	O
severe	O
infections	O
to	O
limit	O
the	O
inflammatory	O
reaction	O
to	O
the	O
dying	O
parasites	O
.	O

When	O
tamoxifen	other-medical
was	O
launched	O
as	O
a	O
drug	O
,	O
it	O
was	O
thought	O
that	O
tamoxifen	other-medical
would	O
act	O
as	O
an	O
ER	O
antagonist	O
in	O
all	O
tissue	O
,	O
including	O
bone	O
,	O
and	O
therefore	O
it	O
was	O
feared	O
that	O
it	O
would	O
contribute	O
to	O
osteoporosis	O
.	O

The	O
association	O
offers	O
education	O
and	O
advocacy	O
services	O
to	O
improve	O
the	O
lives	O
of	O
sleep	other-medical
apnea	other-medical
patients	O
.	O

Sarin	other-medical
acts	O
on	O
acetylcholinesterase	other-medical
by	O
forming	O
a	O
covalent	O
bond	O
with	O
the	O
particular	O
serine	O
residue	O
at	O
the	O
active	O
site	O
.	O

Hydrocodone	other-medical
with	O
paracetamol	other-medical
has	O
also	O
gained	O
favor	O
.	O

5-ARIs	other-medical
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
hirsutism	O
in	O
women	O
.	O

Preclinical	O
usage	O
of	O
epigenetic	O
agents	O
like	O
5-azacytidine	other-medical
(	O
DNMT	other-medical
inhibitor	other-medical
)	O
and	O
romidepsin	other-medical
(	O
HDAC	other-medical
inhibitor	other-medical
)	O
sensitizes	O
cancer	O
cells	O
for	O
further	O
treatment	O
.	O

This	O
can	O
be	O
seen	O
in	O
people	O
who	O
are	O
experiencing	O
the	O
classic	O
signs	O
of	O
pericarditis	O
but	O
then	O
show	O
signs	O
of	O
relief	O
,	O
and	O
progress	O
to	O
show	O
signs	O
of	O
cardiac	O
tamponade	O
which	O
include	O
decreased	O
alertness	O
and	O
lethargy	O
,	O
pulsus	O
paradoxus	O
(	O
decrease	O
of	O
at	O
least	O
10	O
mmHg	O
of	O
the	O
systolic	O
blood	O
pressure	O
upon	O
inspiration	O
)	O
,	O
low	O
blood	O
pressure	O
(	O
due	O
to	O
decreased	O
cardiac	O
index	O
)	O
,	O
(	O
jugular	O
vein	O
distention	O
from	O
right	O
sided	O
heart	O
failure	O
and	O
fluid	O
overload	O
)	O
,	O
distant	O
heart	O
sounds	O
on	O
auscultation	O
,	O
and	O
equilibration	O
of	O
all	O
the	O
diastolic	O
blood	O
pressures	O
on	O
cardiac	other-medical
catheterization	other-medical
due	O
to	O
the	O
constriction	O
of	O
the	O
pericardium	O
by	O
the	O
fluid	O
.	O

ErbB2	other-medical
overexpression	other-medical
can	O
occur	O
in	O
breast	O
,	O
ovarian	O
,	O
bladder	O
,	O
non-small-cell	O
lung	O
carcinoma	O
,	O
as	O
well	O
as	O
several	O
other	O
tumor	O
types	O
.	O

Lubar	O
(	O
1989	O
)	O
studied	O
SMR	O
biofeedback	O
to	O
treat	O
attention	other-medical
disorders	other-medical
and	O
epilepsy	other-medical
in	O
collaboration	O
with	O
Sterman	O
.	O

Severe	O
manifestations	O
are	O
often	O
treated	O
with	O
Cyclophosphamide	other-medical
or	O
Rituximab	other-medical
and	O
three	O
doses	O
of	O
methylprednisolone	other-medical
IV-pulse	O
treatment	O
(	O
as	O
recommended	O
by	O
ACR	O
guidelines	O
)	O
prior	O
to	O
switching	O
to	O
oral	O
prednisolone	O
and	O
azathioprine	O
for	O
maintenance	O
.	O

Malaria	O
as	O
a	O
treatment	O
for	O
syphilis	O
was	O
usually	O
reserved	O
for	O
late	O
disease	O
,	O
especially	O
neurosyphilis	O
,	O
and	O
then	O
followed	O
by	O
either	O
Salvarsan	other-medical
or	O
Neosalvarsan	other-medical
as	O
adjuvant	O
therapy	O
.	O

Ketoconazole	other-medical
has	O
activity	O
against	O
many	O
kinds	O
of	O
fungi	O
that	O
may	O
cause	O
human	O
disease	O
,	O
such	O
as	O
``	O
Candida	O
``	O
,	O
``	O
Histoplasma	O
``	O
,	O
``	O
Coccidioides	O
``	O
,	O
and	O
``	O
Blastomyces	O
``	O
(	O
although	O
it	O
is	O
not	O
active	O
against	O
``	O
Aspergillus	O
``	O
)	O
,	O
chromomycosis	O
and	O
paracoccidioidomycosis	O
.	O

Other	O
biomedical	O
companies	O
also	O
produce	O
brands	O
of	O
hyaluronan	O
for	O
ophthalmic	other-medical
surgery	other-medical
.	O

Fluoxetine	other-medical
was	O
approved	O
for	O
commercial	O
use	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
in	O
1988	O
,	O
becoming	O
the	O
first	O
blockbuster	O
SSRI	other-medical
.	O

Most	O
MDMA	other-medical
production	O
in	O
China	O
is	O
for	O
domestic	O
consumption	O
.	O

When	O
incubated	O
with	O
the	O
carbohydrates	O
lactose	O
,	O
maltose	O
,	O
sucrose	O
,	O
and	O
glucose	O
,	O
``	O
N.	other-medical
gonorrhoeae	other-medical
``	O
will	O
oxidize	O
only	O
the	O
glucose	O
.	O

Hypoventilation	other-medical
exists	O
when	O
the	O
ratio	O
of	O
carbon	O
dioxide	O
production	O
to	O
alveolar	O
ventilation	O
increases	O
above	O
normal	O
values	O
–	O
greater	O
than	O
45mmHg	O
.	O

Methylene	O
blue	O
is	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	other-medical
)	O
,	O
and	O
if	O
infused	O
intravenously	O
at	O
doses	O
exceeding	O
5	O
mg/kg	O
,	O
may	O
precipitate	O
serious	O
serotonin	O
toxicity	O
,	O
serotonin	O
syndrome	O
,	O
if	O
combined	O
with	O
any	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	other-medical
)	O
or	O
other	O
serotonin	O
reuptake	O
inhibitor	O
(	O
e.g.	O
,	O
duloxetine	O
,	O
sibutramine	O
,	O
venlafaxine	O
,	O
clomipramine	O
,	O
imipramine	O
)	O
.	O

Hydralazine	other-medical
is	O
a	O
medication	O
used	O
to	O
treat	O
high	O
blood	O
pressure	O
.	O

Chronic	O
kidney	O
disease	O
is	O
defined	O
as	O
prolonged	O
kidney	other-medical
abnormalities	other-medical
(	O
functional	O
and/or	O
structural	O
in	O
nature	O
)	O
that	O
last	O
for	O
more	O
than	O
three	O
weeks	O
.	O

Serious	O
cardiac	O
events	O
,	O
including	O
some	O
that	O
have	O
been	O
fatal	O
,	O
have	O
occurred	O
following	O
the	O
use	O
of	O
sumatriptan	other-medical
injection	O
or	O
tablets	O
.	O

Benzedrine	other-medical
was	O
supplied	O
to	O
combat	O
troops	O
in	O
World	O
War	O
2	O
for	O
use	O
in	O
exceptional	O
circumstances	O
(	O
e.g	O
.	O

Alles	O
first	O
reported	O
the	O
physiological	O
properties	O
of	O
amphetamine	other-medical
as	O
a	O
synthetic	O
analog	O
of	O
ephedrine	other-medical
,	O
and	O
therefore	O
received	O
credit	O
for	O
this	O
discovery	O
.	O

Taking	O
amoxicillin	other-medical
once	O
a	O
day	O
may	O
be	O
as	O
effective	O
as	O
twice	O
or	O
three	O
times	O
a	O
day	O
.	O

Prazosin	other-medical
has	O
been	O
established	O
as	O
an	O
effective	O
and	O
safe	O
centrally	O
active	O
alpha-1	other-medical
adrenergic	other-medical
receptor	other-medical
antagonist	other-medical
.	O

The	O
Boston	O
Diagnostic	other-medical
Aphasia	other-medical
Examination	other-medical
(	O
BDAE	other-medical
)	O
and	O
the	O
Western	other-medical
Aphasia	other-medical
Battery	other-medical
(	O
WAB	other-medical
)	O
are	O
two	O
commonly	O
used	O
test	O
batteries	O
for	O
diagnosing	O
conduction	O
aphasia	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
if	O
combining	O
aspirin	other-medical
with	O
any	O
``	O
natural	O
''	O
supplements	O
with	O
COX-2-inhibiting	O
properties	O
,	O
such	O
as	O
garlic	O
extracts	O
,	O
curcumin	O
,	O
bilberry	O
,	O
pine	O
bark	O
,	O
ginkgo	O
,	O
fish	O
oil	O
,	O
resveratrol	O
,	O
genistein	O
,	O
quercetin	O
,	O
resorcinol	O
,	O
and	O
others	O
.	O

However	O
,	O
there	O
are	O
two	O
possible	O
causes	O
of	O
the	O
corneal	O
inflammatory	O
response	O
:	O
an	O
infection	O
and/or	O
an	O
immunological	other-medical
response	other-medical
,	O
such	O
as	O
a	O
hypersensitivity	other-medical
type	other-medical
reaction	other-medical
,	O
or	O
(	O
rarely	O
)	O
Cogan	O
syndrome	O
.	O

The	O
drug	O
is	O
an	O
N-protected	O
dipeptide	O
and	O
can	O
be	O
written	O
as	O
Pyz-Phe-boroLeu	other-medical
,	O
which	O
stands	O
for	O
pyrazinoic	O
acid	O
,	O
phenylalanine	O
and	O
Leucine	O
with	O
a	O
boronic	O
acid	O
instead	O
of	O
a	O
carboxylic	O
acid	O
.	O

In	O
particular	O
,	O
immunization	O
with	O
P28GST	other-medical
,	O
a	O
schistosome	O
glutathione	O
``	O
S	O
''	O
-transferase	O
enzyme	O
in	O
rats	O
has	O
been	O
shown	O
to	O
reduce	O
colitis	O
lesions	O
and	O
expression	O
of	O
pro-inflammatory	O
cytokines	O
by	O
eosinophil	O
responses	O
to	O
inflammation	O
.	O

Injecting	O
potassium	other-medical
chloride	other-medical
into	O
the	O
heart	O
muscle	O
disrupts	O
the	O
signal	O
that	O
causes	O
the	O
heart	O
to	O
beat	O
.	O

Tyrosine	O
kinases	O
play	O
a	O
particularly	O
important	O
role	O
in	O
cancer	O
,	O
and	O
several	O
agents	O
that	O
block	O
their	O
activity	O
are	O
now	O
used	O
as	O
anti-cancer	O
drugs	O
,	O
such	O
as	O
Imatinib	other-medical
or	O
Gleevec	other-medical
.	O

Contrary	O
to	O
most	O
other	O
injector	O
pens	O
,	O
epinephrine	other-medical
injector	O
pens	O
are	O
designed	O
to	O
administer	O
the	O
medication	O
via	O
intramuscular	O
injection	O
.	O

In	O
diabetes	O
it	O
is	O
a	O
less	O
preferred	O
agent	O
compared	O
to	O
metformin	other-medical
.	O

Medications	O
with	O
good	O
evidence	O
include	O
topical	other-medical
ivermectin	other-medical
and	O
azelaic	other-medical
acid	other-medical
creams	O
and	O
brimonidine	other-medical
,	O
and	O
doxycycline	other-medical
and	O
isotretinoin	other-medical
by	O
mouth	O
.	O

More	O
heart	other-medical
transplants	other-medical
are	O
performed	O
at	O
Texas	O
Medical	O
Center	O
than	O
anywhere	O
else	O
in	O
the	O
world	O
.	O

2001	O
–	O
Pegylated	other-medical
interferon	other-medical
was	O
approved	O
.	O

In	O
2007	O
,	O
and	O
again	O
during	O
the	O
2009	O
swine	O
flu	O
pandemic	O
,	O
Carter	O
said	O
that	O
rintatolimod	other-medical
could	O
also	O
be	O
used	O
as	O
an	O
H1N1	O
flu	O
vaccine	O
booster	O
,	O
citing	O
``	O
in	O
vitro	O
''	O
studies	O
with	O
Ampligen	other-medical
and	O
neuraminidase	O
inhibitors	O
oseltamivir	other-medical
and	O
zanamivir	other-medical
(	O
brand	O
names	O
Tamiflu	other-medical
and	O
Relenza	other-medical
)	O
.	O

For	O
dental	O
procedures	O
,	O
the	O
American	O
protocol	O
in	O
2017	O
called	O
for	O
the	O
prescription	O
of	O
amoxicillin	other-medical
or	O
ampicillin	other-medical
.	O

25B-NBOH	other-medical
(	O
2C-B-NBOH	other-medical
,	O
NBOH-2C-B	other-medical
)	O
is	O
a	O
derivative	O
of	O
the	O
phenethylamine	O
derived	O
hallucinogen	other-medical
2C-B	other-medical
which	O
has	O
been	O
sold	O
as	O
a	O
designer	O
drug	O
.	O

CAR-302,196	other-medical
(	O
also	O
known	O
as	O
PCMG	other-medical
or	O
just	O
by	O
its	O
code	O
number	O
302196	other-medical
)	O
is	O
a	O
moderately	O
potent	O
and	O
relatively	O
short	O
lasting	O
anticholinergic	O
deliriant	O
drug	O
,	O
related	O
to	O
the	O
chemical	O
warfare	O
agent	O
3-	O
Quinuclidinyl	O
benzilate	O
(	O
QNB	O
)	O
.	O

A	O
Cochrane	O
Systematic	O
Review	O
showed	O
that	O
trifluridine	other-medical
and	O
aciclovir	other-medical
were	O
a	O
more	O
effective	O
treatment	O
than	O
idoxuridine	other-medical
or	O
vidarabine	other-medical
,	O
significantly	O
increasing	O
the	O
relative	O
number	O
of	O
successfully	O
healed	O
eyes	O
in	O
one	O
to	O
two	O
weeks	O
.	O

Oral	other-medical
iron	other-medical
supplementations	other-medical
are	O
the	O
first	O
line	O
of	O
care	O
for	O
iron	O
deficiency	O
and	O
iron	O
deficiency	O
anaemia	O
.	O

In	O
one	O
patient	O
,	O
all	O
of	O
whose	O
routine	O
laboratory	O
tests	O
were	O
normal	O
,	O
the	O
following	O
were	O
attempted	O
,	O
all	O
without	O
success	O
:	O
ibuprofen	other-medical
,	O
400	O
mg	O
on	O
demand	O
;	O
tramadol	other-medical
50	O
mg	O
one	O
hour	O
pre-coitally	O
;	O
and	O
escitalopram	other-medical
10	O
mg	O
daily	O
at	O
bedtime	O
for	O
3	O
months	O
.	O

Following	O
a	O
2016	O
publication	O
of	O
a	O
flawed	O
paper	O
on	O
HPV	other-medical
vaccine	O
in	O
Japan	O
,	O
which	O
was	O
later	O
retracted	O
,	O
the	O
Board	O
responded	O
with	O
a	O
letter	O
,	O
signed	O
by	O
20	O
of	O
its	O
Board	O
members	O
,	O
criticising	O
both	O
the	O
research	O
and	O
the	O
time	O
to	O
retract	O
it	O
.	O

From	O
1972	O
to	O
1975	O
,	O
Niikawa	O
served	O
as	O
a	O
research	O
associate	O
in	O
the	O
embryology	other-medical
and	O
cytogenetics	O
laboratory	O
at	O
the	O
Department	O
of	O
Gynaecology	O
and	O
Obstetrics	O
in	O
the	O
Cantonal	O
Hospital	O
,	O
Geneva	O
University	O
.	O

Methylprednisolone	other-medical
is	O
used	O
to	O
treat	O
several	O
rheumatic	O
diseases	O
,	O
such	O
as	O
Systemic	O
Lupus	O
Erythematosus	O
(	O
SLE	O
)	O
and	O
Rheumatoid	O
Arthritis	O
(	O
RA	O
)	O
.	O

Selank	other-medical
,	O
as	O
well	O
as	O
a	O
related	O
peptide	O
drug	O
,	O
Semax	other-medical
,	O
have	O
been	O
found	O
to	O
inhibit	O
enzymes	O
involved	O
in	O
the	O
degradation	O
of	O
enkephalins	O
and	O
other	O
endogenous	O
regulatory	O
peptides	O
,	O
and	O
this	O
action	O
may	O
be	O
involved	O
in	O
their	O
effects	O
.	O

Clinical	O
vignettes	O
from	O
Green	O
's	O
work	O
on	O
gender	other-medical
identity	other-medical
disorder	other-medical
appear	O
in	O
widely	O
used	O
textbooks	O
,	O
such	O
as	O
``	O
Kaplan	O
and	O
Sadock	O
's	O
Synopsis	O
of	O
Psychiatry	O
``	O
(	O
10th	O
ed	O
.	O
)	O

Numerous	O
clinical	O
trials	O
have	O
been	O
performed	O
to	O
assess	O
the	O
use	O
of	O
dopamine	other-medical
agonists	other-medical
for	O
the	O
treatment	O
of	O
restless	O
leg	O
syndrome	O
(	O
RLS	O
)	O
.	O

It	O
was	O
used	O
to	O
treat	O
symptoms	O
associated	O
with	O
allergies	O
and	O
colds	O
such	O
as	O
itchy	other-medical
and	other-medical
watery	other-medical
eyes	other-medical
,	O
runny	other-medical
nose	other-medical
,	O
nasal	other-medical
and	other-medical
sinus	other-medical
congestion	other-medical
,	O
and	O
sneezing	other-medical
.	O

Air	O
under	O
moderately	O
high	O
pressure	O
,	O
such	O
as	O
is	O
used	O
when	O
diving	O
below	O
about	O
,	O
has	O
an	O
increasing	O
narcotic	other-medical
effect	O
on	O
the	O
nervous	O
system	O
.	O

A	O
pooled	O
analysis	O
of	O
randomized	O
,	O
controlled	O
studies	O
of	O
meloxicam	other-medical
therapy	O
of	O
up	O
to	O
60	O
days	O
duration	O
found	O
that	O
meloxicam	other-medical
was	O
associated	O
with	O
a	O
statistically	O
significantly	O
lower	O
number	O
of	O
thromboembolic	other-medical
complications	other-medical
than	O
the	O
NSAID	other-medical
diclofenac	other-medical
(	O
0.2	O
%	O
versus	O
0.8	O
%	O
respectively	O
)	O
but	O
a	O
similar	O
incidence	O
of	O
thromboembolic	other-medical
events	O
to	O
naproxen	other-medical
and	O
piroxicam	other-medical
.	O

Methylene	other-medical
blue	other-medical
is	O
also	O
used	O
as	O
a	O
dye	O
in	O
chromoendoscopy	O
,	O
and	O
is	O
sprayed	O
onto	O
the	O
mucosa	O
of	O
the	O
gastrointestinal	O
tract	O
in	O
order	O
to	O
identify	O
dysplasia	O
,	O
or	O
pre-cancerous	O
lesions	O
.	O

First	O
described	O
in	O
1913	O
,	O
little	O
was	O
known	O
about	O
the	O
cause	O
of	O
the	O
condition	O
until	O
MRI	other-medical
studies	O
were	O
performed	O
in	O
the	O
1990s	O
.	O

Although	O
the	O
success	O
of	O
Sulphetrone	other-medical
drugs	O
in	O
treating	O
Hansen	O
's	O
disease	O
led	O
to	O
hopes	O
in	O
the	O
early	O
1950s	O
that	O
Fantome	O
Island	O
could	O
close	O
,	O
this	O
did	O
not	O
occur	O
until	O
1973	O
.	O

In	O
genioglossus	other-medical
advancement	other-medical
and	other-medical
hyoid	other-medical
myotomy	other-medical
(	O
GAHM	other-medical
)	O
,	O
a	O
genioglossus	O
advancement	O
is	O
performed	O
at	O
the	O
same	O
time	O
as	O
either	O
a	O
hyo-mandibular	O
or	O
hyo-thyroid	O
suspension	O
.	O

Others	O
have	O
found	O
it	O
to	O
be	O
less	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
constipation	O
than	O
psyllium	other-medical
.	O

In	O
August	O
2012	O
,	O
Johnson	O
&	O
amp	O
;	O
Johnson	O
agreed	O
to	O
pay	O
$	O
181million	O
to	O
36	O
U.S	O
.	O
states	O
in	O
order	O
to	O
settle	O
claims	O
that	O
it	O
had	O
promoted	O
risperidone	other-medical
and	O
paliperidone	other-medical
for	O
off-label	O
uses	O
including	O
for	O
dementia	O
,	O
anger	O
management	O
,	O
and	O
anxiety	O
.	O

5-APDI	other-medical
acts	O
as	O
a	O
potent	O
and	O
weakly	O
selective	other-medical
serotonin	other-medical
releasing	other-medical
agent	other-medical
(	O
SSRA	other-medical
)	O
with	O
IC50	O
values	O
of	O
82	O
nM	O
,	O
1,848	O
nM	O
,	O
and	O
849	O
nM	O
for	O
inhibiting	O
the	O
reuptake	O
of	O
serotonin	O
,	O
dopamine	O
,	O
and	O
norepinephrine	O
,	O
respectively	O
.	O

Therapeutic	O
doses	O
of	O
fluoxetine	other-medical
have	O
been	O
shown	O
to	O
decrease	O
these	O
neuronal	O
fatigue	O
states	O
by	O
inhibiting	O
vesicle	O
release	O
and	O
thereby	O
preventing	O
synaptic	O
fatigue	O
in	O
hippocampal	O
neurons	O
.	O

Targeting	other-medical
Hsp90	other-medical
with	O
drugs	O
has	O
shown	O
promising	O
effects	O
in	O
clinical	O
trials	O
.	O

There	O
is	O
wide	O
variation	O
in	O
the	O
professional	O
practice	O
of	O
behavior	O
analysis	O
and	O
among	O
the	O
assessments	O
and	O
interventions	O
used	O
in	O
school-based	O
ABA	other-medical
programs	O
.	O

Rapid	O
partial	O
correction	O
with	O
3	O
%	O
normal	other-medical
saline	other-medical
is	O
only	O
recommended	O
in	O
those	O
with	O
significant	O
symptoms	O
and	O
occasionally	O
those	O
in	O
whom	O
the	O
condition	O
was	O
of	O
rapid	O
onset	O
.	O

Treatment	O
may	O
include	O
pain	O
medications	O
,	O
NSAIDs	other-medical
,	O
and	O
elevation	O
.	O

Erythromelalgia	O
is	O
caused	O
by	O
an	O
increased	O
platelet	O
count	O
or	O
increased	O
platelet	O
``	O
stickiness	O
''	O
(	O
aggregation	O
)	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
tiny	O
blood	O
clots	O
in	O
the	O
vessels	O
of	O
the	O
extremity	O
;	O
it	O
responds	O
rapidly	O
to	O
treatment	O
with	O
aspirin	other-medical
.	O

Hemorrhage	other-medical
and	O
myonecrosis	other-medical
initiated	O
by	O
D.	O
acuts	O
,	O
A.	O
halys	O
,	O
N.	O
atra	O
,	O
and	O
B.	O
multicinctus	O
in	O
an	O
animal	O
model	O
were	O
significantly	O
reversed	O
by	O
varespladib	other-medical
.	O

Steroids	other-medical
and	O
anti-emetic	other-medical
agents	other-medical
may	O
decrease	O
the	O
incidence	O
of	O
PRS	O
.	O

The	O
problem	O
is	O
with	O
paracetamol	other-medical
(	O
acetaminophen	other-medical
/	O
Tylenol	other-medical
for	O
example	O
)	O
overdose	O
and	O
liver	O
damage	O
.	O

``	O
C	O
.	O
``	O
``	O
tertium	O
``	O
is	O
commonly	O
(	O
but	O
not	O
universally	O
)	O
resistant	O
to	O
many	O
β-lactam	O
antibiotics	O
such	O
as	O
penicillin	other-medical
and	O
cephalosporin	other-medical
;	O
clindamycin	other-medical
;	O
and	O
metronidazole	other-medical
;	O
but	O
it	O
is	O
susceptible	O
to	O
vancomycin	other-medical
,	O
trimethoprim-sulfamethoxazole	other-medical
,	O
and	O
ciprofloxacin	other-medical
.	O

Catatonia	O
due	O
to	O
abrupt	O
or	O
overly	O
rapid	O
withdrawal	O
from	O
benzodiazepines	other-medical
,	O
as	O
part	O
of	O
the	O
benzodiazepine	O
withdrawal	O
syndrome	O
,	O
should	O
also	O
respond	O
to	O
lorazepam	other-medical
treatment	O
.	O

They	O
and	O
their	O
parents	O
sued	O
Merrell	O
Dow	O
Pharmaceuticals	O
Inc	O
.	O
,	O
a	O
subsidiary	O
of	O
Dow	O
Chemical	O
Company	O
,	O
in	O
a	O
California	O
District	O
Court	O
,	O
claiming	O
that	O
the	O
drug	O
Bendectin	other-medical
had	O
caused	O
the	O
birth	O
defects	O
.	O

Several	O
popular	O
products	O
sold	O
by	O
SKF	O
contained	O
amphetamine	other-medical
,	O
including	O
Benzedrine	other-medical
pills	O
and	O
inhalers	O
,	O
Dexedrine	other-medical
pills	O
and	O
Dexamyl	other-medical
tablets	O
.	O

She	O
was	O
interested	O
in	O
the	O
Baháʼí	other-medical
Faith	other-medical
and	other-medical
Theosophy	other-medical
.	O

MPP	O
played	O
an	O
instrumental	O
role	O
in	O
passing	O
this	O
legislation	O
,	O
by	O
funding	O
a	O
two-year	O
lobbying	O
effort	O
and	O
helping	O
elect	O
a	O
governor	O
who	O
supports	O
sensible	O
marijuana	other-medical
policies	O
.	O

Hypotonia	other-medical
is	O
common	O
(	O
75	O
%	O
)	O
,	O
as	O
is	O
an	O
unsteady	O
gait	O
.	O

Certain	O
medications	O
increase	O
the	O
risk	O
of	O
hyperglycemia	O
,	O
including	O
:	O
corticosteroids	other-medical
,	O
octreotide	other-medical
,	O
beta	other-medical
blockers	other-medical
,	O
epinephrine	other-medical
,	O
thiazide	other-medical
diuretics	other-medical
,	O
statins	other-medical
,	O
niacin	other-medical
,	O
pentamidine	other-medical
,	O
protease	other-medical
inhibitors	other-medical
,	O
L-asparaginase	other-medical
,	O
and	O
antipsychotics	other-medical
.	O

SERMs	other-medical
like	O
tamoxifen	other-medical
and	O
raloxifene	other-medical
can	O
also	O
be	O
considered	O
to	O
be	O
nonsteroidal	O
estrogens	O
in	O
some	O
tissues	O
.	O

This	O
has	O
led	O
to	O
carboplatin	other-medical
based	O
adjuvant	O
therapy	O
being	O
generally	O
preferred	O
over	O
adjuvant	O
radiotherapy	O
in	O
clinical	O
practice	O
.	O

There	O
has	O
never	O
been	O
an	O
adequately	O
large	O
randomized	O
controlled	O
trial	O
to	O
prove	O
definitively	O
that	O
HGH	other-medical
provides	O
significant	O
anti-aging	O
benefits	O
and	O
that	O
there	O
are	O
no	O
significant	O
adverse	O
drug	O
reactions	O
;	O
there	O
have	O
been	O
many	O
small	O
studies	O
which	O
are	O
described	O
below	O
.	O

After	O
stable	O
remission	O
was	O
induced	O
,	O
the	O
standard	O
of	O
care	O
previously	O
was	O
to	O
undergo	O
2	O
years	O
of	O
maintenance	O
chemotherapy	O
with	O
methotrexate	other-medical
,	O
mercaptopurine	other-medical
and	O
ATRA	other-medical
.	O

Clenbuterol	other-medical
is	O
a	O
sympathomimetic	O
amine	O
used	O
by	O
sufferers	O
of	O
breathing	O
disorders	O
as	O
a	O
decongestant	O
and	O
bronchodilator	O
.	O

A	O
cerebrospinal	O
fluid	O
sample	O
is	O
taken	O
by	O
lumbar	other-medical
puncture	other-medical
and	O
is	O
tested	O
for	O
leukocyte	O
levels	O
to	O
determine	O
if	O
there	O
is	O
an	O
infection	O
and	O
goes	O
on	O
to	O
further	O
testing	O
to	O
see	O
what	O
the	O
actual	O
cause	O
is	O
.	O

Ketamine	other-medical
is	O
a	O
commonly	O
used	O
drug	O
that	O
can	O
cause	O
this	O
type	O
of	O
sedation	O
.	O

Because	O
it	O
contains	O
pseudoephedrine	other-medical
,	O
its	O
purchase	O
in	O
the	O
United	O
States	O
was	O
severely	O
restricted	O
by	O
the	O
Combat	O
Methamphetamine	O
Epidemic	O
Act	O
of	O
2005	O
over	O
fears	O
that	O
any	O
product	O
containing	O
pseudoephedrine	other-medical
can	O
be	O
used	O
to	O
make	O
methamphetamine	other-medical
.	O

Tamoxifen	other-medical
acts	O
as	O
a	O
selective	O
estrogen	other-medical
receptor	other-medical
modulator	other-medical
(	O
SERM	other-medical
)	O
,	O
or	O
as	O
a	O
partial	O
agonist	O
of	O
the	O
estrogen	O
receptors	O
(	O
ER	O
s	O
)	O
.	O

Pixantrone	other-medical
also	O
reduces	O
the	O
severity	O
of	O
experimental	O
autoimmune	O
myasthenia	O
gravis	O
in	O
Lewis	O
rats	O
,	O
and	O
in	O
vitro	O
cell	O
viability	O
experiments	O
indicated	O
that	O
Pixantrone	other-medical
significantly	O
reduces	O
amyloid	O
beta	O
(	O
A	O
beta	O
(	O
1-42	O
)	O
)	O
neurotoxicity	O
,	O
a	O
mechanism	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Lo	O
was	O
diagnosed	O
with	O
lung	other-medical
cancer	other-medical
in	O
September	O
2001	O
.	O

Cymbalta	other-medical
generated	O
sales	O
of	O
nearly	O
in	O
2012	O
,	O
with	O
of	O
that	O
in	O
the	O
U.S	O
.	O
,	O
but	O
its	O
patent	O
protection	O
terminated	O
January	O
1	O
,	O
2014	O
.	O

Some	O
states	O
and	O
store	O
chains	O
have	O
implemented	O
restrictions	O
,	O
such	O
as	O
requiring	O
signatures	O
for	O
DXM	other-medical
sale	O
,	O
limiting	O
quantities	O
allowable	O
for	O
purchase	O
,	O
and	O
requiring	O
that	O
purchasers	O
be	O
over	O
the	O
age	O
of	O
majority	O
in	O
their	O
state	O
.	O

Folic	other-medical
acid	other-medical
might	O
also	O
be	O
counter-productive	O
for	O
patients	O
taking	O
6-MP	other-medical
and	O
related	O
drugs	O
that	O
inhibit	O
all	O
cell	O
division	O
.	O

West	O
mentions	O
the	O
antidepressant	O
drug	O
Lexapro	other-medical
in	O
reference	O
to	O
his	O
issues	O
with	O
mental	O
health	O
,	O
a	O
subject	O
West	O
mostly	O
touched	O
on	O
in	O
the	O
song	O
``	O
I	O
Feel	O
Like	O
That	O
``	O
from	O
the	O
end	O
of	O
his	O
and	O
Steve	O
McQueen	O
's	O
music	O
video	O
for	O
West	O
's	O
2015	O
single	O
``	O
All	O
Day	O
``	O
.	O

Carfecillin	other-medical
is	O
a	O
beta-lactam	other-medical
antibiotic	other-medical
.	O

Somatostatin	other-medical
and	O
octreotide	other-medical
,	O
while	O
recommended	O
for	O
varicial	O
bleeding	O
,	O
have	O
not	O
been	O
found	O
to	O
be	O
of	O
general	O
use	O
for	O
non	O
variceal	O
bleeds	O
.	O

Patients	O
on	O
high	O
dose	O
sulfasalazine	other-medical
require	O
folic	other-medical
supplementation	O
(	O
1	O
mg/day	O
)	O
(	O
1000	O
µg/day	O
)	O
to	O
maintain	O
normal	O
cell	O
division	O
.	O

Warfarin	other-medical
is	O
tasteless	O
and	O
colourless	O
,	O
and	O
produces	O
symptoms	O
similar	O
to	O
those	O
that	O
Stalin	O
exhibited	O
.	O

The	O
first	O
half	O
of	O
the	O
1960	O
’	O
s	O
saw	O
contraceptions	O
such	O
as	O
the	O
birth	other-medical
control	other-medical
pill	other-medical
and	O
Intrauterine	other-medical
Device	other-medical
(	O
IUD	other-medical
)	O
become	O
widely	O
available	O
,	O
which	O
contributed	O
to	O
sexual	O
freedom	O
for	O
many	O
people	O
without	O
having	O
to	O
rely	O
on	O
less	O
reliable	O
and	O
uncomfortable	O
physical	O
contraceptives	O
such	O
as	O
condoms	other-medical
or	O
diaphragms	other-medical
.	O

These	O
findings	O
show	O
that	O
fluoxetine	other-medical
as	O
well	O
as	O
other	O
antidepressants	O
that	O
act	O
through	O
the	O
same	O
mechanisms	O
as	O
fluoxetine	other-medical
enhance	O
neurorecovery	O
and	O
neurotransmission	O
to	O
reduce	O
the	O
risk	O
of	O
depression	O
.	O

Vintafolide	other-medical
,	O
which	O
consists	O
of	O
an	O
antifolate	O
conjugated	O
with	O
vinblastine	other-medical
,	O
is	O
also	O
in	O
clinical	O
trials	O
;	O
it	O
may	O
prove	O
beneficial	O
because	O
folate	O
receptors	O
are	O
overexpressed	O
in	O
many	O
ovarian	O
cancers	O
.	O

Trimecaine	other-medical
must	O
not	O
be	O
used	O
at	O
hypersensitivity	O
on	O
amide	other-medical
anesthetics	other-medical
,	O
hypervolemia	O
,	O
hypotension	O
,	O
cardial	O
conduction	O
defects	O
,	O
asystole	O
,	O
cardiogenic	O
shock	O
and	O
malignant	O
hyperthermia	O
in	O
anamnesis	O
.	O

A	O
physician	O
may	O
apply	O
cocaine	other-medical
in	O
the	O
few	O
countries	O
that	O
allow	O
it	O
for	O
medical	O
use	O
.	O

Medical	O
management	O
of	O
miscarriage	O
and	O
medical	O
abortion	O
using	O
drugs	O
such	O
as	O
misoprostol	other-medical
and	O
mifepristone	other-medical
are	O
safe	O
,	O
non-invasive	O
and	O
potentially	O
less	O
expensive	O
alternatives	O
to	O
D	other-medical
&	other-medical
amp	other-medical
;	other-medical
C	other-medical
.	O

Many	O
users	O
of	O
dissociatives	O
have	O
been	O
concerned	O
about	O
the	O
possibility	O
of	O
NMDA	other-medical
antagonist	other-medical
neurotoxicity	other-medical
(	O
NAN	other-medical
)	O
.	O

Methicillin	other-medical
-resistant	O
``	O
Staphylococcus	O
aureus	O
``	O
(	O
MRSA	O
)	O
was	O
first	O
detected	O
in	O
Britain	O
in	O
1961	O
,	O
and	O
is	O
now	O
``	O
quite	O
common	O
''	O
in	O
hospitals	O
.	O

The	O
discovery	O
and	O
development	O
of	O
melatonin	other-medical
receptor	other-medical
agonists	other-medical
was	O
motivated	O
by	O
the	O
need	O
for	O
more	O
potent	O
analogues	O
than	O
melatonin	O
,	O
with	O
better	O
pharmacokinetics	O
and	O
longer	O
half-life	O
.	O

Topical	other-medical
retinoids	other-medical
include	O
adapalene	other-medical
,	O
retinol	other-medical
,	O
tazarotene	other-medical
,	O
trifarotene	other-medical
,	O
and	O
tretinoin	other-medical
.	O

Deforolimus	other-medical
(	O
Ridaforolimus	other-medical
)	O
has	O
C43	O
secondary	O
alcohol	O
moiety	O
of	O
the	O
cyclohexyl	O
group	O
of	O
Rapamycin	other-medical
that	O
was	O
substituted	O
with	O
phosphonate	O
and	O
phosphinate	O
groups	O
,	O
preventing	O
the	O
high-affinity	O
binding	O
to	O
mTOR	O
and	O
FKBP	O
.	O

He	O
died	O
in	O
1989	O
of	O
a	O
suspected	O
accidental	O
valium	other-medical
overdose	O
,	O
while	O
attempting	O
to	O
resurrect	O
his	O
football	O
career	O
in	O
the	O
CFL	O
,	O
and	O
while	O
fighting	O
alcoholism	O
.	O

Diethyl	O
ether	other-medical
in	O
anesthetic	O
dosage	O
is	O
an	O
inhalant	O
which	O
has	O
a	O
long	O
history	O
of	O
recreational	O
use	O
.	O

The	O
non-steroidal	O
drug	O
Irosustat	other-medical
has	O
been	O
the	O
most	O
studied	O
to	O
date	O
.	O

Botulinum	other-medical
toxin	other-medical
is	O
used	O
to	O
treat	O
a	O
number	O
of	O
therapeutic	O
indications	O
,	O
many	O
of	O
which	O
are	O
not	O
part	O
of	O
the	O
approved	O
drug	O
label	O
.	O

It	O
is	O
a	O
common	O
protecting	O
group	O
for	O
sugars	O
and	O
sugar	O
alcohols	O
,	O
a	O
simple	O
example	O
being	O
solketal	other-medical
.	O

Of	O
the	O
drugs	O
that	O
cause	O
DIL	O
,	O
hydralazine	other-medical
has	O
been	O
found	O
to	O
cause	O
a	O
higher	O
incidence	O
.	O

Ranitidine	other-medical
has	O
been	O
shown	O
to	O
reduce	O
ulceration	O
when	O
given	O
concurrently	O
during	O
feed	O
deprivation	O
trials	O
.	O

The	O
chemical	O
name	O
of	O
doxepin	other-medical
is	O
(	O
``	O
E	O
''	O
/	O
''	O
Z	O
''	O
)	O
-3-	O
(	O
dibenzo	O
[	O
``	O
b	O
''	O
,	O
''	O
e	O
''	O
]	O
oxepin-11	O
(	O
6	O
''	O
H	O
''	O
)	O
-ylidene	O
)	O
-	O
''	O
N	O
''	O
,	O
''	O
N	O
''	O
-dimethylpropan-1-amine	O
and	O
its	O
free	O
base	O
form	O
has	O
a	O
chemical	O
formula	O
of	O
C19H21NO	O
with	O
a	O
molecular	O
weight	O
of	O
279.376	O
g/mol	O
.	O

Atropine	other-medical
blocks	O
acetylcholine	O
from	O
binding	O
with	O
muscarinic	O
receptors	O
,	O
which	O
reduces	O
the	O
pesticide	O
's	O
impact	O
.	O

It	O
has	O
structural	O
and	O
pharmacodynamic	O
properties	O
similar	O
to	O
the	O
drugs	O
mescaline	other-medical
and	O
2C-T-2	other-medical
.	O

Half	O
of	O
all	O
``	O
S.	O
aureus	O
``	O
infections	O
in	O
the	O
US	O
are	O
resistant	O
to	O
penicillin	other-medical
,	O
methicillin	other-medical
,	O
tetracycline	other-medical
and	O
erythromycin	other-medical
.	O

Antihistamine	O
tablets	O
may	O
be	O
prescribed	O
to	O
provide	O
relief	O
from	O
the	O
itch	O
,	O
although	O
they	O
are	O
generally	O
considered	O
much	O
less	O
effective	O
than	O
corticosteroid	other-medical
treatments	other-medical
,	O
and	O
may	O
decrease	O
itching	O
through	O
blocking	other-medical
histamine	other-medical
release	O
as	O
well	O
as	O
improving	O
sleep	O
quality	O
.	O

Thus	O
,	O
a	O
depressed	O
alpha	O
angle	O
could	O
be	O
treated	O
with	O
cryoprecipitate	other-medical
.	O

Other	O
NSAIDS	other-medical
should	O
be	O
used	O
only	O
in	O
cases	O
refractory	O
to	O
aspirin	O
.	O

Large	O
volume	O
pumps	O
can	O
pump	O
fluid	O
replacement	O
such	O
as	O
saline	O
solution	O
,	O
medications	O
such	O
as	O
antibiotics	other-medical
or	O
nutrient	other-medical
solutions	other-medical
large	O
enough	O
to	O
feed	O
a	O
patient	O
.	O

Their	O
simulations	O
suggested	O
that	O
drug	O
resistance	O
may	O
arise	O
from	O
disruption	O
of	O
the	O
binding	O
process	O
due	O
to	O
electrostatic	O
attraction	O
in	O
charged	O
neuraminidase	O
pathways	O
,	O
in	O
addition	O
to	O
disruption	O
of	O
Tamiflu	other-medical
's	other-medical
pentyl	O
sidegroup	O
.	O

Ether	other-medical
causes	O
a	O
very	O
long	O
excitation	O
stage	O
prior	O
to	O
blacking	O
out	O
.	O

Like	O
other	O
statins	O
,	O
atorvastatin	other-medical
also	O
reduces	O
blood	O
levels	O
of	O
triglycerides	O
and	O
slightly	O
increases	O
levels	O
of	O
HDL-cholesterol	O
.	O

There	O
are	O
no	O
studies	O
suggesting	O
that	O
H2	other-medical
antagonists	other-medical
improve	O
the	O
healing	O
of	O
ulcers	O
already	O
present	O
.	O

Diphenhydramine	O
is	O
the	O
primary	O
constituent	O
of	O
dimenhydrinate	other-medical
and	O
dictates	O
the	O
primary	O
effect	O
.	O

This	O
is	O
likely	O
due	O
to	O
venlafaxine	other-medical
's	O
relatively	O
short	O
half-life	O
and	O
therefore	O
rapid	O
clearance	O
upon	O
discontinuation	O
.	O

In	O
2018	O
and	O
in	O
2019	O
,	O
the	O
U.S	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
found	O
traces	O
of	O
NDMA	O
and	O
NDEA	O
impurities	O
in	O
the	O
angiotensin	O
II	O
receptor	O
blocker	O
(	O
ARB	other-medical
)	O
drug	O
products	O
valsartan	other-medical
,	O
losartan	other-medical
,	O
and	O
irbesartan	other-medical
.	O

Unlike	O
morphine	other-medical
,	O
oxycodone	other-medical
lacks	O
immunosuppressive	O
activity	O
(	O
measured	O
by	O
natural	O
killer	O
cell	O
activity	O
and	O
interleukin	O
2	O
production	O
``	O
in	O
vitro	O
''	O
)	O
;	O
the	O
clinical	O
relevance	O
of	O
this	O
has	O
not	O
been	O
clarified	O
.	O

The	O
cutaneous	O
symptoms	O
vary	O
,	O
and	O
range	O
from	O
rashes	other-medical
and	O
noduli	other-medical
(	O
small	O
bumps	O
)	O
to	O
erythema	other-medical
nodosum	other-medical
,	O
granuloma	other-medical
annulare	other-medical
,	O
or	O
lupus	other-medical
pernio	other-medical
.	O

For	O
example	O
,	O
the	O
Hsp90	other-medical
inhibitor	other-medical
geldanamycin	other-medical
has	O
been	O
used	O
as	O
an	O
anti-	O
tumor	O
agent	O
.	O

Other	O
brand	O
names	O
of	O
MPA	other-medical
formulated	O
alone	O
include	O
Farlutal	other-medical
and	O
Sayana	other-medical
for	O
clinical	O
use	O
and	O
Depo-Promone	other-medical
,	O
Perlutex	other-medical
,	O
Promone-E	other-medical
,	O
and	O
Veramix	other-medical
for	O
veterinary	O
use	O
.	O

Increasing	O
prescription	O
of	O
opioids	other-medical
fueled	O
a	O
growing	O
black	O
market	O
for	O
heroin	other-medical
.	O

On	O
15	O
October	O
2010	O
,	O
the	O
multi-national	O
Reckitt	O
Benckiser	O
was	O
fined	O
£	O
10	O
million	O
for	O
rigging	O
the	O
market	O
for	O
Gaviscon	other-medical
following	O
an	O
investigation	O
by	O
Jones	O
and	O
Martin	O
Shankleman	O
.	O

When	O
international	O
vaccine	O
care	O
standards	O
were	O
being	O
designed	O
in	O
the	O
1970s	O
,	O
the	O
manuals	O
typically	O
generalized	O
from	O
the	O
needs	O
of	O
care	O
for	O
the	O
oral	other-medical
polio	other-medical
vaccine	other-medical
since	O
that	O
was	O
the	O
most	O
delicate	O
vaccine	O
in	O
wide	O
use	O
.	O

PPIs	other-medical
have	O
a	O
half-life	O
in	O
human	O
blood	O
plasma	O
of	O
only	O
60–90	O
minutes	O
,	O
but	O
because	O
they	O
covalently	O
bind	O
to	O
the	O
pump	O
,	O
the	O
half-life	O
of	O
their	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
lasts	O
an	O
estimated	O
24	O
hours	O
.	O

A	O
Cochrane	O
review	O
of	O
clinical	O
research	O
noted	O
that	O
devil	other-medical
's	other-medical
claw	other-medical
seems	O
to	O
reduce	O
low	O
back	O
pain	O
more	O
than	O
placebo	other-medical
,	O
although	O
evidence	O
was	O
of	O
moderate	O
quality	O
at	O
best	O
.	O

Metoclopramide	other-medical
has	O
long	O
been	O
used	O
in	O
all	O
stages	O
of	O
pregnancy	O
with	O
no	O
evidence	O
of	O
harm	O
to	O
the	O
mother	O
or	O
unborn	O
baby	O
.	O

Conservative	O
lobbyist	O
groups	O
with	O
ties	O
to	O
various	O
religious	O
powers	O
such	O
as	O
the	O
Vatican	O
,	O
originally	O
were	O
promoting	O
limiting	O
healthcare	O
coverage	O
of	O
items	O
such	O
as	O
birth	other-medical
control	other-medical
,	O
and	O
once	O
RU-486	other-medical
was	O
made	O
public	O
knowledge	O
these	O
groups	O
actively	O
worked	O
to	O
threaten	O
Hoechst	O
by	O
claiming	O
they	O
would	O
cause	O
the	O
company	O
financial	O
hardship	O
if	O
they	O
did	O
not	O
cease	O
all	O
activity	O
pertaining	O
to	O
RU-486	other-medical
.	O

Proton-pump	O
inhibitors	O
such	O
as	O
omeprazole	O
and	O
the	O
anticonvulsant	O
valproate	O
have	O
been	O
found	O
to	O
increase	O
the	O
plasma	O
concentrations	O
of	O
methotrexate	O
,	O
as	O
have	O
nephrotoxic	O
agents	O
such	O
as	O
cisplatin	other-medical
,	O
the	O
GI	other-medical
drug	other-medical
colestyramine	other-medical
,	O
and	O
dantrolene	other-medical
.	O

Following	O
the	O
season	O
,	O
Ankiel	O
admitted	O
to	O
using	O
human	other-medical
growth	other-medical
hormone	other-medical
(	O
HGH	other-medical
)	O
,	O
but	O
said	O
he	O
was	O
following	O
doctor	O
's	O
orders	O
.	O

Kanuma	other-medical
is	O
a	O
recombinant	O
form	O
of	O
the	O
natural	O
human	O
LAL	O
enzyme	O
and	O
an	O
enzyme	O
replacement	O
therapy	O
being	O
developed	O
for	O
patients	O
with	O
LAL	O
Deficiency	O
.	O

Bevacizumab	other-medical
was	O
approved	O
in	O
the	O
United	O
States	O
in	O
February	O
2004	O
,	O
for	O
use	O
in	O
metastatic	O
colorectal	O
cancer	O
when	O
used	O
with	O
standard	O
chemotherapy	O
treatment	O
(	O
as	O
first-line	O
treatment	O
)	O
and	O
with	O
5-fluorouracil	other-medical
-based	O
therapy	O
for	O
second-line	O
metastatic	O
colorectal	O
cancer	O
.	O

While	O
many	O
statin	O
medications	O
should	O
be	O
administered	O
at	O
bedtime	O
for	O
optimal	O
effect	O
,	O
atorvastatin	other-medical
can	O
be	O
dosed	O
at	O
any	O
time	O
of	O
day	O
,	O
as	O
long	O
as	O
it	O
is	O
continually	O
dosed	O
once	O
daily	O
at	O
the	O
same	O
time	O
.	O

In	O
a	O
large	O
survey	O
of	O
AERD	O
patients	O
,	O
it	O
was	O
reported	O
that	O
Zyflo	other-medical
(	other-medical
zileuton	other-medical
)	other-medical
was	O
significantly	O
more	O
effective	O
at	O
controlling	O
the	O
symptoms	O
of	O
the	O
disease	O
than	O
Singulair	other-medical
(	other-medical
montelukast	other-medical
)	other-medical
.	O

Her	O
work	O
was	O
instrumental	O
in	O
the	O
introduction	O
of	O
vaccine	O
programmes	O
for	O
Haemophilus	other-medical
influenzae	other-medical
type	other-medical
b	other-medical
and	O
meningococcal	other-medical
A	other-medical
and	other-medical
B	other-medical
.	O

The	O
Philadelphia	other-medical
chromosome	other-medical
was	O
first	O
discovered	O
and	O
described	O
in	O
1959	O
by	O
David	O
Hungerford	O
from	O
Fox	O
Chase	O
Cancer	O
Center	O
(	O
then	O
the	O
Institute	O
for	O
Cancer	O
Research	O
)	O
and	O
Peter	O
Nowell	O
from	O
the	O
University	O
of	O
Pennsylvania	O
School	O
of	O
Medicine	O
,	O
and	O
was	O
named	O
after	O
the	O
city	O
in	O
which	O
both	O
facilities	O
are	O
located	O
.	O

Tretinoin	other-medical
is	O
the	O
least	O
expensive	O
of	O
the	O
topical	other-medical
retinoids	other-medical
and	O
is	O
the	O
most	O
irritating	O
to	O
the	O
skin	O
,	O
whereas	O
adapalene	other-medical
is	O
the	O
least	O
irritating	O
but	O
costs	O
significantly	O
more	O
.	O

It	O
is	O
a	O
less	O
profitable	O
plant	O
with	O
``	O
close	O
to	O
no	O
value	O
to	O
traditional	O
marijuana	other-medical
consumers	O
.	O
''	O

Ketamine	other-medical
is	O
likely	O
to	O
be	O
most	O
beneficial	O
for	O
surgical	O
patients	O
when	O
severe	O
post-operative	O
pain	O
is	O
expected	O
and	O
for	O
opioid-tolerant	O
patients	O
.	O

The	O
only	O
time	O
heparin	other-medical
could	O
be	O
used	O
with	O
pericarditis	O
is	O
with	O
coexisting	O
acute	O
MI	O
,	O
in	O
order	O
to	O
prevent	O
further	O
thrombus	O
formation	O
.	O

There	O
has	O
been	O
suggested	O
that	O
4-MTA	other-medical
because	O
of	O
its	O
slow	O
onset	O
of	O
action	O
,	O
is	O
more	O
dangerous	O
than	O
other	O
designer	O
drugs	O
.	O

In	O
the	O
current	O
version	O
of	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
(	O
DSM-IV-TR	O
)	O
,	O
a	O
paraphilia	other-medical
is	O
not	O
diagnosable	O
as	O
a	O
psychiatric	O
disorder	O
unless	O
it	O
causes	O
distress	O
to	O
the	O
individual	O
or	O
harm	O
to	O
others	O
.	O

Guaifenesin	other-medical
is	O
used	O
to	O
try	O
to	O
help	O
with	O
coughing	O
up	O
thick	O
mucus	O
and	O
is	O
sometimes	O
combined	O
with	O
dextromethorphan	other-medical
,	O
an	O
antitussive	O
(	O
cough	other-medical
suppressant	other-medical
)	O
,	O
such	O
as	O
in	O
Mucinex	other-medical
DM	other-medical
or	O
Robitussin	other-medical
DM	other-medical
.	O

The	O
most	O
common	O
side	O
effects	O
for	O
montelukast	other-medical
are	O
,	O
for	O
example	O
,	O
respiratory	O
infection	O
,	O
fever	O
,	O
headache	O
,	O
cough	O
,	O
abdominal	O
pain	O
,	O
otitis	O
media	O
,	O
rhinorrhea	O
,	O
sinusitis	O
and	O
more	O
.	O

Wright	O
had	O
open	O
heart	O
surgery	O
in	O
1983	O
,	O
spurring	O
an	O
interest	O
in	O
health	O
psychology	O
,	O
especially	O
in	O
the	O
relationship	O
between	O
Type	O
A	O
personality	O
and	O
cardiac	other-medical
rehabilitation	other-medical
.	O

Only	O
a	O
small	O
subset	O
of	O
dementia	O
cases	O
have	O
been	O
found	O
to	O
be	O
reversible	O
with	O
vitamin	other-medical
B12	other-medical
therapy	O
.	O

The	O
use	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
Ibuprofen	other-medical
may	O
help	O
some	O
athletes	O
ski	O
through	O
the	O
discomfort	O
,	O
but	O
rest	O
is	O
ultimately	O
the	O
most	O
effective	O
remedy	O
.	O

The	O
patient	O
may	O
need	O
it	O
monthly	O
(	O
Lupron	other-medical
Depot	other-medical
,	O
Lupron	other-medical
Depot-PED	other-medical
)	O
or	O
every	O
3	O
,	O
4	O
or	O
6	O
months	O
(	O
Lupron	other-medical
Depot	other-medical
-3	O
month	O
,	O
Lupron	other-medical
Depot-PED	other-medical
-3	O
month	O
,	O
Lupron	other-medical
Depot	other-medical
-4	O
month	O
,	O
Lupron	other-medical
Depot	other-medical
-6	O
month	O
)	O
.	O

It	O
has	O
been	O
posited	O
that	O
Lavrenty	O
Beria	O
,	O
Nikita	O
Khrushchev	O
,	O
and	O
others	O
conspired	O
to	O
use	O
warfarin	other-medical
to	O
poison	O
Soviet	O
leader	O
Joseph	O
Stalin	O
.	O

The	O
atypical	other-medical
antidepressants	other-medical
mirtazapine	other-medical
and	O
bupropion	other-medical
have	O
been	O
studied	O
for	O
the	O
treatment	O
of	O
social	O
anxiety	O
disorder	O
,	O
and	O
rendered	O
mixed	O
results	O
.	O

An	O
antihistamine	other-medical
such	O
as	O
diphenhydramine	other-medical
may	O
be	O
prescribed	O
.	O

Taking	O
it	O
with	O
vitamin	other-medical
C	other-medical
has	O
been	O
investigated	O
as	O
a	O
method	O
of	O
protecting	O
the	O
stomach	O
lining	O
.	O

Beal	O
also	O
continued	O
to	O
crusade	O
for	O
the	O
use	O
of	O
Ibogaine	other-medical
to	O
treat	O
heroin	O
addicts	O
.	O

P28GST	other-medical
is	O
thus	O
a	O
promising	O
potential	O
therapeutic	O
for	O
treating	O
inflammatory	O
bowel	O
diseases	O
like	O
Crohn	O
’	O
s	O
disease	O
and	O
ulcerative	O
colitis	O
.	O

Criteria	O
for	O
diagnosis	O
of	O
gestational	O
diabetes	O
,	O
using	O
the	O
100	O
gram	O
Glucose	other-medical
Tolerance	other-medical
Test	other-medical
,	O
according	O
to	O
Carpenter	O
and	O
Coustan	O
:	O

They	O
may	O
be	O
hyperplastic	other-medical
or	O
tumorous	other-medical
,	O
but	O
only	O
a	O
small	O
percentage	O
of	O
thyroid	other-medical
tumors	other-medical
are	O
malignant	O
.	O

Another	O
patient	O
,	O
in	O
whom	O
POIS	O
was	O
suspected	O
to	O
be	O
caused	O
by	O
cytokine	O
release	O
,	O
was	O
successfully	O
treated	O
with	O
nonsteroidal	other-medical
anti-inflammatory	other-medical
drugs	other-medical
(	O
NSAIDs	other-medical
)	O
just	O
prior	O
to	O
and	O
for	O
a	O
day	O
or	O
two	O
after	O
ejaculation	O
.	O

Oxacillin	other-medical
(	O
trade	O
name	O
Bactocill	other-medical
)	O
is	O
a	O
narrow-spectrum	other-medical
beta-lactam	other-medical
antibiotic	other-medical
of	other-medical
the	other-medical
penicillin	other-medical
class	O
developed	O
by	O
Beecham	O
.	O

The	O
Neuropsychiatric	other-medical
EEG-Based	other-medical
Assessment	other-medical
Aid	other-medical
(	O
NEBA	other-medical
)	O
System	O
a	O
device	O
used	O
to	O
measure	O
the	O
Theta-to-Beta	O
ratio	O
was	O
approved	O
as	O
a	O
tool	O
to	O
assist	O
in	O
diagnosis	O
of	O
ADHD	O
on	O
July	O
15	O
,	O
2013	O
.	O

It	O
is	O
the	O
main	O
road	O
that	O
gives	O
access	O
to	O
the	O
Jodrell	other-medical
Bank	other-medical
Observatory	other-medical
and	O
the	O
Quinta	other-medical
Arboretum	other-medical
,	O
planted	O
by	O
Sir	O
Bernard	O
Lovell	O
in	O
1948	O
.	O

This	O
drug	O
is	O
commonly	O
misused	O
by	O
college	O
students	O
as	O
a	O
``	O
study	O
drug	O
,	O
''	O
although	O
research	O
suggests	O
that	O
stimulants	other-medical
are	O
more	O
efficient	O
at	O
correcting	O
shortfalls	O
than	O
enhancing	O
performance	O
.	O

Many	O
studies	O
have	O
found	O
that	O
tolerance	O
develops	O
to	O
the	O
anticonvulsant	O
properties	O
of	O
clonazepam	other-medical
with	O
chronic	O
use	O
,	O
which	O
limits	O
its	O
long-term	O
effectiveness	O
as	O
an	O
anticonvulsant	O
.	O

Snakebite	O
envenomation	O
can	O
cause	O
local	O
tissue	O
damage	O
,	O
with	O
edema	other-medical
,	O
hemorrhage	other-medical
,	O
myonecrosis	other-medical
,	O
and	O
systemic	other-medical
toxic	other-medical
responses	other-medical
,	O
including	O
organ	O
failure	O
.	O

On	O
January	O
25	O
,	O
2011	O
,	O
the	O
FDA	O
approved	O
over-the-counter	O
sales	O
of	O
fexofenadine	other-medical
in	O
the	O
United	O
States	O
,	O
and	O
Sanofi	O
Aventis	O
'	O
version	O
became	O
available	O
on	O
March	O
4	O
,	O
2011	O
.	O

Nefiracetam	other-medical
is	O
able	O
to	O
reverse	O
the	O
amnesia	O
caused	O
by	O
the	O
GABAA	O
receptor	O
antagonists	O
picrotoxin	O
and	O
bicuculline	O
in	O
mice	O
,	O
although	O
it	O
failed	O
to	O
prevent	O
seizures	O
induced	O
by	O
these	O
drugs	O
.	O

Vigabatrin	other-medical
is	O
a	O
drug	O
that	O
is	O
irreparably	O
suppresses	O
GABA	O
transaminase	O
that	O
causes	O
increased	O
amount	O
of	O
GABA	O
in	O
the	O
brain	O
.	O

Neuraminidase	other-medical
inhibitors	other-medical
(	O
NAIs	other-medical
)	O
are	O
a	O
class	O
of	O
drugs	O
which	O
block	O
the	O
neuraminidase	O
enzyme	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
explore	O
which	O
opioid	other-medical
drugs	O
are	O
most	O
effective	O
in	O
implementing	O
in	O
an	O
opioid	other-medical
rotation	O
,	O
but	O
have	O
so	O
far	O
found	O
no	O
difference	O
in	O
efficacy	O
between	O
opioid	other-medical
drugs	O
like	O
methadone	other-medical
and	O
fentanyl	other-medical
in	O
cancer	O
patients	O
.	O

Dialysis	other-medical
is	O
seen	O
only	O
as	O
a	O
temporary	O
measure	O
for	O
children	O
compared	O
with	O
renal	other-medical
transplantation	other-medical
because	O
this	O
enables	O
the	O
best	O
chance	O
of	O
rehabilitation	O
in	O
terms	O
of	O
educational	O
and	O
psychosocial	O
functioning	O
.	O

Cambodia	O
remains	O
a	O
major	O
supplier	O
of	O
cannabis	other-medical
to	O
countries	O
in	O
East	O
and	O
Southeast	O
Asia	O
and	O
other	O
parts	O
of	O
the	O
world	O
.	O

In	O
the	O
2000	O
European	O
APL	O
study	O
,	O
the	O
2-year	O
relapse	O
rate	O
for	O
those	O
that	O
did	O
not	O
receive	O
consolidation	O
chemotherapy	O
(	O
ATRA	other-medical
not	O
included	O
)	O
therapy	O
was	O
27	O
%	O
compared	O
to	O
11	O
%	O
in	O
those	O
that	O
did	O
receive	O
consolidation	O
therapy	O
(	O
p	O
&	O
lt	O
;	O
0.01	O
)	O
.	O

Allergan	O
,	O
the	O
manufacturer	O
of	O
Botox	other-medical
,	O
agreed	O
to	O
a	O
$	O
600	O
million	O
settlement	O
to	O
resolve	O
all	O
civil	O
and	O
criminal	O
liability	O
surrounding	O
the	O
promotion	O
of	O
Botox	other-medical
for	O
treatment	O
of	O
chronic	O
migraines	O
before	O
FDA	O
review	O
or	O
approval	O
of	O
the	O
drug	O
for	O
such	O
use	O
.	O

Vardenafil	other-medical
's	O
relatively	O
short	O
effective	O
time	O
is	O
comparable	O
to	O
but	O
somewhat	O
longer	O
than	O
sildenafil	other-medical
's	O
.	O

Imatinib	other-medical
is	O
used	O
to	O
treat	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
and	O
a	O
number	O
of	O
other	O
malignancies	O
.	O

Ativan	other-medical
would	O
cause	O
the	O
patient	O
to	O
have	O
slurred	O
speech	O
but	O
propofol	other-medical
would	O
not	O
,	O
it	O
is	O
``	O
quick	O
onset	O
,	O
quick	O
offset	O
.	O
''	O

A	O
subsequent	O
double-blind	O
RCT	O
,	O
that	O
treated	O
patients	O
who	O
self-poisoned	O
,	O
found	O
no	O
benefit	O
of	O
pralidoxime	other-medical
,	O
including	O
specifically	O
in	O
chlorpyrifos	O
patients	O
.	O

It	O
is	O
a	O
combination	O
of	O
lisinopril	other-medical
an	O
ACE	O
inhibitor	O
with	O
amlodipine	other-medical
a	O
calcium	O
channel	O
blocker	O
.	O

Polythiazide	other-medical
is	O
a	O
thiazide	other-medical
diuretic	other-medical
.	O

Aticaprant	other-medical
is	O
a	O
potent	O
,	O
selective	O
,	O
short-acting	O
(	O
i.e.	O
,	O
non-	O
''	O
inactivating	O
''	O
)	O
antagonist	O
of	O
the	O
KOR	O
(	O
Ki	O
=	O
0.81	O
nM	O
vs.	O
24.0	O
nM	O
and	O
155	O
nM	O
for	O
the	O
μ-opioid	O
receptor	O
(	O
MOR	O
)	O
and	O
δ-opioid	O
receptor	O
(	O
DOR	O
)	O
,	O
respectively	O
;	O
approximately	O
30-fold	O
selectivity	O
for	O
the	O
KOR	O
)	O
.	O

Metoclopramide	other-medical
is	O
excreted	O
into	O
milk	O
.	O

The	O
disease	O
presents	O
as	O
a	O
bleeding	other-medical
disorder	other-medical
with	O
easy	other-medical
bruising	other-medical
,	O
mucosal	other-medical
bleeding	other-medical
,	O
such	O
as	O
nosebleeds	other-medical
,	O
and	O
mild	O
to	O
severe	other-medical
anemia	other-medical
.	O

Carbapenem-resistant	other-medical
Enterobacteriaceae	other-medical
(	O
CRE	other-medical
)	O
have	O
been	O
defined	O
as	O
carbapenem	O
-nonsusceptible	O
and	O
extended-spectrum	O
cephalosporin-resistant	O
``	O
Escherichia	O
coli	O
,	O
Enterobacter	O
aerogenes	O
,	O
Enterobacter	O
cloacae	O
``	O
complex	O
,	O
``	O
Klebsiella	O
pneumoniae	O
``	O
,	O
or	O
``	O
Klebsiella	O
oxytoca	O
``	O
.	O

He	O
is	O
also	O
credited	O
with	O
discovering	O
and	O
publishing	O
the	O
physiological	O
effects	O
of	O
amphetamine	other-medical
and	O
methylenedioxyamphetamine	other-medical
(	O
MDA	other-medical
)	O
.	O

See	O
the	O
latest	O
package	O
insert	O
for	O
ofloxacin	other-medical
for	O
additional	O
details	O
.	O

The	O
Demon	O
Under	O
the	O
Microscope	O
:	O
From	O
Battlefield	O
Hospitals	O
to	O
Nazi	O
Labs	O
,	O
One	O
Doctor	O
's	O
Heroic	O
Search	O
for	O
the	O
World	O
's	O
First	O
Miracle	O
Drug	O
is	O
a	O
2006	O
nonfiction	O
book	O
about	O
the	O
discovery	O
of	O
Prontosil	other-medical
,	O
the	O
first	O
commercially	O
available	O
antibacterial	other-medical
antibiotic	other-medical
and	O
sulfanilamide	other-medical
,	O
the	O
second	O
commercial	O
antibiotic	other-medical
.	O

Severe	O
allergic	O
reactions	O
(	O
anaphalaxis	O
)	O
may	O
require	O
treatment	O
with	O
an	O
epinephrine	other-medical
pen	other-medical
,	O
which	O
is	O
an	O
injection	O
device	O
designed	O
to	O
be	O
used	O
by	O
a	O
non-healthcare	O
professional	O
when	O
emergency	O
treatment	O
is	O
warranted	O
.	O

Ibuprofen	other-medical
is	O
a	O
weaker	O
anti-inflammatory	O
agent	O
than	O
other	O
NSAIDs	other-medical
.	O

Small	O
,	O
asymptomatic	O
nodules	other-medical
are	O
common	O
,	O
and	O
often	O
go	O
unnoticed	O
.	O

The	O
biosynthesis	O
of	O
tacrolimus	other-medical
is	O
hybrid	O
synthesis	O
of	O
both	O
type	O
1	O
polyketide	O
synthases	O
(	O
PKS	O
1	O
)	O
and	O
nonribosomal	O
peptide	O
synthases	O
(	O
NRPS	O
)	O
.	O

Nguyen	O
also	O
testified	O
that	O
Murray	O
never	O
mentioned	O
propofol	other-medical
.	O

Methylprednisolon	other-medical
e	O
dosage	O
and	O
administration	O
for	O
these	O
diseases	O
is	O
highly	O
variable	O
due	O
to	O
varied	O
pathophysiology	O
between	O
the	O
diseases	O
and	O
within	O
patients	O
diagnosed	O
with	O
a	O
given	O
disease	O
.	O

ACC	other-medical
is	O
roughly	O
40	O
%	O
more	O
bioavailable	O
than	O
crystalline	O
calcium	O
carbonate	O
.	O

Consuming	O
an	O
adult	O
dose	O
of	O
10	O
oz	O
of	O
laxative	other-medical
syrup	other-medical
(	O
@	O
1.745	O
g/oz	O
)	O
implies	O
a	O
consumption	O
of	O
17.45	O
g	O
o	O
f	O
magnesium	O
citrate	O
in	O
a	O
single	O
10	O
oz	O
dose	O
resulting	O
in	O
a	O
consumption	O
of	O
approximately	O
2.0	O
g	O
of	O
elemental	O
magnesium	O
per	O
single	O
dose	O
.	O

While	O
all	O
opioids	other-medical
cause	O
constipation	O
,	O
there	O
are	O
some	O
differences	O
between	O
drugs	O
,	O
with	O
studies	O
suggesting	O
tramadol	other-medical
,	O
tapentadol	other-medical
,	O
methadone	other-medical
and	O
fentanyl	other-medical
may	O
cause	O
relatively	O
less	O
constipation	O
,	O
while	O
with	O
codeine	other-medical
,	O
morphine	other-medical
,	O
oxycodone	other-medical
or	O
hydromorphone	other-medical
constipation	other-medical
may	O
be	O
comparatively	O
more	O
severe	O
.	O

The	O
Chinese	O
herbal	O
medicine	O
long-dan-xie-gan-tan	other-medical
(	O
LDGXT	other-medical
)	O
has	O
also	O
been	O
shown	O
to	O
have	O
a	O
similar	O
anti	O
inflammatory	O
effect	O
,	O
and	O
in	O
mild	O
cases	O
may	O
be	O
used	O
alone	O
to	O
relieve	O
symptoms	O
while	O
infection	O
resolves	O
itself	O
.	O

An	O
additional	O
aim	O
of	O
the	O
study	O
was	O
to	O
further	O
evaluate	O
the	O
cardiovascular	O
safety	O
of	O
rofecoxib	other-medical
.	O

Second-line	O
therapy	O
for	O
adults	O
is	O
phenytoin	other-medical
or	O
fosphenytoin	other-medical
and	O
phenobarbital	other-medical
for	O
children	O
.	O

In	O
2002	O
,	O
Swedish	O
Covenant	O
Hospital	O
completed	O
its	O
hyperbaric	other-medical
oxygen	other-medical
chambers	other-medical
to	O
help	O
wounds	O
heal	O
seven	O
days	O
faster	O
than	O
the	O
national	O
average	O
.	O

It	O
is	O
the	O
only	O
TCA	other-medical
with	O
a	O
dibenzoxepin	O
ring	O
system	O
to	O
have	O
been	O
marketed	O
.	O

Approximately	O
10	O
percent	O
of	O
testosterone	other-medical
enanthate	other-medical
will	O
be	O
converted	O
to	O
dihydrotestosterone	O
in	O
normal	O
men	O
.	O

The	O
residual	O
fungus	O
is	O
treated	O
with	O
topical	O
antifungals	O
,	O
usually	O
either	O
1	O
%	O
tolnaftate	other-medical
(	O
Tinactin	other-medical
)	O
or	O
1	O
%	O
chlortrimazole	other-medical
(	O
Lotrimin	other-medical
)	O
solution	O
,	O
10	O
drops	O
twice	O
a	O
day	O
for	O
3	O
days	O
.	O

Treatment	O
options	O
include	O
eye	O
exercises	O
,	O
wearing	O
an	O
eye	O
patch	O
on	O
alternative	O
eyes	O
,	O
prism	O
correction	O
,	O
and	O
in	O
more	O
extreme	O
situations	O
,	O
surgery	O
or	O
botulinum	other-medical
toxin	other-medical
.	O

H2	other-medical
antagonists	other-medical
are	O
cheaper	O
and	O
will	O
decrease	O
stomach	O
acid	O
production	O
but	O
require	O
more	O
frequent	O
administration	O
compared	O
to	O
PPIs	other-medical
,	O
usually	O
every	O
eight	O
hours	O
.	O

The	O
increased	O
iron	O
stores	O
in	O
the	O
organs	O
involved	O
,	O
especially	O
in	O
the	O
liver	O
and	O
pancreas	O
,	O
result	O
in	O
characteristic	O
findings	O
on	O
unenhanced	O
CT	other-medical
and	O
a	O
decreased	O
signal	O
intensity	O
in	O
MRI	other-medical
scans	O
.	O

Freudians	O
claimed	O
that	O
premature	O
ejaculation	O
could	O
be	O
cured	O
using	O
psychoanalysis	other-medical
.	O

Tamoxifen	other-medical
has	O
been	O
used	O
effectively	O
to	O
improve	O
blood	O
flow	O
,	O
reduce	O
uterine	O
contractility	O
and	O
pain	O
in	O
dysmenorrhea	O
patients	O
.	O

If	O
a	O
malignant	O
neoplastic	O
chylothorax	O
is	O
present	O
,	O
then	O
treatment	O
with	O
radiotherapy	other-medical
and/or	O
chemotherapy	other-medical
is	O
warranted	O
.	O

Doxepin	other-medical
is	O
a	O
tricyclic	O
compound	O
,	O
specifically	O
a	O
dibenzoxepin	O
,	O
and	O
possesses	O
three	O
rings	O
fused	O
together	O
with	O
a	O
side	O
chain	O
attached	O
in	O
its	O
chemical	O
structure	O
.	O

The	O
crew	O
conducted	O
the	O
first	O
intravenous	other-medical
saline	other-medical
solution	O
injection	O
in	O
space	O
as	O
part	O
of	O
an	O
experiment	O
to	O
study	O
the	O
human	O
body	O
's	O
response	O
to	O
direct	O
fluid	O
replacement	O
as	O
a	O
countermeasure	O
for	O
amounts	O
lost	O
during	O
space	O
flight	O
.	O

Nystatin	other-medical
(	O
``	O
Streptomyces	other-medical
noursei	other-medical
``	O
)	O
,	O
amphotericin	other-medical
B	other-medical
(	O
``	O
Streptomyces	other-medical
nodosus	other-medical
``	O
)	O
,	O
and	O
natamycin	other-medical
(	O
``	O
Streptomyces	other-medical
natalensis	other-medical
``	O
)	O
are	O
antifungals	O
isolated	O
from	O
``	O
Streptomyces	O
``	O
.	O

The	O
MHA-TP	other-medical
is	O
used	O
to	O
confirm	O
a	O
syphilis	O
infection	O
after	O
another	O
method	O
tests	O
positive	O
for	O
the	O
syphilis	O
bacteria	O
.	O

Artemether	other-medical
has	O
been	O
demonstrated	O
``	O
in	O
vitro	O
''	O
to	O
be	O
equally	O
effective	O
.	O

Mary	O
Ellen	O
Beck	O
Wohl	O
was	O
chief	O
of	O
the	O
respiratory	other-medical
diseases	O
division	O
at	O
Children	O
's	O
Hospital	O
Boston	O
(	O
a	O
teaching	O
hospital	O
of	O
Harvard	O
Medical	O
School	O
)	O
,	O
and	O
served	O
as	O
associate	O
director	O
of	O
the	O
general	O
clinical	O
research	O
center	O
until	O
a	O
few	O
years	O
before	O
her	O
death	O
in	O
November	O
2009	O
.	O

It	O
may	O
have	O
potential	O
as	O
a	O
broad	O
spectrum	O
antibiotic	other-medical
,	O
as	O
demonstrated	O
in	O
tests	O
against	O
``	O
Staphylococcus	other-medical
aureus	other-medical
``	O
,	O
``	O
Bacillus	other-medical
subtilis	other-medical
``	O
,	O
``	O
Pseudomonas	other-medical
aeruginosa	other-medical
``	O
,	O
and	O
``	O
Escherichia	other-medical
coli	other-medical
``	O
.	O

A	O
follow-on	O
drug	O
to	O
Inotersen	other-medical
is	O
being	O
developed	O
by	O
Ionis	O
Pharmaceuticals	O
and	O
under	O
license	O
to	O
Akcea	O
Therapeutics	O
for	O
hereditary	O
transthyretin-mediated	O
amyloidosis	O
.	O

In	O
March	O
2010	O
Health	O
Canada	O
advised	O
the	O
public	O
that	O
illegal	O
``	O
Herbal	O
Diet	O
Natural	O
``	O
had	O
been	O
found	O
on	O
the	O
market	O
,	O
containing	O
sibutramine	other-medical
,	O
which	O
is	O
a	O
prescription	O
drug	O
in	O
Canada	O
,	O
without	O
listing	O
sibutramine	other-medical
as	O
an	O
ingredient	O
.	O

People	O
who	O
have	O
either	O
type	O
of	O
diabetes	O
are	O
at	O
risk	O
for	O
low	other-medical
and	other-medical
high	other-medical
blood	other-medical
sugar	other-medical
,	O
with	O
potentially	O
severe	O
consequences	O
.	O

In	O
January	O
1940	O
Seddon	O
was	O
appointed	O
to	O
the	O
Nuffield	other-medical
Chair	other-medical
of	other-medical
Orthopaedic	other-medical
Surgery	other-medical
at	O
the	O
University	O
of	O
Oxford	O
.	O

It	O
is	O
also	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
chemotherapeutic	O
drugs	O
5-fluorouracil	other-medical
and	O
tegafur	other-medical
.	O

Dressler	O
syndrome	O
is	O
best	O
treated	O
with	O
high	O
dose	O
aspirin	other-medical
.	O

She	O
also	O
likened	O
his	O
calm	O
political	O
style	O
and	O
persona	O
to	O
the	O
calming	O
effect	O
of	O
Valium	other-medical
,	O
telling	O
a	O
reporter	O
,	O
``	O
If	O
you	O
chopped	O
(	O
him	O
)	O
into	O
little	O
pieces	O
,	O
you	O
could	O
sell	O
him	O
as	O
Valium	other-medical
tablets	O
.	O
''	O

This	O
includes	O
epinephrine	other-medical
,	O
which	O
when	O
used	O
to	O
treat	O
anaphylaxis	O
must	O
work	O
as	O
soon	O
as	O
possible	O
.	O

GHB	O
is	O
the	O
active	O
ingredient	O
of	O
the	O
prescription	O
medication	O
sodium	other-medical
oxybate	other-medical
(	O
Xyrem	other-medical
)	O
.	O

Testosterone	other-medical
enanthate	other-medical
can	O
also	O
be	O
converted	O
to	O
estradiol	O
by	O
aromatase	O
,	O
which	O
may	O
lead	O
to	O
gynecomastia	O
in	O
males	O
.	O

Regarding	O
the	O
incident	O
,	O
DeLong	O
stated	O
that	O
``	O
You	O
can	O
thank	O
the	O
Tylenol	other-medical
killer	O
for	O
the	O
fact	O
that	O
it	O
now	O
takes	O
a	O
blow	O
torch	O
to	O
get	O
into	O
a	O
bottle	O
of	O
Tylenol	other-medical
.	O
''	O

Pralidoxime	other-medical
is	O
intended	O
to	O
reactivate	O
acetylcholinesterase	O
,	O
but	O
the	O
benefit	O
of	O
oxime	O
treatment	O
is	O
questioned	O
.	O

Recent	O
challenges	O
in	O
drug	O
testing	O
include	O
the	O
development	O
of	O
effective	O
regulatory	O
methods	O
for	O
the	O
newer	O
hormonal	O
products	O
such	O
as	O
the	O
various	O
human	other-medical
recombinant	other-medical
erythropoietin	other-medical
products	other-medical
and	O
variants	O
and	O
growth	other-medical
hormones	other-medical
.	O

Pharmacologically	O
,	O
it	O
is	O
of	O
interest	O
as	O
an	O
acetylcholinesterase	other-medical
inhibitor	other-medical
and	O
accordingly	O
as	O
possibly	O
relevant	O
to	O
Alzheimer	O
's	O
disease	O
.	O

Doxorubicin	other-medical
is	O
loaded	O
into	O
the	O
liposomes	O
just	O
before	O
administration	O
to	O
patients	O
with	O
a	O
maximum	O
single	O
dose	O
of	O
75	O
mg/m2	O
every	O
3	O
weeks	O
.	O

Unlike	O
for	O
egg	O
allergy	O
,	O
for	O
which	O
there	O
is	O
active	O
research	O
on	O
trying	O
oral	other-medical
immunotherapy	other-medical
(	O
OIT	other-medical
)	O
to	O
desensitize	O
people	O
to	O
egg	O
allergens	O
,	O
a	O
2015	O
review	O
mentioned	O
that	O
there	O
are	O
no	O
published	O
clinical	O
trials	O
evaluating	O
oral	other-medical
immunotherapy	other-medical
for	O
fish	O
allergy	O
.	O

Adam	O
Dicker	O
,	O
an	O
associate	O
professor	O
at	O
Jefferson	O
Medical	O
College	O
of	O
Thomas	O
Jefferson	O
University	O
in	O
Philadelphia	O
,	O
supports	O
that	O
chemotherapy	other-medical
is	O
often	O
used	O
in	O
the	O
highest	O
possible	O
doses	O
.	O

However	O
,	O
people	O
can	O
also	O
combine	O
ezetimibe	other-medical
with	O
either	O
simvastatin	other-medical
or	O
atorvastatin	other-medical
and	O
other	O
agents	O
on	O
their	O
own	O
,	O
for	O
somewhat	O
similar	O
augmented	O
response	O
rates	O
.	O

Rheumatic	O
fever	O
,	O
since	O
the	O
advent	O
of	O
routine	O
penicillin	other-medical
administration	O
for	O
Strep	O
throat	O
,	O
has	O
become	O
less	O
common	O
in	O
developed	O
countries	O
.	O

In	O
2016	O
Israel	O
's	O
State	O
Comptroller	O
concluded	O
his	O
inquiry	O
into	O
the	O
affair	O
by	O
claiming	O
that	O
injections	O
of	O
Depo-Provera	other-medical
had	O
not	O
been	O
forced	O
on	O
the	O
women	O
by	O
the	O
State	O
of	O
Israel	O
.	O

Cannabicyclohexanol	other-medical
is	O
not	O
listed	O
in	O
the	O
schedules	O
set	O
out	O
by	O
the	O
United	O
Nations	O
'	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
from	O
1961	O
nor	O
their	O
Convention	O
on	O
Psychotropic	O
Substances	O
from	O
1971	O
,	O
so	O
the	O
signatory	O
countries	O
to	O
these	O
international	O
drug	O
control	O
treaties	O
are	O
not	O
required	O
by	O
said	O
treaties	O
to	O
control	O
Cannabicyclohexanol	other-medical
.	O

Flunitrazepam	other-medical
was	O
discovered	O
at	O
Roche	O
as	O
part	O
of	O
the	O
benzodiazepine	O
work	O
led	O
by	O
Leo	O
Sternbach	O
;	O
the	O
patent	O
application	O
was	O
filed	O
in	O
1962	O
and	O
it	O
was	O
first	O
marketed	O
in	O
1974	O
.	O

A	O
brand	O
name	O
for	O
bumetanide	other-medical
is	O
Bumex	other-medical
.	O

Diazepam	other-medical
has	O
been	O
studied	O
as	O
an	O
anti-convulsive	O
on	O
the	O
GABA	O
system	O
,	O
and	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
anisatin	O
-induced	O
convulsions	O
.	O

Some	O
reviewers	O
recommended	O
rosiglitazone	other-medical
be	O
taken	O
off	O
the	O
market	O
,	O
but	O
an	O
FDA	O
panel	O
disagreed	O
,	O
and	O
it	O
remains	O
available	O
in	O
the	O
U.S	O
.	O
From	O
November	O
2011	O
until	O
November	O
2013	O
,	O
the	O
federal	O
government	O
did	O
not	O
allow	O
Avandia	other-medical
to	O
be	O
sold	O
without	O
a	O
prescription	O
from	O
a	O
certified	O
doctor	O
;	O
moreover	O
,	O
patients	O
were	O
required	O
to	O
be	O
informed	O
of	O
the	O
risks	O
associated	O
with	O
its	O
use	O
,	O
and	O
the	O
drug	O
had	O
to	O
be	O
purchased	O
by	O
mail	O
order	O
through	O
specified	O
pharmacies	O
.	O

Fluoxetine	other-medical
was	O
developed	O
at	O
Eli	O
Lilly	O
and	O
Company	O
in	O
the	O
early	O
1970s	O
by	O
Bryan	O
Molloy	O
,	O
Klaus	O
Schmiegel	O
,	O
David	O
T.	O
Wong	O
and	O
others	O
.	O

After	O
residency	O
in	O
Pediatrics	other-medical
at	O
Hokkaido	O
University	O
Hospital	O
,	O
he	O
worked	O
as	O
a	O
pediatrician	other-medical
in	O
Japan	O
for	O
several	O
years	O
.	O

A	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
supported	O
the	O
use	O
of	O
higher	O
doses	O
of	O
pralidoxime	other-medical
rather	O
than	O
lower	O
doses	O
.	O

For	O
the	O
treatment	O
of	O
yeast	O
keratitis	O
,	O
``	O
topical	O
amphotericin	other-medical
B	other-medical
is	O
usually	O
the	O
first	O
choice	O
.	O
''	O

25	O
%	O
of	O
ingested	O
seletracetam	other-medical
is	O
metabolized	O
and	O
excreted	O
unchanged	O
and	O
about	O
53	O
%	O
is	O
excreted	O
in	O
the	O
form	O
of	O
an	O
inactive	O
carboxylic	O
acid	O
metabolite	O
.	O

If	O
use	O
of	O
amitriptyline	other-medical
is	O
warranted	O
,	O
therapeutic	O
drug	O
monitoring	O
is	O
recommended	O
to	O
guide	O
dose	O
adjustments	O
.	O

Itraconazole	other-medical
is	O
given	O
with	O
the	O
steroids	other-medical
,	O
as	O
it	O
is	O
considered	O
to	O
have	O
a	O
``	O
steroid-sparing	O
''	O
effect	O
,	O
causing	O
the	O
steroids	other-medical
to	O
be	O
more	O
effective	O
,	O
allowing	O
a	O
lower	O
dose	O
.	O

Oral	O
colchicine	other-medical
had	O
been	O
used	O
for	O
many	O
years	O
as	O
an	O
unapproved	O
drug	O
with	O
no	O
FDA	O
-approved	O
prescribing	O
information	O
,	O
dosage	O
recommendations	O
,	O
or	O
drug	O
interaction	O
warnings	O
.	O

Long-term	other-medical
chronic	other-medical
dialysis	other-medical
,	O
however	O
,	O
the	O
highest	O
standards	O
should	O
be	O
applied	O
to	O
these	O
children	O
to	O
preserve	O
their	O
future	O
``	O
cardiovascular	O
life	O
''	O
—which	O
might	O
include	O
more	O
dialysis	other-medical
time	O
and	O
on-line	O
hemodiafiltration	O
online	O
hdf	O
with	O
synthetic	O
high	O
flux	O
membranes	O
with	O
the	O
surface	O
area	O
of	O
0.2sq.m	O
to	O
0.8sq.m	O
and	O
blood	O
tubing	O
lines	O
with	O
the	O
low	O
volume	O
yet	O
large	O
blood	O
pump	O
segment	O
of	O
6.4/8.0mm	O
,	O
if	O
we	O
are	O
able	O
to	O
improve	O
on	O
the	O
rather	O
restricted	O
concept	O
of	O
small-solute	other-medical
urea	other-medical
dialysis	other-medical
clearance	O
.	O

A	O
number	O
of	O
the	O
endogenous	O
compounds	O
have	O
been	O
reported	O
to	O
be	O
affected	O
by	O
ofloxacin	other-medical
as	O
inhibitors	O
,	O
alteraters	O
,	O
and	O
depletors	O
.	O

Discontinuation	O
syndrome	O
has	O
been	O
reported	O
to	O
be	O
markedly	O
worse	O
for	O
venlafaxine	other-medical
when	O
compared	O
to	O
other	O
SNRIs	other-medical
.	O

A	O
number	O
of	O
high-profile	O
infant	O
rapes	O
appeared	O
since	O
2001	O
(	O
including	O
the	O
fact	O
that	O
they	O
required	O
extensive	O
reconstructive	other-medical
surgery	other-medical
to	O
rebuild	O
urinary	O
,	O
genital	O
,	O
abdominal	O
,	O
or	O
tracheal	O
systems	O
)	O
.	O

Spirorenone	other-medical
possesses	O
5–8	O
times	O
the	O
antimineralocorticoid	O
activity	O
of	O
spironolactone	other-medical
in	O
animal	O
studies	O
.	O

Levomethorphan	other-medical
is	O
a	O
prodrug	O
to	O
levorphanol	other-medical
,	O
analogously	O
to	O
DXM	other-medical
acting	O
as	O
a	O
prodrug	O
to	O
dextrorphan	other-medical
or	O
codeine	O
behaving	O
as	O
a	O
prodrug	O
to	O
morphine	other-medical
.	O

The	O
variety	O
shows	O
potential	O
for	O
medical	O
usage	O
,	O
especially	O
for	O
those	O
who	O
do	O
not	O
wish	O
to	O
experience	O
the	O
typical	O
high	O
of	O
recreational	O
marijuana	other-medical
use	O
.	O

However	O
,	O
scopolamine	other-medical
has	O
greater	O
effects	O
on	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
than	O
atropine	other-medical
due	O
to	O
its	O
ability	O
to	O
cross	O
the	O
blood–brain	O
barrier	O
.	O

In	O
breast	O
cancer	O
,	O
the	O
acquisition	O
of	O
tamoxifen	other-medical
resistance	O
is	O
another	O
major	O
therapeutic	O
problem	O
.	O

Like	O
NSAIDs	other-medical
and	O
unlike	O
opioid	O
analgesics	O
,	O
paracetamol	other-medical
has	O
not	O
been	O
found	O
to	O
cause	O
euphoria	O
or	O
alter	O
mood	O
although	O
recent	O
research	O
shows	O
some	O
evidence	O
that	O
paracetamol	other-medical
can	O
ease	O
psychological	O
pain	O
.	O

In	O
May	O
2004	O
,	O
at	O
the	O
conclusion	O
of	O
MPP	O
's	O
intensive	O
,	O
three-year	O
lobbying	O
campaign	O
,	O
Vermont	O
became	O
the	O
ninth	O
state	O
to	O
enact	O
a	O
medical	O
marijuana	other-medical
law	O
—	O
and	O
only	O
the	O
second	O
state	O
(	O
after	O
Hawaii	O
)	O
to	O
do	O
so	O
through	O
its	O
legislature	O
,	O
rather	O
than	O
through	O
a	O
ballot	O
initiative	O
.	O

Serotonin-norepinephrine	other-medical
reuptake	other-medical
inhibitors	other-medical
(	O
SNRIs	other-medical
)	O
such	O
as	O
venlafaxine	other-medical
have	O
shown	O
similar	O
effectiveness	O
to	O
the	O
SSRIs	O
.	O

At	O
higher-than-therapeutic	O
doses	O
,	O
atropine	other-medical
and	O
scopolamine	other-medical
cause	O
CNS	O
depression	O
characterized	O
by	O
amnesia	O
,	O
fatigue	O
,	O
and	O
reduction	O
in	O
rapid	O
eye	O
movement	O
sleep	O
.	O

The	O
degree	O
of	O
tolerance	O
is	O
more	O
pronounced	O
with	O
clonazepam	other-medical
than	O
with	O
chlordiazepoxide	other-medical
.	O

Emodepside	other-medical
is	O
an	O
anthelmintic	O
drug	O
that	O
is	O
effective	O
against	O
a	O
number	O
of	O
gastrointestinal	O
nematodes	O
,	O
is	O
licensed	O
for	O
use	O
in	O
cats	O
and	O
belongs	O
to	O
the	O
class	O
of	O
drugs	O
known	O
as	O
the	O
``	O
octadepsipeptides	other-medical
``	O
,	O
a	O
relatively	O
new	O
class	O
of	O
anthelmintic	O
(	O
research	O
into	O
these	O
compounds	O
began	O
in	O
the	O
early	O
1990s	O
)	O
,	O
which	O
are	O
suspected	O
to	O
achieve	O
their	O
anti-parasitic	other-medical
effect	O
by	O
a	O
novel	O
mechanism	O
of	O
action	O
due	O
to	O
their	O
ability	O
to	O
kill	O
nematodes	O
resistant	O
to	O
other	O
anthelmintics	other-medical
.	O

Use	O
is	O
widespread	O
among	O
amphetamine	O
users	O
,	O
with	O
those	O
that	O
use	O
amphetamines	other-medical
and	O
benzodiazepines	other-medical
having	O
greater	O
levels	O
of	O
mental	O
health	O
problems	O
and	O
social	O
deterioration	O
.	O

Though	O
it	O
has	O
affinity	O
for	O
a	O
large	O
number	O
of	O
sites	O
as	O
shown	O
above	O
,	O
at	O
clinical	O
doses	O
rotigotine	other-medical
behaves	O
mostly	O
as	O
a	O
selective	O
D1-like	O
(	O
D1	O
,	O
D5	O
)	O
and	O
D2-like	O
(	O
D2	O
,	O
D3	O
,	O
D4	O
)	O
receptor	O
agonist	O
,	O
with	O
its	O
α2B-adrenergic	O
and	O
5-HT1A	O
activity	O
also	O
possibly	O
having	O
some	O
minor	O
relevance	O
.	O

Precious	O
Blood	O
Hospital	O
offers	O
specialist	O
outpatient	O
and	O
inpatient	O
services	O
in	O
General	other-medical
medicine	other-medical
,	O
Surgery	other-medical
,	O
Obstetrics	other-medical
and	O
Gynaecology	other-medical
,	O
Orthopaedics	other-medical
and	O
Ophthalmology	other-medical
.	O

Chemotherapy	other-medical
can	O
be	O
given	O
as	O
cycles	O
of	O
treatment	O
.	O

In	O
the	O
first	O
trial	O
,	O
42	O
%	O
of	O
subjects	O
in	O
the	O
fluoxetine	other-medical
-treated	O
arm	O
were	O
free	O
of	O
panic	O
attacks	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
vs.	O
28	O
%	O
in	O
the	O
placebo	other-medical
arm	O
.	O

Oseltamivir	other-medical
(	O
Tamiflu	other-medical
)	O
a	O
prodrug	other-medical
,	O
Zanamivir	other-medical
(	O
Relenza	other-medical
)	O
,	O
Laninamivir	other-medical
(	O
Inavir	other-medical
)	O
,	O
and	O
Peramivir	other-medical
belong	O
to	O
this	O
class	O
.	O

Anemia	other-medical
is	O
a	O
condition	O
in	O
which	O
there	O
is	O
an	O
insufficient	O
number	O
of	O
red	O
blood	O
cells	O
to	O
carry	O
adequate	O
levels	O
of	O
oxygen	O
to	O
the	O
body	O
's	O
tissues	O
.	O

For	O
people	O
who	O
have	O
severe	O
congenital	O
protein	O
C	O
deficiency	O
,	O
protein	other-medical
C	other-medical
replacement	other-medical
therapies	other-medical
are	O
available	O
,	O
which	O
is	O
indicated	O
and	O
approved	O
for	O
use	O
in	O
the	O
United	O
States	O
and	O
Europe	O
for	O
the	O
prevention	O
of	O
purpura	O
fulminans	O
.	O

Prior	O
to	O
the	O
1930s	O
naturally	O
occurring	O
stimulants	O
such	O
as	O
camphor	other-medical
and	O
caffeine	other-medical
were	O
utilized	O
in	O
the	O
treatment	O
of	O
barbiturate	other-medical
overdose	O
.	O

Active	O
secondary	O
spermicidal	O
ingredients	O
can	O
include	O
octoxynol-9	other-medical
,	O
benzalkonium	other-medical
chloride	other-medical
and	O
menfegol	other-medical
.	O

In	O
treating	O
high	O
blood	O
pressure	O
,	O
ACE	other-medical
inhibitors	other-medical
are	O
often	O
the	O
first	O
drug	O
choice	O
,	O
particularly	O
when	O
diabetes	O
is	O
present	O
,	O
but	O
age	O
can	O
lead	O
to	O
different	O
choices	O
and	O
it	O
is	O
common	O
to	O
need	O
more	O
than	O
one	O
drug	O
to	O
obtain	O
the	O
desired	O
improvement	O
.	O

Crofelemer	other-medical
(	O
USAN	other-medical
,	O
trade	O
name	O
Mytesi	other-medical
)	O
is	O
a	O
botanical	O
drug	O
for	O
the	O
treatment	O
of	O
diarrhea	O
associated	O
with	O
anti-	O
HIV	O
drugs	O
such	O
as	O
nucleoside	O
analog	O
reverse	O
transcriptase	O
inhibitors	O
and	O
protease	O
inhibitors	O
.	O

Nonoxynol-9	other-medical
is	O
the	O
primary	O
chemical	O
in	O
spermicides	O
to	O
inhibit	O
sperm	O
motility	O
.	O

HLA-B15	O
allele	O
*	O
1502	O
is	O
associated	O
with	O
the	O
severe	O
skin	O
conditions	O
Stevens–Johnson	O
syndrome	O
(	O
SJS	O
)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)	O
caused	O
by	O
carbamazepine	other-medical
drug	O
sensitivity	O
in	O
East	O
Asians	O
.	O

All	O
GH	other-medical
prescribed	O
in	O
North	O
America	O
,	O
Europe	O
,	O
and	O
most	O
of	O
the	O
rest	O
of	O
the	O
world	O
is	O
a	O
human	O
GH	other-medical
,	O
manufactured	O
by	O
recombinant	O
DNA	O
technology	O
.	O

Tinnitus	O
may	O
be	O
associated	O
with	O
vitamin	other-medical
B12	other-medical
deficiency	O
.	O

H2	other-medical
antagonists	other-medical
require	O
doses	O
much	O
higher	O
than	O
other	O
species	O
to	O
block	O
acid	O
production	O
in	O
the	O
equine	O
stomach	O
,	O
possibly	O
because	O
so	O
little	O
histamine	O
is	O
needed	O
to	O
produce	O
maximal	O
secretion	O
of	O
acid	O
.	O

The	O
sPLA2	O
inhibitor	O
,	O
LY315920	other-medical
(	O
varespladib	other-medical
sodium	other-medical
)	O
,	O
and	O
its	O
orally	other-medical
bioavailable	other-medical
prodrug	other-medical
,	O
LY333013	other-medical
(	O
varespladib	other-medical
methyl	other-medical
)	O
were	O
highly	O
effective	O
in	O
preventing	O
lethality	O
following	O
experimental	O
envenoming	O
by	O
M.	O
fulvius	O
in	O
a	O
porcine	O
animal	O
model	O
.	O

Clinical	O
trials	O
began	O
in	O
Europe	O
in	O
November	O
1998	O
for	O
the	O
MicroMed	other-medical
DeBakey	other-medical
VAD	other-medical
.	O

Ribociclib	other-medical
,	O
an	O
inhibitor	O
of	O
CDK4	O
and	O
CDK6	O
,	O
is	O
US	O
FDA	O
approved	O
in	O
combination	O
with	O
letrozole	other-medical
for	O
treatment	O
of	O
breast	O
cancer	O
in	O
patients	O
with	O
a	O
hormone	O
receptor	O
positive	O
,	O
HER2	O
negative	O
advanced	O
metastatic	O
breast	O
cancer	O
.	O

After	O
24	O
hours	O
,	O
a	O
severe	O
bleeding	O
disorder	O
ensues	O
,	O
leading	O
to	O
ecchymosis	other-medical
,	O
hematuria	other-medical
,	O
pulmonary	other-medical
,	O
and	O
intracranial	other-medical
hemorrhages	other-medical
,	O
and	O
acute	other-medical
kidney	other-medical
injury	other-medical
.	O

For	O
many	O
opioid	other-medical
users	O
,	O
heroin	other-medical
was	O
cheaper	O
,	O
more	O
potent	O
,	O
and	O
often	O
easier	O
to	O
acquire	O
than	O
prescription	O
medications	O
.	O

He	O
is	O
the	O
first	O
person	O
to	O
have	O
prepared	O
amphetamine	other-medical
sulfate	other-medical
,	O
although	O
not	O
the	O
amphetamine	other-medical
molecule	O
.	O

Advice	O
for	O
the	O
management	O
of	O
an	O
acute	O
overdose	O
of	O
ofloxacin	other-medical
is	O
emptying	O
of	O
the	O
stomach	O
,	O
along	O
with	O
close	O
observation	O
,	O
and	O
making	O
sure	O
that	O
the	O
patient	O
is	O
appropriately	O
hydrated	O
.	O

In	O
1996	O
,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
approved	O
Gemzar	other-medical
for	O
the	O
treatment	O
of	O
pancreatic	O
cancer	O
.	O

The	O
Dependency	O
,	O
Emotional	O
,	O
Attachment	O
Programme	O
(	O
DEAP	O
)	O
is	O
another	O
abstinence	O
based	O
treatment	O
Acorn	other-medical
developed	O
which	O
incorporates	O
psychodynamic	O
therapy	O
,	O
Gestalt	other-medical
psychology	other-medical
,	other-medical
Cognitive	other-medical
behavioral	other-medical
therapy	other-medical
and	O
Rational	other-medical
Emotive	other-medical
Therapy	other-medical
in	O
a	O
12-	O
to	O
20-week	O
program	O
.	O

It	O
is	O
a	O
component	O
of	O
the	O
PCDAI	other-medical
(	O
Pediatric	O
Crohn	O
's	O
Disease	O
Activity	O
Index	O
)	O
,	O
an	O
index	O
for	O
assessment	O
of	O
the	O
severity	O
of	O
inflammatory	O
bowel	O
disease	O
in	O
children	O
.	O

The	O
precise	O
mechanism	O
of	O
action	O
of	O
niacin	other-medical
therapeutic	other-medical
effects	O
has	O
not	O
been	O
fully	O
elucidated	O
,	O
but	O
appears	O
to	O
work	O
in	O
part	O
through	O
activation	O
of	O
HCA2	O
which	O
reduces	O
the	O
levels	O
of	O
intracellular	O
cAMP	other-medical
thereby	other-medical
inhibiting	O
lipolysis	O
in	O
adipocytes	O
.	O

Sodium	other-medical
docusate	other-medical
is	O
recommended	O
as	O
a	O
stool	O
softener	O
for	O
children	O
.	O

One	O
issue	O
with	O
opioid	other-medical
rotation	O
is	O
that	O
an	O
opioid	other-medical
therapy	O
failure	O
poorly	O
predicts	O
whether	O
other	O
opioids	other-medical
would	O
be	O
effective	O
.	O

This	O
is	O
also	O
true	O
for	O
omeprazole	other-medical
doses	O
,	O
especially	O
if	O
given	O
orally	O
.	O

Piracetam	other-medical
is	O
not	O
permitted	O
in	O
compounded	O
drugs	O
or	O
dietary	O
supplements	O
in	O
the	O
United	O
States	O
.	O

Haloperidol	other-medical
is	O
excreted	O
in	O
breast	O
milk	O
.	O

2α-	other-medical
(	other-medical
Propanoyl	other-medical
)	other-medical
-3β-	other-medical
(	other-medical
2-	other-medical
(	other-medical
6-methoxynaphthyl	other-medical
)	other-medical
)	other-medical
-tropane	other-medical
or	O
WF-33	other-medical
is	O
a	O
cocaine	other-medical
analogue	O
.	O

Spironolactone	other-medical
has	O
a	O
very	O
short	O
biological	O
half-life	O
and	O
is	O
considered	O
to	O
be	O
a	O
prodrug	O
;	O
hence	O
,	O
its	O
active	O
metabolites	O
are	O
responsible	O
for	O
most	O
of	O
its	O
pharmacodynamics	O
.	O

In	O
the	O
European	O
Union	O
pioglitazone	other-medical
/	O
glimepiride	other-medical
is	O
indicated	O
for	O
the	O
treatment	O
of	O
people	O
with	O
type	O
2	O
diabetes	O
mellitus	O
who	O
show	O
intolerance	O
to	O
metformin	other-medical
or	O
for	O
whom	O
metformin	other-medical
is	O
contraindicated	O
and	O
who	O
are	O
already	O
treated	O
with	O
a	O
combination	O
of	O
pioglitazone	other-medical
and	O
glimepiride	other-medical
.	O

Fentanyl	other-medical
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family	O
,	O
which	O
includes	O
sufentanil	other-medical
,	O
alfentanil	other-medical
,	O
remifentanil	other-medical
,	O
and	O
carfentanil	other-medical
.	O

Iobenguane	other-medical
I	other-medical
131	other-medical
,	O
marketed	O
under	O
the	O
trade	O
name	O
Azedra	other-medical
,	O
has	O
had	O
a	O
clinical	O
trial	O
as	O
a	O
treatment	O
for	O
malignant	O
,	O
recurrent	O
or	O
unresectable	O
pheochromocytoma	O
and	O
paraganglioma	O
,	O
and	O
the	O
FDA	O
approved	O
it	O
on	O
July	O
30	O
,	O
2018	O
.	O

In	O
the	O
early	O
hours	O
of	O
22	O
September	O
2015	O
,	O
Gray	O
and	O
fellow	O
South	O
Sydney	O
teammate	O
and	O
best	O
friend	O
Dylan	O
Walker	O
were	O
hospitalized	O
after	O
the	O
pair	O
overdosed	O
on	O
prescription	O
drugs	O
Oxycodone	other-medical
and	O
Tramadol	other-medical
at	O
Gray	O
's	O
apartment	O
in	O
Rosebery	O
.	O

An	O
established	O
brain	O
stimulation	O
treatment	O
is	O
electroconvulsive	other-medical
therapy	other-medical
.	O

Coronary	other-medical
bypass	other-medical
surgery	other-medical
involves	O
bypassing	O
constricted	O
arteries	O
with	O
venous	O
grafts	O
.	O

As	O
several	O
HBS	O
case	O
studies	O
point	O
out	O
,	O
Tylenol	other-medical
was	O
the	O
country	O
's	O
best-selling	O
over-the-counter	O
pain	O
reliever	O
at	O
the	O
time	O
of	O
the	O
poisonings	O
,	O
with	O
35	O
percent	O
of	O
the	O
market-more	O
than	O
the	O
next	O
three	O
brands	O
combined	O
.	O

Psychoactive	O
drugs	O
,	O
such	O
as	O
caffeine	other-medical
,	O
amphetamine	other-medical
,	O
mescaline	other-medical
,	O
lysergic	other-medical
acid	other-medical
diethylamide	other-medical
(	O
LSD	other-medical
)	O
,	O
marijuana	other-medical
,	O
chloral	other-medical
hydrate	other-medical
,	O
theophylline	other-medical
,	O
IBMX	other-medical
and	O
others	O
,	O
can	O
have	O
strong	O
effects	O
on	O
certain	O
animals	O
.	O

All	O
PPIs	other-medical
react	O
with	O
cysteine	O
813	O
in	O
the	O
loop	O
between	O
TM5	O
and	O
TM6	O
on	O
the	O
H+	O
/	O
K+	O
ATPase	O
,	O
fixing	O
the	O
enzyme	O
in	O
the	O
E2	O
configuration	O
.	O

ADEP	other-medical
antibiotics	other-medical
can	O
be	O
used	O
to	O
defeat	O
resistant	O
bacterial	O
infections	O
.	O

Other	O
blood	O
thinners	O
sometimes	O
used	O
in	O
this	O
setting	O
include	O
bivalirudin	other-medical
and	O
fondaparinux	other-medical
.	O

Growth	other-medical
hormone	other-medical
secretagogues	other-medical
or	other-medical
GH	other-medical
secretagogues	other-medical
(	O
GHSs	other-medical
)	O
are	O
a	O
class	O
of	O
drugs	O
which	O
act	O
as	O
secretagogues	O
(	O
i.e.	O
,	O
induce	O
the	O
secretion	O
)	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
.	O

But	O
even	O
years	O
of	O
psychoanalysis	other-medical
accomplished	O
little	O
,	O
if	O
anything	O
,	O
in	O
curing	O
premature	O
ejaculation	O
.	O

In	O
December	O
1927	O
,	O
Frank	O
M.	O
Dillard	O
and	O
William	O
C.	O
Nalle	O
formed	O
the	O
Dillard-Nalle	O
company	O
and	O
sought	O
U.S	O
.	O
trademark	O
protection	O
for	O
Aspergum	other-medical
.	O

Blocking	O
CCR5	O
with	O
Maraviroc	other-medical
(	O
a	O
drug	O
approved	O
for	O
HIV	O
)	O
may	O
enhance	O
recovery	O
after	O
stroke	O
.	O

Botulinum	other-medical
toxin	other-medical
does	O
not	O
appear	O
to	O
be	O
helpful	O
.	O

Individuals	O
with	O
hemodynamically	O
``	O
unstable	O
''	O
ventricular	O
tachycardia	O
``	O
should	O
not	O
''	O
initially	O
receive	O
amiodarone	other-medical
.	O

Beyond	O
suggestions	O
that	O
PET	O
receptor	O
occupancy	O
must	O
not	O
be	O
used	O
routinely	O
to	O
cap	O
dosing	O
for	O
new	O
medical	O
indications	O
for	O
this	O
class	O
,	O
or	O
that	O
&	O
gt	O
;	O
99	O
%	O
human	O
receptor	O
occupancy	O
might	O
be	O
required	O
for	O
consistent	O
psycho-pharmacological	O
or	O
other	O
therapeutic	O
effects	O
,	O
critical	O
scientific	O
dissection	O
and	O
debate	O
of	O
the	O
above	O
data	O
might	O
be	O
needed	O
to	O
enable	O
aprepitant	other-medical
,	O
and	O
the	O
class	O
of	O
NK1	O
antagonists	O
as	O
a	O
whole	O
,	O
to	O
fulfill	O
preclinically	O
predicted	O
utilities	O
beyond	O
CINV	O
(	O
i.e.	O
,	O
for	O
other	O
psychiatric	O
disorders	O
,	O
addictions	O
,	O
neuropathic	other-medical
pain	other-medical
,	O
migraine	other-medical
,	O
osteoarthritis	other-medical
,	O
overactive	other-medical
bladder	other-medical
,	O
inflammatory	other-medical
bowel	other-medical
disease	other-medical
and	O
other	O
disorders	O
with	O
suspected	other-medical
inflammatory	other-medical
or	O
immunological	O
components	O
.	O

This	O
process	O
created	O
a	O
variety	O
with	O
less	O
tetrahydrocannabinol	O
(	O
THC	O
)	O
and	O
more	O
cannabidiol	O
(	O
CBD	O
)	O
than	O
typical	O
varieties	O
of	O
marijuana	other-medical
.	O

Even	O
patients	O
desensitized	O
to	O
aspirin	other-medical
may	O
continue	O
to	O
need	O
other	O
medications	O
including	O
nasal	other-medical
steroids	other-medical
,	O
inhaled	other-medical
steroids	other-medical
,	O
and	O
leukotriene	other-medical
antagonists	other-medical
.	O

Current	O
advances	O
in	O
further	O
treatments	O
include	O
evaluations	O
of	O
triazoles	O
such	O
as	O
itraconazole	other-medical
and	O
fluconazole	other-medical
``	O
as	O
therapeutic	O
options	O
in	O
ophthalmic	O
mycoses	O
.	O
''	O

Yuri	O
Larionov	O
a	O
male	O
pairs	O
skater	O
Junior	O
World	O
Championships	O
and	O
winner	O
of	O
the	O
2007	O
Junior	O
Grand	O
Prix	O
finals	O
paired	O
with	O
Vera	O
Bazarova	O
,	O
was	O
suspended	O
for	O
an	O
anti-doping	O
violation	O
for	O
18	O
months	O
(	O
January	O
2008	O
to	O
July	O
2009	O
)	O
for	O
using	O
Furosemide	other-medical
a	O
powerful	O
diuretic	O
which	O
the	O
World	O
Anti-Doping	O
Agency	O
classifies	O
as	O
“	O
masking	O
”	O
anabolic	O
and	O
steroids	O
.	O

One	O
NSAID	other-medical
in	O
particular	O
,	O
indomethacin	O
,	O
can	O
inhibit	O
new	O
collagen	O
deposition	O
,	O
thus	O
impairing	O
the	O
healing	O
process	O
for	O
the	O
infarcted	O
region	O
.	O

The	O
overexpression	O
of	O
FITM2	O
was	O
also	O
displayed	O
when	O
the	O
3T3-L1	O
cells	O
were	O
combined	O
with	O
rosiglitazone	other-medical
(	O
a	O
PPAR	other-medical
γ	other-medical
agonist	other-medical
)	O
.	O

In	O
the	O
17th	O
century	O
the	O
practice	O
of	O
mixing	O
opium	other-medical
with	O
tobacco	other-medical
for	O
smoking	O
spread	O
from	O
Southeast	O
Asia	O
,	O
creating	O
a	O
far	O
greater	O
demand	O
.	O

Methyltestosterone	O
,	O
one	O
of	O
the	O
first	O
synthetic	O
AAS	other-medical
and	O
orally	O
active	O
androgens	O
,	O
was	O
introduced	O
in	O
1935	O
,	O
but	O
was	O
associated	O
with	O
hepatotoxicity	O
and	O
eventually	O
became	O
largely	O
medically	O
obsolete	O
.	O

NSAIDs	other-medical
have	O
also	O
been	O
found	O
to	O
fatally	O
interact	O
with	O
methotrexate	O
in	O
numerous	O
case	O
reports	O
.	O

A	O
few	O
studies	O
have	O
examined	O
the	O
impact	O
of	O
haloperidol	other-medical
exposure	O
on	O
breastfed	O
infants	O
and	O
in	O
most	O
cases	O
,	O
there	O
were	O
no	O
adverse	O
effects	O
on	O
infant	O
growth	O
and	O
development	O
.	O

Unlike	O
other	O
racetams	O
,	O
nefiracetam	other-medical
shows	O
high	O
affinity	O
for	O
the	O
GABAA	O
receptor	O
(	O
IC50	O
)	O
=	O
8.5	O
nM	O
)	O
,	O
where	O
it	O
is	O
presumed	O
to	O
be	O
an	O
agonist	O
.	O

Pentobarbital	other-medical
also	O
has	O
an	O
application	O
in	O
reducing	O
intracranial	O
pressure	O
in	O
Reye	O
's	O
syndrome	O
,	O
traumatic	O
brain	O
injury	O
and	O
induction	O
of	O
coma	O
in	O
cerebral	O
ischemia	O
patients	O
.	O

KvLQT1	O
are	O
also	O
expressed	O
in	O
the	O
pancreas	O
,	O
and	O
KvLQT1	O
Long	O
QT	O
syndrome	O
patients	O
has	O
been	O
shown	O
to	O
have	O
hyperinsulinemic	O
hypoglycaemia	O
following	O
an	O
oral	other-medical
glucose	other-medical
load	O
.	O

He	O
is	O
credited	O
with	O
the	O
invention	O
of	O
transcutaneous	other-medical
electrical	other-medical
nerve	other-medical
stimulator	other-medical
,	O
spinal	other-medical
cord	other-medical
stimulator	other-medical
,	O
and	O
radiofrequency	other-medical
ablation	other-medical
for	O
back	O
pain	O
arising	O
from	O
facet	O
arthropathy	O
.	O

Furosemide	other-medical
also	O
can	O
lead	O
to	O
gout	O
caused	O
by	O
hyperuricemia	O
.	O

Cryotherapy	other-medical
may	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
tissue	O
lesions	O
.	O

HGH	other-medical
was	O
not	O
banned	O
by	O
Major	O
League	O
Baseball	O
until	O
2005	O
.	O

Furthermore	O
,	O
edema	other-medical
in	other-medical
gastrocnemius	other-medical
muscle	other-medical
was	O
also	O
attenuated	O
.	O

Electrosurgery	other-medical
is	O
defined	O
as	O
“	O
the	O
intentional	O
passage	O
of	O
high	O
frequency	O
waveforms	O
or	O
currents	O
through	O
tissues	O
of	O
the	O
body	O
to	O
achieve	O
a	O
controllable	O
surgical	O
effect	O
”	O
and	O
has	O
been	O
used	O
for	O
over	O
50	O
years	O
in	O
dentistry	O
.	O

Proline	other-medical
racemase	O
is	O
inhibited	O
by	O
pyrrole-2-carboxylic	O
acid	O
,	O
a	O
transition	O
state	O
analogue	O
that	O
is	O
flat	O
like	O
the	O
transition	O
state	O
.	O

Flumazenil	other-medical
effectively	O
blocks	O
the	O
effects	O
of	O
benzodiazepine	other-medical
agonists	O
such	O
as	O
alprazolam	other-medical
and	O
diazepam	other-medical
and	O
so	O
is	O
used	O
for	O
treating	O
overdoses	O
of	O
these	O
drugs	O
but	O
is	O
ineffective	O
in	O
blocking	O
alcohol	O
actions	O
.	O

Creatine	other-medical
is	O
a	O
mass-produced	O
fitness	O
supplement	O
that	O
is	O
supposed	O
to	O
increase	O
the	O
user	O
's	O
muscle	O
mass	O
,	O
strength	O
and	O
power	O
.	O

The	O
Jiajing	O
Emperor	O
in	O
the	O
Ming	O
Dynasty	O
died	O
from	O
ingesting	O
a	O
lethal	O
dosage	O
of	O
mercury	O
in	O
the	O
supposed	O
``	O
Elixir	other-medical
of	other-medical
Life	other-medical
``	O
conjured	O
by	O
alchemists	O
.	O

Nelfinavir	other-medical
is	O
an	O
orally	O
bioavailable	O
human	O
immunodeficiency	O
virus	O
HIV-1	O
protease	O
inhibitor	O
(	O
Ki=2nM	O
)	O
and	O
is	O
widely	O
prescribed	O
in	O
combination	O
with	O
HIV	O
reverse	O
transcriptase	O
inhibitors	O
for	O
the	O
treatment	O
of	O
HIV	O
infection	O
.	O

Secondary	O
amine	O
TCAs	other-medical
like	O
desipramine	other-medical
and	O
nortriptyline	other-medical
have	O
a	O
lower	O
risk	O
of	O
orthostatic	O
hypotension	O
than	O
other	O
TCAs	other-medical
,	O
although	O
desipramine	O
can	O
still	O
cause	O
moderate	O
orthostatic	O
hypotension	O
.	O

Natalizumab	other-medical
halves	O
the	O
risk	O
of	O
suffering	O
relapses	O
when	O
compared	O
to	O
interferons	O
,	O
having	O
an	O
overall	O
efficacy	O
of	O
over	O
70	O
%	O
.	O

In	O
King	O
County	O
outcomes	O
of	O
attempted	O
out-of-hospital	O
resuscitations	O
are	O
recorded	O
,	O
following	O
the	O
Utstein	other-medical
uniform	O
reporting	O
guidelines	O
,	O
in	O
a	O
cardiac	O
arrest	O
registry	O
.	O

However	O
,	O
whether	O
the	O
effect	O
of	O
omeprazole	other-medical
and	O
esomeprazole	other-medical
on	O
clopidogrel	other-medical
's	O
metabolism	O
actually	O
leads	O
to	O
poor	O
clinical	O
outcomes	O
is	O
still	O
a	O
matter	O
of	O
intense	O
debate	O
among	O
healthcare	O
professionals	O
.	O

Dillard-Nalle	O
then	O
began	O
selling	O
their	O
Dellard	other-medical
's	other-medical
Aspergum	other-medical
in	O
the	O
United	O
States	O
in	O
1928.	O
it	O
was	O
an	O
early	O
example	O
of	O
a	O
functional	O
gum	O
–	O
chewing	O
gum	O
as	O
a	O
drug	O
delivery	O
system	O
.	O

Fentanyl	other-medical
intoxication	O
and	O
recent	O
methamphetamine	O
use	O
might	O
have	O
increased	O
the	O
likelihood	O
of	O
death	O
.	O

Blockade	O
of	O
COX-1	O
by	O
aspirin	other-medical
apparently	O
results	O
in	O
the	O
upregulation	O
of	O
COX-2	O
as	O
part	O
of	O
a	O
gastric	O
defense	O
and	O
that	O
taking	O
COX-2	O
inhibitors	O
concurrently	O
with	O
aspirin	other-medical
increases	O
the	O
gastric	O
mucosal	O
erosion	O
.	O

This	O
may	O
,	O
however	O
,	O
be	O
counter-productive	O
for	O
patients	O
who	O
are	O
also	O
taking	O
methotrexate	other-medical
,	O
which	O
is	O
a	O
folic	other-medical
acid	other-medical
inhibitor	other-medical
.	O

Mitoxantrone	other-medical
is	O
also	O
highly	O
useful	O
to	O
reduce	O
attacks	O
and	O
disability	O
,	O
but	O
it	O
is	O
generally	O
not	O
considered	O
as	O
a	O
long-term	O
therapy	O
due	O
to	O
its	O
severe	O
cardiac	O
toxicity	O
.	O

ADHD	O
,	O
which	O
affects	O
the	O
majority	O
of	O
boys	O
and	O
30	O
%	O
of	O
girls	O
with	O
FXS	O
,	O
is	O
frequently	O
treated	O
using	O
stimulants	other-medical
.	O

Niimi	O
received	O
an	O
injection	O
of	O
atropine	other-medical
and	O
pralidoxime	other-medical
iodine	other-medical
,	O
saving	O
his	O
life	O
.	O

Protease	other-medical
inhibitors	other-medical
can	O
cause	O
a	O
syndrome	O
of	O
lipodystrophy	O
,	O
hyperlipidemia	O
,	O
diabetes	O
mellitus	O
type	O
2	O
,	O
and	O
kidney	O
stones	O
.	O

Modafinil	other-medical
first	O
came	O
into	O
attention	O
when	O
world	O
champion	O
runner	O
Kelli	O
White	O
was	O
tested	O
positive	O
for	O
illegally	O
consuming	O
modafinil	O
in	O
the	O
Athletics	O
World	O
Championship	O
in	O
2003	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
her	O
two	O
gold	O
medals	O
.	O

Growth	other-medical
hormone	other-medical
deficiency	O
is	O
treated	O
by	O
replacing	O
GH	other-medical
.	O

A	O
single	O
intramuscular	O
injection	O
of	O
20	O
to	O
30	O
mg	O
estradiol	O
undecylate	O
has	O
been	O
found	O
to	O
inhibit	O
ovulation	O
when	O
used	O
as	O
an	O
estrogen	O
-only	O
injectable	other-medical
contraceptive	other-medical
in	O
premenopausal	O
women	O
for	O
1	O
to	O
3	O
months	O
(	O
mean	O
1.7	O
months	O
)	O
as	O
well	O
.	O

In	O
2005	O
,	O
she	O
was	O
found	O
guilty	O
of	O
pemoline	other-medical
doping	O
.	O

The	O
drug	O
is	O
also	O
not	O
associated	O
with	O
weight	O
gain	O
,	O
in	O
contrast	O
to	O
many	O
other	O
TCAs	other-medical
.	O

Cinqair	other-medical
is	O
approved	O
for	O
patients	O
who	O
have	O
a	O
history	O
of	O
severe	O
asthma	O
attacks	O
(	O
exacerbations	O
)	O
despite	O
receiving	O
their	O
current	O
asthma	O
medicines	O
.	O

FITM2	O
has	O
been	O
identified	O
as	O
being	O
overexpressed	O
throughout	O
the	O
time	O
3T3-L1	O
(	O
from	O
the	O
adipocyte	O
cell	O
line	O
)	O
is	O
being	O
differentiated	O
which	O
shows	O
resemblance	O
to	O
the	O
peroxisome	other-medical
proliferator-activated	other-medical
receptor	other-medical
gamma	other-medical
(	O
PPAR	other-medical
γ	other-medical
)	O
at	O
a	O
specific	O
period	O
when	O
lipid	O
droplets	O
have	O
been	O
identified	O
to	O
build-up	O
which	O
results	O
in	O
the	O
adipocyte	O
phenotype	O
that	O
is	O
seen	O
in	O
the	O
3T3-L1	O
cells	O
.	O

BAT	other-medical
has	O
been	O
used	O
to	O
treat	O
a	O
case	O
of	O
type	O
F	O
infant	O
botulism	O
and	O
,	O
on	O
a	O
case-by-case	O
basis	O
,	O
may	O
be	O
used	O
for	O
future	O
cases	O
of	O
non-type	O
A	O
and	O
non-type	O
B	O
infant	O
botulism	O
.	O

Cryosurgery	other-medical
is	O
the	O
application	O
of	O
extremely	O
low	O
temperatures	O
to	O
destroy	O
abnormal	O
or	O
diseased	O
tissue	O
and	O
is	O
used	O
most	O
commonly	O
to	O
treat	O
skin	O
conditions	O
.	O

CHMP	O
stated	O
that	O
doctors	O
should	O
not	O
prescribe	O
oral	other-medical
norfloxacin	other-medical
for	O
complicated	other-medical
pyelonephritis	other-medical
and	O
should	O
consider	O
switching	O
patients	O
already	O
taking	O
oral	other-medical
norfloxacin	other-medical
for	O
this	O
type	O
of	O
infection	O
to	O
an	O
alternative	O
antibiotic	O
.	O

Individuals	O
with	O
coexisting	O
seizure	O
disorder	O
may	O
require	O
treatment	O
with	O
anticonvulsants	other-medical
.	O

Cervarix	other-medical
had	O
been	O
used	O
routinely	O
in	O
young	O
females	O
from	O
its	O
introduction	O
in	O
2008	O
,	O
but	O
was	O
only	O
effective	O
against	O
the	O
high-risk	O
HPV	O
types	O
16	O
and	O
18	O
,	O
neither	O
of	O
which	O
typically	O
causes	O
warts	O
.	O

In	O
cases	O
of	O
meningitis	O
caused	O
by	O
Herpes	O
simplex	O
virus	O
,	O
antiviral	O
therapy	O
with	O
(	O
acyclovir	other-medical
or	O
vidarabine	other-medical
)	O
must	O
be	O
started	O
immediately	O
for	O
a	O
favorable	O
outcome	O
.	O

In	O
Lupus	O
Nephritis	O
,	O
a	O
common	O
manifestation	O
of	O
SLE	O
,	O
patients	O
are	O
often	O
prescribed	O
methylprednisolone	other-medical
concomitantly	O
with	O
immunosuppressants	other-medical
.	O

Bevacizumab	other-medical
was	O
approved	O
in	O
the	O
United	O
States	O
in	O
February	O
2004	O
,	O
for	O
use	O
in	O
metastatic	O
colorectal	O
cancer	O
when	O
used	O
with	O
standard	O
chemotherapy	O
treatment	O
(	O
as	O
first-line	O
treatment	O
)	O
and	O
with	O
5-fluorouracil-based	O
therapy	O
for	O
second-line	O
metastatic	O
colorectal	O
cancer	O
.	O

He	O
survived	O
the	O
initial	O
surgery	O
,	O
but	O
after	O
a-five-and-a-half-month	O
battle	O
with	O
cancer	other-medical
,	O
he	O
died	O
in	O
Los	O
Angeles	O
on	O
July	O
31	O
,	O
1980	O
,	O
and	O
is	O
interred	O
at	O
Mount	O
Sinai	O
Memorial	O
Park	O
Cemetery	O
,	O
a	O
Jewish	O
cemetery	O
in	O
Los	O
Angeles	O
.	O

Topically	O
,	O
clotrimazole	other-medical
is	O
used	O
for	O
vulvovaginal	O
candidiasis	O
(	O
yeast	O
infection	O
)	O
or	O
yeast	O
infections	O
of	O
the	O
skin	O
.	O

Clonazepam	other-medical
(	O
Klonopin	other-medical
,	O
Rivotril	other-medical
)	O
is	O
effective	O
in	O
the	O
short	O
term	O
but	O
is	O
not	O
generally	O
recommended	O
for	O
treatment	O
of	O
absence	O
seizure	O
because	O
of	O
the	O
rapid	O
development	O
of	O
tolerance	O
and	O
high	O
frequency	O
of	O
side	O
effects	O
.	O

It	O
was	O
formerly	O
used	O
as	O
an	O
antidepressant	other-medical
in	O
the	O
1960s	O
,	O
but	O
has	O
since	O
been	O
discontinued	O
.	O

Isolated	O
situations	O
like	O
pregnancy	other-medical
,	O
thyroid	O
disease	O
or	O
ones	O
occupation	O
(	O
desk	O
work	O
or	O
intense	O
physical	O
labour	O
)	O
can	O
lead	O
to	O
mononeuropathy	O
as	O
a	O
result	O
entrapped	O
nerve	O
sites	O
.	O

The	O
gel	O
typically	O
contains	O
potassium	O
chloride	O
–	O
sometimes	O
silver	O
chloride	O
as	O
well	O
–	O
to	O
permit	O
electron	O
conduction	O
from	O
the	O
skin	O
to	O
the	O
wire	O
and	O
to	O
the	O
electrocardiogram	other-medical
.	O

Chlomethiazole	other-medical
appears	O
to	O
also	O
have	O
another	O
mechanism	O
of	O
action	O
mediating	O
some	O
of	O
its	O
hypothermic	O
and	O
neuroprotective	O
effects	O
.	O

The	O
Royal	O
London	O
Hospital	O
for	O
Integrated	O
Medicine	O
offers	O
clinical	O
services	O
including	O
complementary	other-medical
cancer	other-medical
treatments	other-medical
,	O
allergy	other-medical
services	other-medical
,	O
acupuncture	other-medical
,	O
homeopathy	other-medical
,	O
rheumatology	other-medical
,	O
weight	O
loss	O
management	O
,	O
sleep	O
management	O
,	O
musculoskeletal	O
medicine	O
and	O
stress	O
management	O
,	O
and	O
has	O
access	O
to	O
conventional	O
medicine	O
.	O

As	O
with	O
SSRIs	other-medical
,	O
the	O
abrupt	O
discontinuation	O
of	O
an	O
SNRI	other-medical
usually	O
leads	O
to	O
withdrawal	O
,	O
or	O
``	O
discontinuation	O
syndrome	O
``	O
,	O
which	O
could	O
include	O
states	O
of	O
anxiety	O
and	O
other	O
symptoms	O
.	O

Doxepin	other-medical
is	O
a	O
tertiary	O
amine	O
TCA	other-medical
,	O
with	O
its	O
side	O
chain-demethylated	O
metabolite	O
nordoxepin	O
being	O
a	O
secondary	O
amine	O
.	O

This	O
occurs	O
naturally	O
in	O
the	O
adrenal	O
cortex	O
and	O
during	O
first-pass	O
metabolism	O
in	O
the	O
liver	O
and	O
intestines	O
when	O
exogenous	other-medical
DHEA	other-medical
is	O
administered	O
orally	O
.	O

Proton	O
pump	O
inhibitors	O
(	O
PPI	other-medical
)	O
may	O
reduce	O
mortality	O
in	O
those	O
with	O
severe	O
disease	O
as	O
well	O
as	O
the	O
risk	O
of	O
re-bleeding	O
and	O
the	O
need	O
for	O
surgery	O
among	O
this	O
group	O
.	O

But	O
there	O
is	O
also	O
a	O
genetic	O
connection	O
of	O
STPD	O
to	O
mood	other-medical
disorders	other-medical
and	O
depression	O
in	O
particular	O
.	O

A	O
single	O
,	O
modified	O
TEG	other-medical
assay	O
with	O
exogenous	O
tissue	other-medical
plasminogen	other-medical
activator	other-medical
(	O
tPA	other-medical
)	O
demonstrated	O
remarkable	O
efficiency	O
in	O
unmasking	O
patients	O
'	O
impending	O
risk	O
for	O
massive	O
transfusion	O
in	O
trauma	O
patients	O
.	O

Patients	O
should	O
therefore	O
always	O
be	O
screened	O
for	O
G6PD	O
deficiency	O
prior	O
to	O
being	O
prescribed	O
pamaquine	other-medical
.	O

Note	O
that	O
treatment	O
of	O
a	O
keloid	other-medical
scar	other-medical
is	O
age	O
dependent	O
:	O
radiotherapy	other-medical
,	O
anti-metabolites	other-medical
and	O
corticosteroids	other-medical
would	O
not	O
be	O
recommended	O
to	O
be	O
used	O
in	O
children	O
,	O
in	O
order	O
to	O
avoid	O
harmful	O
side	O
effects	O
,	O
like	O
growth	other-medical
abnormalities	other-medical
.	O

In	O
general	O
,	O
cytotoxic	other-medical
chemotherapy	other-medical
for	O
ALL	O
combines	O
multiple	O
antileukemic	other-medical
drugs	O
tailored	O
to	O
each	O
person	O
.	O

Damage	other-medical
to	other-medical
the	other-medical
arcuate	other-medical
fasciculus	other-medical
is	O
implicated	O
as	O
a	O
possible	O
cause	O
of	O
specific	O
language	O
impairment	O
,	O
however	O
further	O
data	O
is	O
required	O
to	O
validate	O
this	O
claim	O
.	O

Doctors	O
may	O
search	O
for	O
Thyroid	other-medical
peroxidase	other-medical
Antibodies	other-medical
(	O
TPOAb	other-medical
)	O
when	O
a	O
person	O
has	O
symptoms	O
of	O
hypothyroidism	O
,	O
or	O
when	O
a	O
person	O
will	O
be	O
started	O
on	O
a	O
drug	O
therapy	O
associated	O
with	O
risks	O
of	O
developing	O
hypothyroidism	O
,	O
such	O
as	O
lithium	other-medical
or	O
Interferon	other-medical
alfa	other-medical
.	O

In	O
breast	O
tissue	O
,	O
tamoxifen	other-medical
acts	O
as	O
an	O
ER	O
antagonist	O
so	O
that	O
transcription	O
of	O
estrogen-responsive	O
genes	O
is	O
inhibited	O
.	O

As	O
a	O
pharmaceutical	O
drug	O
it	O
is	O
called	O
cholecalciferol	other-medical
(	O
USAN	other-medical
)	O
or	O
colecalciferol	other-medical
(	O
INN	other-medical
,	O
BAN	other-medical
)	O
.	O

Hypopigmented	other-medical
skin	other-medical
macules	other-medical
have	O
occasionally	O
been	O
reported	O
.	O

Methylene	other-medical
blue	other-medical
is	O
used	O
in	O
endoscopic	O
polypectomy	O
as	O
an	O
adjunct	O
to	O
saline	O
or	O
epinephrine	O
,	O
and	O
is	O
used	O
for	O
injection	O
into	O
the	O
submucosa	O
around	O
the	O
polyp	O
to	O
be	O
removed	O
.	O

Sibutramine	other-medical
is	O
not	O
listed	O
on	O
the	O
product	O
label	O
.	O
''	O

Ultrasound	other-medical
of	O
the	O
lung	O
may	O
also	O
be	O
able	O
to	O
detect	O
Kerley	O
lines	O
.	O

Quinine	other-medical
is	O
also	O
used	O
to	O
treat	O
lupus	O
and	O
arthritis	O
.	O

The	O
U.S.	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
recommends	O
the	O
use	O
of	O
oseltamivir	other-medical
(	O
Tamiflu	other-medical
)	O
or	O
zanamivir	other-medical
(	O
Relenza	other-medical
)	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
infection	O
with	O
swine	O
influenza	O
viruses	O
;	O
however	O
,	O
the	O
majority	O
of	O
people	O
infected	O
with	O
the	O
virus	O
make	O
a	O
full	O
recovery	O
without	O
requiring	O
medical	O
attention	O
or	O
antiviral	O
drugs	O
.	O

Oral	other-medical
iron	other-medical
tablets	other-medical
are	O
not	O
easily	O
tolerated	O
and	O
may	O
cause	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
constipation	O
and	O
diarrhoea	O
.	O

Turmeric	other-medical
has	O
been	O
used	O
in	O
Asia	O
for	O
centuries	O
and	O
is	O
a	O
major	O
part	O
of	O
Ayurveda	other-medical
,	O
Siddha	other-medical
medicine	other-medical
,	O
traditional	other-medical
Chinese	other-medical
medicine	other-medical
,	O
Unani	other-medical
,	O
and	O
the	O
animistic	O
rituals	O
of	O
Austronesian	O
peoples	O
.	O

Flupamesone	other-medical
(	O
brand	O
name	O
Flutenal	other-medical
)	O
,	O
also	O
known	O
as	O
triamcinolone	other-medical
acetonide	other-medical
metembonate	other-medical
,	O
is	O
a	O
synthetic	O
glucocorticoid	O
corticosteroid	O
which	O
is	O
marketed	O
in	O
Spain	O
.	O

The	O
term	O
``	O
gender	other-medical
identity	other-medical
disorder	other-medical
``	O
itself	O
introduced	O
in	O
DSM-III	O
was	O
taken	O
from	O
Green	O
's	O
1974	O
work	O
.	O
Sexual	O
Identity	O
Conflict	O
in	O
Children	O
and	O
Adults	O
.	O

The	O
main	O
interest	O
in	O
Ro15-4513	other-medical
was	O
as	O
an	O
antidote	O
to	O
alcohol	O
.	O

As	O
a	O
prodrug	O
of	O
levorphanol	other-medical
,	O
levomethorphan	other-medical
functions	O
as	O
a	O
potent	O
agonist	O
of	O
all	O
three	O
of	O
the	O
opioid	O
receptors	O
,	O
μ	O
,	O
κ	O
(	O
κ1	O
and	O
κ3	O
but	O
notably	O
not	O
κ2	O
)	O
,	O
and	O
δ	O
,	O
as	O
an	O
NMDA	O
receptor	O
antagonist	O
,	O
and	O
as	O
a	O
serotonin-norepinephrine	O
reuptake	O
inhibitor	O
.	O

Relative	O
to	O
other	O
SNRIs	other-medical
,	O
levomilnacipran	other-medical
,	O
as	O
well	O
as	O
milnacipran	other-medical
,	O
differ	O
in	O
that	O
they	O
are	O
much	O
more	O
balanced	O
reuptake	O
inhibitors	O
of	O
serotonin	O
and	O
norepinephrine	O
.	O

The	O
analgesic	O
properties	O
of	O
the	O
plant	O
seem	O
to	O
be	O
related	O
to	O
its	O
effect	O
on	O
prostaglandin	other-medical
synthesis	other-medical
.	O

The	O
agency	O
subsidizes	O
a	O
methadone	other-medical
maintenance	O
treatment	O
program	O
in	O
Taiwan	O
.	O

Skele-Gro	other-medical
is	O
a	O
medicinal	O
potion	O
that	O
can	O
regrow	O
missing	O
or	O
removed	O
bones	O
,	O
though	O
it	O
tastes	O
terrible	O
and	O
the	O
process	O
is	O
very	O
slow	O
and	O
extremely	O
painful	O
.	O

Carbamazepine	other-medical
is	O
most	O
commonly	O
prescribed	O
to	O
treat	O
trigeminal	O
neuralgia	O
due	O
to	O
clinical	O
experience	O
and	O
early	O
clinical	O
trials	O
showing	O
strong	O
efficacy	O
.	O

Combretastatin	other-medical
and	O
pazopanib	other-medical
are	O
being	O
researched	O
in	O
combination	O
for	O
recurrent	O
ovarian	O
cancer	O
.	O

Menopause	O
can	O
be	O
surgically	O
induced	O
by	O
bilateral	other-medical
oophorectomy	other-medical
(	O
removal	O
of	O
ovaries	O
)	O
,	O
which	O
is	O
often	O
,	O
but	O
not	O
always	O
,	O
done	O
in	O
conjunction	O
with	O
removal	O
of	O
the	O
Fallopian	other-medical
tubes	other-medical
(	O
salpingo-oophorectomy	O
)	O
and	O
uterus	other-medical
(	O
hysterectomy	O
)	O
.	O

Lesser	O
evidence	O
supports	O
topical	other-medical
metronidazole	other-medical
cream	O
and	O
tetracycline	other-medical
by	O
mouth	O
.	O

They	O
can	O
also	O
be	O
found	O
in	O
combination	O
with	O
vasoconstrictor	other-medical
drugs	other-medical
such	O
as	O
pseudoephedrine	other-medical
for	O
sinus-related	O
preparations	O
,	O
or	O
with	O
antihistamine	other-medical
drugs	other-medical
for	O
allergy	O
sufferers	O
.	O

It	O
is	O
not	O
yet	O
known	O
whether	O
imatinib	other-medical
has	O
an	O
effect	O
on	O
catalase	O
,	O
or	O
if	O
its	O
reversal	O
of	O
the	O
graying	O
process	O
is	O
due	O
to	O
something	O
else	O
.	O

A	O
selective	other-medical
estrogen	other-medical
receptor	other-medical
degrader	other-medical
or	other-medical
downregulator	other-medical
(	O
SERD	other-medical
)	O
is	O
a	O
type	O
of	O
drug	O
which	O
binds	O
to	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
and	O
,	O
in	O
the	O
process	O
of	O
doing	O
so	O
,	O
causes	O
the	O
ER	O
to	O
be	O
degraded	O
and	O
thus	O
downregulated	O
.	O

The	O
usefulness	O
of	O
5-ARIs	other-medical
for	O
the	O
potential	O
treatment	O
of	O
acne	O
is	O
uncertain	O
.	O

Side	O
effects	O
of	O
testosterone	other-medical
enanthate	other-medical
include	O
virilization	O
among	O
others	O
.	O

The	O
raceday	O
ban	O
on	O
Lasix	other-medical
would	O
eventually	O
be	O
removed	O
for	O
the	O
2014	O
event	O
.	O

Recommended	O
antibiotics	O
in	O
those	O
who	O
are	O
young	O
and	O
sexually	O
active	O
are	O
ceftriaxone	other-medical
and	O
doxycycline	other-medical
.	O

In	O
addition	O
he	O
became	O
a	O
professorial	O
fellow	O
of	O
Worcester	O
College	O
,	O
Oxford	O
and	O
for	O
clinical	O
duties	O
he	O
became	O
clinical	O
director	O
at	O
the	O
Wingfield-Morris	O
Hospital	O
,	O
later	O
renamed	O
the	O
Nuffield	other-medical
Orthopaedic	other-medical
Centre	other-medical
(	O
NOC	other-medical
)	O
and	O
subsequently	O
part	O
of	O
Oxford	O
University	O
Hospitals	O
NHS	O
Trust	O
.	O

In	O
May	O
2011	O
,	O
the	O
Vermont	O
Legislature	O
approved	O
S.	O
17	O
,	O
which	O
added	O
four	O
non-profit	O
marijuana	other-medical
dispensaries	O
to	O
the	O
existing	O
law	O
.	O

Mescaline	other-medical
is	O
biosynthesized	O
from	O
tyrosine	O
which	O
,	O
in	O
turn	O
,	O
is	O
derived	O
from	O
phenylalanine	O
by	O
the	O
enzyme	O
phenylalanine	O
hydroxylase	O
.	O

CPA	other-medical
is	O
used	O
as	O
an	O
antiandrogen	O
to	O
treat	O
high	O
androgen	O
levels	O
and	O
associated	O
symptoms	O
such	O
as	O
masculinization	O
due	O
to	O
conditions	O
like	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
and	O
congenital	O
adrenal	O
hyperplasia	O
(	O
CAH	O
)	O
in	O
women	O
.	O

Milloy	O
has	O
campaigned	O
against	O
the	O
1972	O
ban	O
on	O
non-public-health	O
uses	O
of	O
DDT	other-medical
in	O
the	O
United	O
States	O
and	O
in	O
favour	O
of	O
wider	O
use	O
of	O
DDT	other-medical
against	O
malaria	O
,	O
which	O
he	O
claims	O
could	O
be	O
largely	O
eliminated	O
if	O
DDT	other-medical
were	O
used	O
more	O
aggressively	O
.	O

some	O
published	O
information	O
for	O
comparing	O
rosuvastatin	other-medical
,	O
atorvastatin	other-medical
,	O
and	O
ezetimibe	other-medical
/	O
simvastatin	other-medical
results	O
is	O
available	O
,	O
but	O
many	O
of	O
the	O
relevant	O
studies	O
are	O
still	O
in	O
progress	O
.	O

Third-line	O
medications	O
include	O
phenytoin	other-medical
for	O
children	O
and	O
phenobarbital	other-medical
for	O
adults	O
.	O

Because	O
of	O
its	O
increasing	O
popularity	O
with	O
young	other-medical
party	other-medical
goers	other-medical
in	O
Beijing	O
,	O
Shanghai	O
,	O
Nanjing	O
,	O
Guangzhou	O
,	O
and	O
Shenzhen	O
,	O
Chinese	O
law	O
enforcement	O
officials	O
report	O
significant	O
increases	O
in	O
the	O
domestic	O
production	O
of	O
MDMA	other-medical
(	O
``	O
Ecstasy	other-medical
``	O
)	O
.	O

The	O
US	O
patent	O
for	O
Zoloft	other-medical
expired	O
in	O
2006	O
,	O
and	O
sertraline	O
is	O
available	O
in	O
generic	O
form	O
and	O
is	O
marketed	O
under	O
many	O
brand	O
names	O
worldwide	O
.	O

In	O
the	O
test	O
for	O
anti-inflammatory	O
activity	O
the	O
extract	O
exhibited	O
17.6	O
%	O
inhibition	O
at	O
a	O
concentration	O
25	O
mg/ml	O
,	O
Ibuprofen	other-medical
being	O
used	O
as	O
a	O
standard	O
drug	O
for	O
comparison	O
and	O
showing	O
73.2	O
%	O
inhibition	O
at	O
the	O
same	O
concentration	O
.	O

Celecoxib	other-medical
had	O
already	O
been	O
approved	O
for	O
this	O
indication	O
,	O
and	O
it	O
was	O
hoped	O
to	O
add	O
this	O
to	O
the	O
indications	O
for	O
rofecoxib	other-medical
as	O
well	O
.	O

It	O
has	O
a	O
reasonably	O
fast	O
rate	O
of	O
occupancy	O
of	O
dopamine	O
transporters	O
in	O
the	O
brain	O
,	O
though	O
slower	O
than	O
that	O
of	O
cocaine	other-medical
itself	O
.	O

Similarly	O
,	O
lamotrigine	other-medical
treats	O
multiple	O
seizure	O
types	O
including	O
partial	O
seizures	O
and	O
generalized	O
seizures	O
,	O
therefore	O
it	O
is	O
also	O
an	O
option	O
for	O
patients	O
with	O
multiple	O
seizure	O
types	O
.	O

A	O
palpable	O
spleen	O
is	O
not	O
always	O
a	O
clinical	O
significance	O
,	O
therefore	O
CT	other-medical
scan	O
,	O
MRI	other-medical
,	O
or	O
ultrasound	O
can	O
be	O
administered	O
in	O
order	O
to	O
help	O
diagnose	O
the	O
condition	O
.	O

People	O
taking	O
lithium	other-medical
thus	O
should	O
routinely	O
be	O
assessed	O
for	O
hypothyroidism	O
and	O
treated	O
with	O
synthetic	other-medical
thyroxine	other-medical
if	O
necessary	O
.	O

Pentobarbital	other-medical
(	O
previously	O
known	O
as	O
pentobarbitone	other-medical
in	O
Britain	O
and	O
Australia	O
)	O
is	O
a	O
short-acting	O
barbiturate	O
typically	O
used	O
as	O
a	O
sedative	O
,	O
a	O
preanesthetic	O
,	O
and	O
to	O
control	O
convulsions	O
in	O
emergencies	O
.	O

Vardenafil	other-medical
's	O
indications	O
and	O
contraindications	O
are	O
the	O
same	O
as	O
with	O
other	O
PDE5	other-medical
inhibitors	other-medical
;	O
it	O
is	O
closely	O
related	O
in	O
function	O
to	O
sildenafil	other-medical
citrate	other-medical
(	O
Viagra	other-medical
)	O
and	O
tadalafil	other-medical
(	O
Cialis	other-medical
)	O
.	O

Isavuconazonium	other-medical
comprises	O
an	O
``	O
N	O
''	O
-	O
(	O
3-acetoxypropyl	O
)	O
-	O
''	O
N	O
''	O
-methylamino-carboxymethyl	O
group	O
linked	O
through	O
an	O
ester	O
moiety	O
to	O
the	O
triazole	O
nitrogen	O
in	O
isavuconazole	O
.	O

RLS	O
symptoms	O
decrease	O
with	O
the	O
use	O
of	O
drugs	O
that	O
stimulate	O
dopamine	O
receptors	O
and	O
increase	O
dopamine	O
levels	O
,	O
such	O
as	O
dopamine	other-medical
agonists	other-medical
.	O

Enasidenib	other-medical
is	O
used	O
to	O
treat	O
relapsed	O
or	O
refractory	O
acute	O
myeloid	O
leukemia	O
in	O
people	O
with	O
specific	O
mutations	O
of	O
the	O
IDH2	O
gene	O
,	O
determined	O
by	O
an	O
FDA-	O
approved	O
IDH2	O
companion	O
diagnostic	O
test	O
.	O

Gemzar	other-medical
also	O
is	O
routinely	O
used	O
in	O
the	O
treatment	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Small-volume	O
pumps	O
infuse	O
hormones	O
,	O
such	O
as	O
insulin	O
,	O
or	O
other	O
medicines	O
,	O
such	O
as	O
opiates	other-medical
.	O

Scopolamine	other-medical
(	O
Hyoscine	other-medical
)	O
has	O
anti-emetic	O
activity	O
and	O
is	O
,	O
therefore	O
,	O
used	O
to	O
treat	O
motion	O
sickness	O
.	O

As	O
with	O
other	O
opioids	other-medical
,	O
chronic	O
use	O
of	O
oxycodone	other-medical
(	O
particularly	O
with	O
higher	O
doses	O
)	O
often	O
causes	O
concurrent	O
hypogonadism	O
(	O
low	O
sex	O
hormone	O
levels	O
)	O
.	O

The	O
High	other-medical
Runner	other-medical
lines	O
have	O
been	O
proposed	O
as	O
a	O
model	O
to	O
study	O
human	O
attention-deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
and	O
administration	O
of	O
Ritalin	O
reduces	O
their	O
wheel	O
running	O
approximately	O
to	O
the	O
levels	O
of	O
control	O
mice	O
.	O

There	O
is	O
not	O
good	O
evidence	O
that	O
it	O
works	O
better	O
than	O
other	O
PPIs	other-medical
.	O

The	O
facility	O
,	O
located	O
in	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
,	O
produced	O
BCG	other-medical
vaccine	O
products	O
,	O
made	O
with	O
the	O
Glaxo	other-medical
1077	other-medical
strain	other-medical
,	O
such	O
as	O
a	O
tuberculosis	O
vaccine	O
ImmuCYST	other-medical
,	O
a	O
BCG	other-medical
immunotherapeutic	O
,	O
a	O
bladder	O
cancer	O
drug	O
.	O

This	O
concern	O
is	O
partly	O
due	O
to	O
William	O
E.	O
White	O
,	O
the	O
author	O
of	O
the	O
DXM	other-medical
FAQ	other-medical
,	O
who	O
claimed	O
that	O
dissociatives	O
definitely	O
cause	O
brain	O
damage	O
.	O

Pilocarpine	other-medical
drops	other-medical
may	O
be	O
administered	O
as	O
a	O
treatment	O
as	O
well	O
as	O
a	O
diagnostic	O
measure	O
.	O

As	O
the	O
number	O
of	O
opioid	other-medical
prescriptions	O
rose	O
,	O
drug	O
cartels	O
began	O
flooding	O
the	O
US	O
with	O
heroin	O
from	O
Mexico	O
.	O

However	O
,	O
this	O
can	O
lead	O
to	O
fat	other-medical
deficiency	other-medical
and	O
malnutrition	other-medical
over	O
time	O
.	O

Pajer	O
lobbied	O
against	O
Washington	O
State	O
HB1638	O
,	O
a	O
bill	O
that	O
banned	O
personal	O
exemptions	O
to	O
the	O
MMR	other-medical
vaccine	O
in	O
the	O
state	O
.	O

The	O
main	O
suppliers	O
of	O
heroin	other-medical
to	O
the	O
US	O
have	O
been	O
Mexican	O
transnational	O
criminal	O
organizations	O
.	O

Guanfacine	other-medical
has	O
been	O
studied	O
as	O
a	O
treatment	O
for	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

Blizzard	O
also	O
negotiated	O
major	O
settlements	O
over	O
diet	O
drugs	O
and	O
Ephedra	other-medical
supplements	O
including	O
products	O
Fen-Phen	other-medical
and	O
Metabolife	other-medical
.	O

A	O
landmark	O
study	O
found	O
that	O
fluoxetine	other-medical
(	O
Prozac	other-medical
)	O
was	O
more	O
likely	O
to	O
increase	O
overall	O
suicidal	O
behavior	O
.	O

Anxiety	O
,	O
as	O
well	O
as	O
mood	O
and	O
obsessive-compulsive	O
symptoms	O
,	O
may	O
be	O
treated	O
using	O
SSRIs	other-medical
,	O
although	O
these	O
can	O
also	O
aggravate	O
hyperactivity	O
and	O
cause	O
disinhibited	O
behavior	O
.	O

The	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
lomitapide	other-medical
on	O
21	O
December	O
2012	O
,	O
as	O
an	O
orphan	O
drug	O
to	O
reduce	O
LDL	O
cholesterol	O
,	O
total	O
cholesterol	O
,	O
apolipoprotein	O
B	O
,	O
and	O
non-high-density	O
lipoprotein	O
(	O
non-HDL	O
)	O
cholesterol	O
in	O
patients	O
with	O
homozygous	O
familial	O
hypercholesterolemia	O
(	O
HoFH	O
)	O
.	O

A	O
new	O
model	O
has	O
recently	O
surfaced	O
in	O
the	O
literature	O
regarding	O
the	O
HPA	other-medical
axis	other-medical
(	O
structures	O
in	O
the	O
brain	O
that	O
get	O
activated	O
in	O
response	O
to	O
stress	O
)	O
and	O
its	O
involvement	O
with	O
dysthymia	other-medical
(	O
e.g	O
.	O

These	O
two	O
drugs	O
,	O
in	O
combination	O
with	O
other	O
drugs	O
like	O
Nyquil	other-medical
and	O
Theraflu	other-medical
,	O
can	O
cause	O
death	O
by	O
multiple	O
drug	O
intake	O
and/or	O
drug	O
overdose	O
.	O

Moreover	O
,	O
spirorenone	other-medical
itself	O
has	O
virtually	O
no	O
affinity	O
for	O
the	O
androgen	O
receptor	O
while	O
its	O
progestogenic	O
activity	O
shows	O
species	O
differences	O
,	O
being	O
somewhat	O
greater	O
than	O
that	O
of	O
spironolactone	O
in	O
rabbits	O
but	O
absent	O
in	O
mice	O
and	O
rats	O
.	O

Gene	other-medical
therapy	other-medical
in	other-medical
SMA	other-medical
aims	O
at	O
restoring	O
the	O
``	O
SMN1	O
``	O
gene	O
function	O
through	O
inserting	O
specially	O
crafted	O
nucleotide	O
sequence	O
(	O
a	O
``	O
SMN1	O
``	O
transgene	O
)	O
into	O
the	O
cell	O
nucleus	O
using	O
a	O
viral	O
vector	O
;	O
scAAV-9	O
and	O
scAAV-10	O
are	O
the	O
primary	O
viral	O
vectors	O
under	O
investigation	O
.	O

Another	O
potentially	O
serious	O
complication	O
associated	O
with	O
heparin	other-medical
use	O
is	O
called	O
heparin-induced	O
thrombocytopenia	O
(	O
HIT	O
)	O
.	O

It	O
has	O
been	O
concluded	O
in	O
various	O
studies	O
that	O
benzodiazepine	other-medical
use	O
causes	O
greater	O
levels	O
of	O
risk	O
and	O
psycho-social	O
dysfunction	O
among	O
drug	O
misusers	O
.	O

The	O
anti-cancer	O
drug	O
imatinib	other-medical
has	O
recently	O
been	O
shown	O
to	O
reverse	O
the	O
graying	O
process	O
.	O

Ibuprofen	other-medical
can	O
also	O
worsen	O
asthma	O
.	O

GFAP	other-medical
has	O
also	O
been	O
shown	O
to	O
be	O
important	O
in	O
repair	O
after	O
CNS	O
injury	O
.	O

Neuromuscular	other-medical
medicine	other-medical
is	O
subspecialty	O
of	O
neurology	O
and	O
physiatry	O
that	O
focuses	O
the	O
diagnosis	O
and	O
treatment	O
of	O
neuromuscular	O
diseases	O
.	O

Among	O
those	O
who	O
are	O
older	O
,	O
ofloxacin	other-medical
may	O
be	O
used	O
.	O

This	O
antigen	O
is	O
recognized	O
by	O
the	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
OKM5	other-medical
and	O
OKM8	other-medical
.	O

Muscle	other-medical
relaxants	other-medical
are	O
typically	O
used	O
for	O
and	O
are	O
helpful	O
with	O
acute	other-medical
post-traumatic	other-medical
TTH	other-medical
rather	O
than	O
ETTH	other-medical
.	O

Vomiting	other-medical
agents	other-medical
are	O
chemical	O
weapon	O
agents	O
causing	O
vomiting	O
.	O

Human	other-medical
PTRF	other-medical
mutations	other-medical
may	O
cause	O
secondary	O
deficiency	O
of	O
caveolins	O
,	O
resulting	O
in	O
generalized	O
lipodystrophy	other-medical
in	O
association	O
with	O
in	O
muscular	other-medical
dystrophy	other-medical
.	O

For	O
vulvovaginal	O
candidiasis	O
,	O
clotrimazole	other-medical
tablets	other-medical
and	O
creams	O
are	O
inserted	O
into	O
the	O
vagina	O
.	O

The	O
council	O
,	O
who	O
support	O
licensing	O
poppy	O
cultivation	O
in	O
Afghanistan	O
to	O
create	O
Afghan	O
morphine	O
,	O
believe	O
the	O
opium	O
supply	O
in	O
this	O
country	O
could	O
go	O
a	O
long	O
way	O
to	O
easing	O
the	O
pain	O
relief	O
needs	O
of	O
sufferers	O
in	O
emerging	O
countries	O
by	O
producing	O
a	O
cheap	O
poppy-based	O
medicine	O
solution	O
(	O
see	O
[	O
The	O
Senlis	O
Council	O
]	O
:	O
``	O
Poppy	other-medical
for	other-medical
Medicine	other-medical
.	O
''	O

Conversely	O
,	O
naltrexone	other-medical
antagonism	O
at	O
the	O
opioid	O
receptor	O
can	O
be	O
overcome	O
with	O
higher	O
doses	O
of	O
opioids	O
.	O

In	O
an	O
early	O
report	O
on	O
inhibition	O
of	O
snake	O
venom	O
toxicities	O
,	O
Varespladib	other-medical
,	O
and	O
its	O
orally	other-medical
bioavailable	other-medical
prodrug	other-medical
methyl-varespladib	other-medical
(	O
LY333013	other-medical
)	O
showed	O
strong	O
inhibition	O
of	O
28	O
types	O
of	O
svPLA2s	O
from	O
six	O
continents	O
.	O

Exposure	O
to	O
light	O
during	O
the	O
hours	O
of	O
melatonin	other-medical
production	O
reduces	O
melatonin	other-medical
production	O
.	O

Flatulence	other-medical
has	O
been	O
recorded	O
in	O
whales	O
.	O

Both	O
diabetes	O
mellitus	O
type	O
1	O
and	O
diabetes	O
mellitus	O
type	O
2	O
are	O
marked	O
by	O
a	O
loss	other-medical
of	other-medical
pancreatic	other-medical
function	other-medical
,	O
though	O
to	O
differing	O
degrees	O
.	O

In	O
2008	O
Medic	O
One	O
's	O
survival	O
rate	O
for	O
witnessed	O
cardiac	other-medical
arrests	other-medical
due	O
to	O
heart	O
disease	O
prior	O
to	O
EMS	O
arrival	O
with	O
initial	O
rhythm	O
of	O
ventricular	other-medical
fibrillation	other-medical
or	O
ventricular	other-medical
tachycardia	other-medical
was	O
49	O
%	O
.	O

Benzodiazepines	other-medical
,	O
including	O
lorazepam	other-medical
,	O
clonazepam	other-medical
and	O
diazepam	other-medical
,	O
are	O
types	O
of	O
anti-anxiety	O
medications	O
.	O

There	O
has	O
been	O
controversy	O
over	O
the	O
decision	O
by	O
NHS	O
Greater	O
Glasgow	O
to	O
downgrade	O
facilities	O
at	O
the	O
local	O
Stobhill	O
Hospital	O
in	O
nearby	O
Springburn	O
to	O
an	O
Ambulatory	O
care	O
facility	O
,	O
which	O
will	O
result	O
in	O
the	O
nearest	O
Accident	O
and	O
Emergency	O
and	O
inpatient	O
facilities	O
being	O
located	O
at	O
the	O
Glasgow	O
Royal	O
Infirmary	O
in	O
the	O
city	O
centre	O
,	O
as	O
well	O
as	O
the	O
development	O
of	O
an	O
inpatient	O
Psychiatric	other-medical
hospital	O
at	O
the	O
site	O
.	O

Lamivudine	other-medical
(	O
3TC	other-medical
)	O
significantly	O
inhibits	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	O
to	O
the	O
active	O
form	O
,	O
and	O
accordingly	O
the	O
drugs	O
should	O
not	O
be	O
administered	O
together	O
.	O

This	O
was	O
considered	O
an	O
acceptable	O
risk	O
because	O
the	O
malaria	O
could	O
later	O
be	O
treated	O
with	O
quinine	other-medical
,	O
which	O
was	O
available	O
at	O
that	O
time	O
.	O

Because	O
armodafinil	other-medical
has	O
a	O
longer	O
half-life	O
than	O
modafinil	other-medical
does	O
,	O
it	O
may	O
be	O
more	O
effective	O
at	O
improving	O
wakefulness	O
in	O
patients	O
with	O
excessive	O
daytime	O
sleepiness	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
1980s	O
that	O
buprenorphine	other-medical
binds	O
to	O
at	O
high	O
affinity	O
and	O
antagonizes	O
the	O
KOR	other-medical
.	O

Insulin	O
regulates	O
blood	O
glucose	O
levels	O
while	O
CCK	O
adjusts	O
gastric	other-medical
emptying	other-medical
,	O
pancreatic	other-medical
secretion	other-medical
and	O
gall	other-medical
bladder	other-medical
contraction	other-medical
.	O

His	O
apparent	O
ADHD	O
affected	O
his	O
play	O
in	O
high	O
school	O
,	O
and	O
he	O
took	O
Ritalin	other-medical
to	O
treat	O
the	O
condition	O
.	O

If	O
there	O
is	O
resistance	O
or	O
use	O
of	O
amoxicillin	other-medical
in	O
the	O
last	O
30	O
days	O
then	O
amoxicillin-clavulanate	other-medical
or	O
another	O
penicillin	other-medical
derivative	O
plus	O
beta	O
lactamase	other-medical
inhibitor	other-medical
is	O
recommended	O
.	O

It	O
was	O
picked	O
up	O
by	O
Bio-Technology	O
General	O
Corporation	O
,	O
which	O
changed	O
its	O
name	O
to	O
Savient	other-medical
Pharmaceuticals	other-medical
,	O
which	O
following	O
successful	O
clinical	O
trials	O
in	O
1995	O
,	O
released	O
it	O
under	O
the	O
brand	O
name	O
Oxandrin	other-medical
.	O

Established	O
diagnoses	O
include	O
Down	other-medical
syndrome	other-medical
,	O
Fragile	other-medical
X	other-medical
syndrome	other-medical
,	O
Trisomy	other-medical
8	other-medical
mosaic	other-medical
syndrome	other-medical
,	O
Trisomy	other-medical
13	other-medical
syndrome	other-medical
,	O
Williams	other-medical
syndrome	other-medical
,	O
Angelman	other-medical
syndrome	other-medical
,	O
Smith–Magenis	other-medical
syndrome	other-medical
,	O
PKU	other-medical
,	O
Tuberous	other-medical
sclerosis	other-medical
,	O
Neurofibromatosis	other-medical
,	O
Sturge–Weber	other-medical
syndrome	other-medical
,	O
Congenital	other-medical
rubella	other-medical
syndrome	other-medical
,	O
the	O
syndrome	O
of	O
hypoxic	other-medical
/	O
ischemic	other-medical
perinatal	other-medical
brain	other-medical
injury	other-medical
,	O
lead	other-medical
encephalopathy	other-medical
,	O
hydrocephalus	other-medical
,	O
prosencephaly	other-medical
,	O
schizencephaly	other-medical
,	O
and	O
other	O
diagnoses	O
.	O

62	O
%	O
of	O
people	O
taking	O
gabapentin	other-medical
may	O
have	O
at	O
least	O
one	O
adverse	O
event	O
,	O
however	O
the	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
found	O
to	O
be	O
low	O
.	O

The	O
boxed	O
warning	O
about	O
heart	other-medical
attack	other-medical
was	O
removed	O
;	O
the	O
warning	O
about	O
heart	other-medical
failure	other-medical
remained	O
in	O
place	O
.	O

Combined	O
use	O
of	O
clonazepam	other-medical
with	O
certain	O
antidepressants	O
,	O
anticonvulsants	O
(	O
such	O
as	O
phenobarbital	other-medical
,	O
phenytoin	other-medical
,	O
and	O
carbamazepine	other-medical
)	O
,	O
sedative	O
antihistamines	O
,	O
opiates	O
,	O
and	O
antipsychotics	O
,	O
nonbenzodiazepines	O
(	O
such	O
as	O
zolpidem	other-medical
)	O
,	O
and	O
alcohol	O
may	O
result	O
in	O
enhanced	O
sedative	O
effects	O
.	O

Ketamine	other-medical
infusions	O
are	O
used	O
for	O
the	O
acute	O
pain	O
treatment	O
in	O
emergency	O
departments	O
and	O
in	O
the	O
perioperative	O
period	O
in	O
individuals	O
with	O
refractory	O
pain	O
.	O

Non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
such	O
as	O
Aspirin	other-medical
or	O
Ibuprofen	other-medical
,	O
are	O
contraindicated	O
because	O
they	O
interfere	O
with	O
bone	O
healing	O
.	O

Myocet	other-medical
has	O
similar	O
efficacy	O
as	O
conventional	O
doxorubicin	other-medical
,	O
while	O
significantly	O
reducing	O
cardiac	O
toxicity	O
.	O

The	O
CDC	O
,	O
the	O
IOM	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
Australia	O
's	O
Department	O
of	O
Health	O
,	O
and	O
the	O
UK	O
National	O
Health	O
Service	O
have	O
all	O
concluded	O
that	O
there	O
is	O
no	O
evidence	O
of	O
a	O
link	O
between	O
the	O
MMR	other-medical
vaccine	other-medical
and	O
autism	O
.	O

While	O
chloroform	O
has	O
no	O
known	O
environmental	O
hazards	O
,	O
large	O
amounts	O
of	O
exposure	O
to	O
chloroform	O
can	O
cause	O
alterations	O
in	O
the	O
mind	O
,	O
such	O
as	O
depression	other-medical
and	O
irritability	other-medical
.	O

The	O
anti	O
convulsion	O
drug	O
Lamotrigine	other-medical
has	O
shown	O
some	O
success	O
in	O
treating	O
symptoms	O
of	O
depersonalization	O
,	O
often	O
in	O
combination	O
with	O
a	O
Selective	O
serotonin	O
reuptake	O
inhibitor	O
and	O
is	O
the	O
first	O
drug	O
of	O
choice	O
at	O
the	O
depersonalisation	O
research	O
unit	O
at	O
King	O
's	O
College	O
London	O
.	O

While	O
there	O
is	O
good	O
evidence	O
for	O
the	O
efficacy	O
of	O
opioid	other-medical
rotation	O
as	O
a	O
treatment	O
approach	O
in	O
general	O
,	O
there	O
is	O
less	O
evidence	O
for	O
what	O
particular	O
opioid	other-medical
analgesics	O
are	O
most	O
suitable	O
,	O
and	O
in	O
practice	O
the	O
choice	O
of	O
opioid	other-medical
drugs	O
used	O
depends	O
on	O
many	O
factors	O
such	O
as	O
patient	O
characteristics	O
,	O
prescriber	O
preferences	O
and	O
safety	O
.	O

Various	O
agents	O
can	O
inhibit	O
5-HT	O
reuptake	O
,	O
including	O
cocaine	other-medical
,	O
dextromethorphan	other-medical
(	O
an	O
antitussive	other-medical
)	O
,	O
tricyclic	other-medical
antidepressants	other-medical
and	O
selective	other-medical
serotonin	other-medical
reuptake	other-medical
inhibitors	other-medical
(	O
SSRIs	other-medical
)	O
.	O

Adjunctive	O
to	O
morphine	other-medical
or	O
on	O
its	O
own	O
,	O
ketamine	other-medical
reduces	O
morphine	other-medical
use	O
,	O
pain	O
level	O
,	O
nausea	O
,	O
and	O
vomiting	O
after	O
surgery	O
.	O

Another	O
medication	O
formulated	O
as	O
an	O
injector	O
pen	O
to	O
ensure	O
quick	O
onset	O
of	O
action	O
is	O
glucagon	other-medical
for	O
hypoglycemia	O
.	O

Due	O
to	O
disagreement	O
and	O
misconceptions	O
among	O
health	O
and	O
mental	O
health	O
professionals	O
,	O
cyclothymia	O
is	O
often	O
diagnosed	O
as	O
``	O
bipolar	other-medical
not	other-medical
otherwise	other-medical
specified	other-medical
``	O
.	O

Though	O
slightly	O
less	O
potent	O
,	O
artesunate	other-medical
is	O
also	O
useful	O
in	O
human	O
fasciolosis	O
.	O

It	O
also	O
participates	O
in	O
beta-alanine	other-medical
metabolism	other-medical
and	O
pantothenate	other-medical
and	O
coa	other-medical
biosynthesis	other-medical
.	O

Petacchi	O
was	O
then	O
absolved	O
by	O
the	O
FCI	O
when	O
they	O
deemed	O
any	O
overuse	O
of	O
Salbutamol	other-medical
as	O
simple	O
human	O
error	O
.	O

Self-catheterization	other-medical
is	O
an	O
option	O
in	O
BPH	other-medical
when	O
it	O
is	O
difficult	O
or	O
impossible	O
to	O
completely	O
empty	O
the	O
bladder	O
.	O

Dexlansoprazole	other-medical
is	O
used	O
to	O
heal	O
and	O
maintain	O
healing	O
of	O
erosive	O
esophagitis	O
and	O
to	O
treat	O
heartburn	O
associated	O
with	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
.	O

It	O
is	O
closely	O
related	O
on	O
a	O
structural	O
level	O
to	O
a	O
number	O
of	O
other	O
stimulants	O
,	O
such	O
as	O
MDPV	other-medical
and	O
prolintane	other-medical
(	O
Promotil	other-medical
,	O
Katovit	other-medical
)	O
.	O

These	O
treatments	O
were	O
finally	O
rendered	O
obsolete	O
by	O
the	O
discovery	O
of	O
penicillin	other-medical
,	O
and	O
its	O
widespread	O
manufacture	O
after	O
World	O
War	O
II	O
allowed	O
syphilis	O
to	O
be	O
effectively	O
and	O
reliably	O
cured	O
.	O

Bupropion	other-medical
inhibits	O
the	O
reuptake	O
of	O
dopamine	O
through	O
the	O
human	O
dopamine	O
transporter	O
and	O
norepinephrine	O
transporter	O
;	O
the	O
inhibition	O
of	O
dopamine	O
reuptake	O
through	O
the	O
norepinephrine	O
transporter	O
is	O
most	O
pronounced	O
in	O
the	O
prefrontal	O
cortex	O
of	O
humans	O
.	O

In	O
2013	O
,	O
the	O
FDA	O
lifted	O
its	O
earlier	O
restrictions	O
on	O
rosiglitazone	other-medical
after	O
reviewing	O
the	O
results	O
of	O
a	O
2009	O
trial	O
which	O
failed	O
to	O
show	O
increased	O
heart	O
attack	O
risk	O
.	O

Cimetidine	other-medical
inhibits	O
ALA	other-medical
synthase	O
activity	O
and	O
hence	O
may	O
have	O
some	O
therapeutic	O
value	O
in	O
preventing	O
and	O
treating	O
acute	O
porphyria	O
attacks	O
.	O

Dihydrotestosterone	O
also	O
plays	O
an	O
important	O
role	O
in	O
male	O
sexual	O
function	O
and	O
may	O
also	O
be	O
a	O
contributing	O
factor	O
of	O
ischemic	O
priapism	O
in	O
males	O
as	O
shown	O
in	O
a	O
study	O
conducted	O
on	O
the	O
use	O
of	O
finasteride	other-medical
to	O
treat	O
ischemic	O
priapism	O
in	O
males	O
.	O

Levels	O
of	O
anti-GM1	other-medical
antibodies	O
are	O
especially	O
elevated	O
in	O
patients	O
with	O
prodromal	O
diarrhea	O
.	O

Penicillins	other-medical
may	O
decrease	O
the	O
elimination	O
of	O
methotrexate	O
,	O
so	O
increase	O
the	O
risk	O
of	O
toxicity	O
.	O

The	O
rate	O
of	O
hypothyroidism	O
is	O
around	O
six	O
times	O
higher	O
in	O
people	O
who	O
take	O
lithium	other-medical
.	O

Like	O
primaquine	other-medical
,	O
pamaquine	other-medical
causes	O
haemolytic	O
anaemia	O
in	O
patients	O
with	O
G6PD	O
deficiency	O
.	O

Intravenously	O
injected	O
methylene	other-medical
blue	other-medical
is	O
readily	O
released	O
into	O
the	O
urine	O
and	O
thus	O
can	O
be	O
used	O
to	O
test	O
the	O
urinary	O
tract	O
for	O
leaks	O
or	O
fistulas	O
.	O

Generally	O
speaking	O
,	O
nootropics	other-medical
are	O
said	O
to	O
be	O
effective	O
for	O
enhancing	O
focus	O
,	O
learning	O
,	O
memory	O
function	O
,	O
mood	O
,	O
and	O
in	O
some	O
cases	O
,	O
physical	O
brain	O
development	O
.	O

Piperazine	other-medical
containing	O
designer	O
drugs	O
have	O
effects	O
similar	O
to	O
MDMA	other-medical
(	O
ecstasy	other-medical
)	O
.	O

In	O
type	O
3	O
diabetes	O
,	O
the	O
neurons	other-medical
lack	O
glucose	other-medical
,	O
a	O
key	O
element	O
needed	O
for	O
the	O
neurons	other-medical
to	O
function	O
effectively	O
in	O
body	O
however	O
more	O
specifically	O
the	O
hippocampus	other-medical
and	O
the	O
cerebral	other-medical
cortex	other-medical
.	O

Albendazole	other-medical
was	O
shown	O
to	O
be	O
highly	O
effective	O
and	O
is	O
advocated	O
as	O
the	O
drug	O
of	O
choice	O
.	O

Prior	O
to	O
joining	O
City	O
of	O
Hope	O
,	O
he	O
served	O
as	O
tenured	O
Professor	O
of	O
Medicine	O
,	O
Pathology	other-medical
and	O
Dermatology	other-medical
,	O
Director	O
of	O
the	O
Thoracic	other-medical
Oncology	other-medical
Program	O
and	O
the	O
Aerodigestive	O
Tract	O
Program	O
Translational	O
Research	O
Lab	O
in	O
the	O
section	O
of	O
Hematology	other-medical
/	O
Oncology	other-medical
,	O
Vice	O
Chair	O
for	O
Translational	O
Research	O
in	O
the	O
Department	O
of	O
Medicine	O
and	O
Associate	O
Director	O
for	O
Translational	O
Science	O
at	O
the	O
University	O
of	O
Chicago	O
Comprehensive	O
Cancer	O
Center	O
in	O
Chicago	O
.	O

The	O
first	O
such	O
compound	O
to	O
be	O
patented	O
was	O
zimelidine	other-medical
in	O
1971	O
,	O
while	O
the	O
first	O
released	O
clinically	O
was	O
indalpine	other-medical
.	O

Her	O
struggle	O
with	O
PPP	O
was	O
brought	O
on	O
by	O
the	O
prescription	O
drug	O
Zoloft	other-medical
which	O
resulted	O
in	O
an	O
SSRI	O
syndrome	O
.	O

After	O
Townley	O
suffered	O
a	O
concussion	other-medical
at	O
Pocono	O
during	O
an	O
ARCA	O
race	O
,	O
Clint	O
Bowyer	O
drove	O
the	O
No	O
.	O

Lidocaine	other-medical
was	O
reported	O
to	O
be	O
much	O
less	O
effective	O
in	O
reducing	O
pain	O
in	O
another	O
study	O
of	O
humans	O
with	O
MC1R	O
mutations	O

For	O
example	O
,	O
if	O
breakfast	O
cereal	O
in	O
Canada	O
is	O
fortified	O
,	O
they	O
must	O
contain	O
the	O
following	O
specific	O
amounts	O
per	O
100	O
grams	O
of	O
cereal	O
:	O
Thiamine	O
(	O
2.0	O
mg	O
)	O
,	O
Niacin	O
(	O
4.8	O
mg	O
)	O
,	O
Vitamin	other-medical
B6	other-medical
(	O
0.6	O
mg	O
)	O
,	O
Folic	O
Acid	O
(	O
0.06	O
mg	O
)	O
,	O
Pantothenic	O
Acid	O
(	O
1.6	O
mg	O
)	O
,	O
Magnesium	O
(	O
160.0	O
mg	O
)	O
,	O
Iron	O
(	O
13.3	O
mg	O
)	O
,	O
Zinc	O
(	O
3.5	O
mg	O
)	O
.	O

Some	O
drugs	O
,	O
like	O
tolcapone	other-medical
(	O
a	O
central	O
COMT-inhibitor	other-medical
)	O
,	O
raise	O
the	O
levels	O
of	O
all	O
the	O
catecholamines	O
.	O

The	O
physician	O
will	O
provide	O
you	O
a	O
course	O
of	O
2	O
weeks	O
of	O
antibiotics	other-medical
to	O
eliminate	O
any	O
possible	O
bacterial	O
overgrowth	O
and	O
repeat	O
the	O
test	O
to	O
check	O
whether	O
radio-labeled	O
Vitamin	O
B12	O
would	O
be	O
found	O
in	O
urine	O
or	O
not	O
.	O

In	O
2019	O
an	O
AAV9	other-medical
therapy	other-medical
was	O
approved	O
:	O
Onasemnogene	other-medical
abeparvovec	other-medical
.	O

By	O
weight	O
,	O
dimenhydrinate	other-medical
is	O
between	O
53	O
%	O
to	O
55.5	O
%	O
diphenhydramine	O
.	O

``	O
N.	other-medical
gonorrhoeae	other-medical
``	O
is	O
oxidase	O
positive	O
(	O
possessing	O
cytochrome	O
c	O
oxidase	O
)	O
and	O
catalase	O
positive	O
(	O
able	O
to	O
convert	O
hydrogen	other-medical
peroxide	other-medical
to	O
oxygen	O
)	O
.	O

According	O
to	O
William	O
Clarence-Smith	O
,	O
Islamic	O
Southeast	O
Asia	O
``	O
overwhelmingly	O
''	O
follows	O
the	O
Shafi	O
`	O
i	O
school	O
of	O
law	O
,	O
the	O
only	O
one	O
to	O
make	O
FGM	other-medical
obligatory	O
.	O

A	O
solution	O
of	O
1	O
%	O
potassium	O
permanganate	O
dissolved	O
in	O
hot	O
water	O
is	O
an	O
alternative	O
to	O
antifungal	other-medical
drugs	other-medical
.	O

A	O
short	O
trial	O
period	O
of	O
gabapentin	other-medical
therapy	O
is	O
recommended	O
,	O
to	O
determine	O
the	O
effectiveness	O
for	O
that	O
person	O
.	O

In	O
2011	O
,	O
after	O
pressure	O
by	O
activist	O
organizations	O
,	O
the	O
manufacturers	O
of	O
pentobarbital	other-medical
and	O
sodium	other-medical
thiopental	other-medical
halted	O
the	O
supply	O
of	O
the	O
drugs	O
to	O
U.S	O
.	O
prisons	O
performing	O
lethal	O
injections	O
and	O
required	O
all	O
resellers	O
to	O
do	O
the	O
same	O
.	O

Other	O
major	O
estradiol	O
esters	O
that	O
are	O
or	O
have	O
been	O
used	O
in	O
medicine	O
include	O
estradiol	O
acetate	O
,	O
estradiol	O
cypionate	O
,	O
estradiol	O
dipropionate	O
,	O
estradiol	O
enantate	O
,	O
estradiol	O
undecylate	O
,	O
and	O
polyestradiol	O
phosphate	O
(	O
an	O
estrogen	O
ester	O
polymer	O
)	O
,	O
as	O
well	O
as	O
the	O
nitrogen	other-medical
mustard	other-medical
alkylating	other-medical
antineoplastic	other-medical
agent	other-medical
estramustine	other-medical
phosphate	other-medical
(	O
estradiol	O
normustine	O
phosphate	O
)	O
.	O

Peripheral	O
edema	O
(	O
fluid	O
accumulation	O
in	O
the	O
tissues	O
)	O
occurs	O
at	O
rate	O
of	O
10.8	O
%	O
at	O
a	O
10-mg	O
dose	O
(	O
versus	O
0.6	O
%	O
for	O
placebos	other-medical
)	O
,	O
and	O
is	O
three	O
times	O
more	O
likely	O
in	O
women	O
than	O
in	O
men	O
.	O

Opioid	other-medical
rotation	other-medical
is	O
one	O
method	O
suggested	O
to	O
minimise	O
the	O
impact	O
of	O
constipation	O
in	O
long-term	O
users	O
.	O

He	O
enjoyed	O
large	O
royalties	O
from	O
Smith	O
,	O
Kline	O
&	O
amp	O
;	O
French	O
(	O
SKF	O
)	O
because	O
he	O
sold	O
his	O
patent	O
rights	O
for	O
amphetamine	other-medical
to	O
the	O
company	O
and	O
it	O
enjoyed	O
large	O
sales	O
.	O

MDMA	other-medical
tablets	O
are	O
also	O
imported	O
from	O
the	O
Netherlands	O
into	O
China	O
to	O
meet	O
the	O
demand	O
.	O

GSK	O
used	O
the	O
``	O
JAACAP	O
``	O
article	O
to	O
promote	O
paroxetine	other-medical
to	O
doctors	O
for	O
use	O
in	O
their	O
teenage	O
patients	O
.	O

However	O
,	O
the	O
use	O
of	O
stimulants	other-medical
in	O
the	O
fragile	O
X	O
population	O
is	O
associated	O
with	O
a	O
greater	O
frequency	O
of	O
adverse	O
events	O
including	O
increased	O
anxiety	O
,	O
irritability	O
and	O
mood	O
lability	O
.	O

He	O
has	O
been	O
particularly	O
critical	O
of	O
Rachel	O
Carson	O
who	O
,	O
he	O
wrote	O
,	O
``	O
misrepresented	O
the	O
existing	O
science	O
on	O
bird	O
reproduction	O
and	O
was	O
wrong	O
about	O
DDT	other-medical
causing	O
cancer	O
.	O
''	O

Care	O
must	O
be	O
taken	O
when	O
prescribing	O
benzodiazepines	other-medical
due	O
to	O
the	O
risk	O
of	O
the	O
person	O
developing	O
tolerance	O
and	O
dependence	O
.	O

Warfarin	other-medical
is	O
not	O
recommended	O
until	O
platelets	O
have	O
normalized	O
.	O

The	O
visual	other-medical
disturbance	other-medical
is	O
due	O
solely	O
to	O
the	O
forced	O
closure	O
of	O
the	O
eyelids	O
.	O

The	O
first	O
hyaluronan	O
biomedical	O
product	O
,	O
Healon	O
,	O
was	O
developed	O
in	O
the	O
1970s	O
and	O
1980s	O
by	O
Pharmacia	O
,	O
and	O
approved	O
for	O
use	O
in	O
eye	O
surgery	O
(	O
i.e.	O
,	O
corneal	other-medical
transplantation	other-medical
,	O
cataract	other-medical
surgery	other-medical
,	O
glaucoma	other-medical
surgery	other-medical
,	O
and	O
surgery	O
to	O
repair	other-medical
retinal	other-medical
detachment	other-medical
)	O
.	O

in	O
2008	O
16	O
Anadin	other-medical
Paracetamol	other-medical
tablets	other-medical
each	O
containing	O
500	O
mg	O
of	O
paracetamol	O
cost	O
around	O
£2.09	O
while	O
non-branded	O
equivalents	O
retailed	O
for	O
around	O
£0.35	O
)	O
.	O

In	O
October	O
2001	O
,	O
a	O
9-month-old	O
girl	O
named	O
Tshepang	O
was	O
raped	O
by	O
an	O
HIV-positive	O
man	O
and	O
had	O
to	O
undergo	O
extensive	O
reconstructive	other-medical
surgery	other-medical
in	O
Cape	O
Town	O
.	O

A	O
Cochrane	O
review	O
concluded	O
that	O
there	O
is	O
no	O
credible	O
link	O
between	O
the	O
MMR	other-medical
vaccine	other-medical
and	O
autism	O
,	O
that	O
MMR	other-medical
has	O
prevented	O
diseases	O
that	O
still	O
carry	O
a	O
heavy	O
burden	O
of	O
death	O
and	O
complications	O
,	O
that	O
the	O
lack	O
of	O
confidence	O
in	O
MMR	other-medical
has	O
damaged	O
public	O
health	O
,	O
and	O
that	O
the	O
design	O
and	O
reporting	O
of	O
safety	O
outcomes	O
in	O
MMR	other-medical
vaccine	other-medical
studies	O
are	O
largely	O
inadequate	O
.	O

The	O
difference	O
between	O
the	O
vardenafil	other-medical
molecule	other-medical
and	O
sildenafil	other-medical
citrate	other-medical
is	O
a	O
nitrogen	O
atom	O
's	O
position	O
and	O
the	O
change	O
of	O
sildenafil	other-medical
's	O
piperazine	other-medical
ring	other-medical
methyl	other-medical
group	other-medical
to	O
an	O
ethyl	other-medical
group	other-medical
.	O

It	O
has	O
been	O
shown	O
that	O
phosphorylation	O
of	O
STAT3	O
and	O
RANTES	O
expression	O
are	O
increased	O
in	O
response	O
to	O
tamoxifen	other-medical
in	O
human	O
breast	O
cancer	O
cells	O
.	O

It	O
was	O
developed	O
under	O
contract	O
to	O
Edgewood	O
Arsenal	O
during	O
the	O
1960s	O
as	O
part	O
of	O
the	O
US	O
military	O
chemical	O
weapons	O
program	O
,	O
during	O
research	O
to	O
improve	O
upon	O
the	O
properties	O
of	O
earlier	O
agents	O
such	O
as	O
QNB	other-medical
.	O

Recently	O
,	O
analeptics	O
have	O
been	O
turned	O
to	O
the	O
treatment	O
of	O
ADHD	O
due	O
to	O
more	O
efficient	O
ways	O
to	O
treat	O
barbiturate	other-medical
overdoses	O
.	O

Carbamazepine	other-medical
is	O
relatively	O
slowly	O
but	O
well	O
absorbed	O
after	O
oral	O
administration	O
.	O

BAT	other-medical
is	O
the	O
only	O
product	O
available	O
for	O
treating	O
botulism	O
in	O
adults	O
,	O
and	O
for	O
botulism	O
in	O
infants	O
caused	O
by	O
botulinum	O
toxins	O
other	O
than	O
types	O
A	O
and	O
B	O
.	O

Melatonin	other-medical
receptor	other-medical
agonists	other-medical
are	O
analogues	O
of	O
melatonin	O
that	O
bind	O
to	O
and	O
activate	O
the	O
melatonin	O
receptor	O
.	O

One	O
advantage	O
is	O
a	O
well-defined	O
margin	O
between	O
therapeutic	O
and	O
toxic	O
doses	O
,	O
which	O
means	O
one	O
would	O
lose	O
consciousness	O
before	O
dangerous	O
levels	O
of	O
dissolved	O
ether	other-medical
in	O
blood	O
would	O
be	O
reached	O
.	O

Three	O
tests	O
that	O
are	O
commonly	O
used	O
in	O
diagnosing	O
narcolepsy	O
are	O
polysomnography	other-medical
(	O
PSG	other-medical
)	O
,	O
the	O
multiple	O
sleep	O
latency	O
test	O
(	O
MSLT	other-medical
)	O
,	O
and	O
the	O
Epworth	other-medical
Sleepiness	other-medical
Scale	other-medical
(	O
ESS	other-medical
)	O
.	O

Chemotherapy	other-medical
is	O
justified	O
for	O
cancers	O
whose	O
prognosis	O
after	O
surgery	O
is	O
poor	O
without	O
additional	O
intervention	O
.	O

Sodium	other-medical
oxybate	other-medical
is	O
approved	O
by	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
cataplexy	O
associated	O
with	O
narcolepsy	O
and	O
excessive	O
daytime	O
sleepiness	O
(	O
EDS	O
)	O
associated	O
with	O
narcolepsy	O
.	O

The	O
oral	O
bioavailability	O
of	O
seletracetam	other-medical
is	O
&	O
gt	O
;	O
90	O
%	O
and	O
its	O
half-life	O
is	O
approximately	O
8	O
hours	O
.	O

As	O
GH	other-medical
is	O
a	O
large	O
peptide	O
molecule	O
,	O
it	O
must	O
be	O
injected	O
into	O
subcutaneous	O
tissue	O
or	O
muscle	O
to	O
get	O
it	O
into	O
the	O
blood	O
.	O

On	O
June	O
30	O
,	O
2009	O
,	O
an	O
FDA	O
advisory	O
panel	O
recommended	O
that	O
Vicodin	other-medical
and	O
another	O
painkiller	O
,	O
Percocet	other-medical
,	O
be	O
removed	O
from	O
the	O
market	O
because	O
they	O
have	O
allegedly	O
caused	O
over	O
400	O
deaths	O
a	O
year	O
.	O

There	O
is	O
tentative	O
evidence	O
of	O
benefit	O
for	O
tranexamic	other-medical
acid	other-medical
which	O
inhibits	O
clot	O
breakdown	O
.	O

Ectrodactyly	O
,	O
or	O
Split	O
hand/split	O
foot	O
malformation	O
(	O
SHFM	O
)	O
type	O
1	O
is	O
the	O
only	O
form	O
of	O
split	O
hand/	O
malformation	O
associated	O
with	O
sensorineural	other-medical
hearing	other-medical
loss	other-medical
.	O

In	O
the	O
United	O
States	O
,	O
piracetam	other-medical
is	O
not	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
.	O

In	O
animal	O
models	O
of	O
depression	O
,	O
aticaprant	O
has	O
been	O
found	O
to	O
have	O
potent	O
synergistic	O
efficacy	O
in	O
combination	O
with	O
other	O
antidepressants	O
such	O
as	O
citalopram	other-medical
and	O
imipramine	other-medical
.	O

Traditionally	O
,	O
gonorrhea	O
was	O
diagnosed	O
with	O
Gram	other-medical
stain	other-medical
and	O
culture	O
;	O
however	O
,	O
newer	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
testing	O
methods	O
are	O
becoming	O
more	O
common	O
.	O

Lamivudine	other-medical
is	O
administered	O
by	O
mouth	O
,	O
and	O
it	O
is	O
rapidly	O
absorbed	O
with	O
a	O
bio-availability	O
of	O
over	O
80	O
%	O
.	O

His	O
paper	O
``	O
Severe	O
Dopaminergic	O
Neurotoxicity	O
in	O
Primates	O
After	O
a	O
Common	O
Recreational	O
Dose	O
Regimen	O
of	O
MDMA	O
(	O
'Ecstasy	O
'	O
)	O
``	O
in	O
``	O
Science	O
``	O
was	O
later	O
retracted	O
after	O
it	O
became	O
clear	O
that	O
the	O
monkeys	O
had	O
in	O
fact	O
been	O
injected	O
not	O
with	O
MDMA	other-medical
,	O
but	O
with	O
extremely	O
high	O
doses	O
of	O
methamphetamine	other-medical
.	O

In	O
July	O
2008	O
,	O
Mr	O
.	O
Patel	O
designed	O
and	O
initiated	O
Synageva	O
's	O
lead	O
program	O
,	O
Kanuma	other-medical
®	O
(	O
sebelipase	other-medical
alfa	other-medical
)	O
to	O
address	O
a	O
rare	O
and	O
devastating	O
disease	O
known	O
as	O
lysosomal	O
acid	O
lipase	O
deficiency	O
(	O
LAL	O
Deficiency	O
)	O
.	O

Varespladib	other-medical
treatment	O
exerted	O
a	O
significant	O
inhibitory	O
effect	O
on	O
snake	O
venom	O
PLA₂	O
both	O
``	O
in	O
vitro	O
''	O
and	O
in	O
``	O
vivo	O
''	O
.	O

He	O
and	O
his	O
colleagues	O
often	O
served	O
as	O
their	O
own	O
lab	O
rats	O
,	O
voluntarily	O
undergoing	O
such	O
procedures	O
as	O
self-induced	O
iron	other-medical
deficiency	other-medical
anemia	other-medical
,	O
sub-dermal	other-medical
bone	other-medical
transplantation	other-medical
,	O
and	O
consumption	O
of	O
radio-labeled	other-medical
iron	other-medical
.	O

Chest	other-medical
X-rays	other-medical
are	O
frequently	O
used	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
CHF	O
.	O

Cases	O
of	O
individuals	O
being	O
sentenced	O
to	O
time	O
in	O
prison	O
and	O
other	O
penalties	O
for	O
selling	O
pure	O
dextromethorphan	other-medical
in	O
this	O
form	O
have	O
been	O
reported	O
,	O
because	O
of	O
the	O
incidental	O
violation	O
of	O
more	O
general	O
laws	O
for	O
the	O
sale	O
of	O
legitimate	O
drugs	O
–	O
such	O
as	O
resale	O
of	O
a	O
medication	O
without	O
proper	O
warning	O
labels	O
.	O

One	O
reason	O
hypoglycemia	other-medical
due	O
to	O
excessive	O
insulin	O
can	O
be	O
more	O
dangerous	O
is	O
that	O
insulin	O
lowers	O
the	O
available	O
amounts	O
of	O
most	O
alternate	O
brain	O
fuels	O
,	O
such	O
as	O
ketones	other-medical
.	O

Thus	O
,	O
a	O
significantly	O
depressed	O
MA	O
could	O
be	O
treated	O
with	O
platelet	O
transfusion	O
or	O
medications	O
that	O
improve	O
platelet	O
function	O
,	O
such	O
as	O
DDAVP	other-medical
.	O

Diagnosis	O
of	O
patients	O
with	O
even	O
mild	O
hirsutism	O
should	O
include	O
assessment	O
of	O
ovulation	other-medical
and	O
ovarian	other-medical
ultrasound	other-medical
,	O
due	O
to	O
the	O
high	O
prevalence	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
,	O
as	O
well	O
as	O
17α-hydroxyprogesterone	O
(	O
because	O
of	O
the	O
possibility	O
of	O
finding	O
nonclassic	O
21-hydroxylase	O
deficiency	O
)	O
.	O

Some	O
common	O
dose-dependent	O
adverse	O
effects	O
of	O
amlodipine	other-medical
include	O
vasodilatory	O
effects	O
,	O
[	O
[	O
peripheral	O
edema	O
]	O
]	O
,	O
[	O
[	O
dizziness	O
]	O
]	O
,	O
[	O
[	O
palpitations	O
]	O
]	O
,	O
and	O
[	O
[	O
Flushing	O
(	O
physiology	O
)	O
|flushing	O
]	O
]	O
.	O

``	O
N.	other-medical
gonorrhoeae	other-medical
''	other-medical
is	O
usually	O
isolated	O
on	O
Thayer-Martin	O
agar	O
(	O
or	O
VPN	O
)	O
agar	O
in	O
an	O
environment	O
enriched	O
with	O
3-7	O
%	O
carbon	O
dioxide	O
.	O

It	O
is	O
also	O
combined	O
with	O
ephedrine	O
to	O
produce	O
Primatene	other-medical
and	O
Bronkaid	other-medical
tablets	O
for	O
symptomatic	O
relief	O
of	O
asthma	O
.	O

However	O
,	O
chloral	other-medical
hydrate	other-medical
products	O
,	O
licensed	O
for	O
short-term	O
management	O
of	O
severe	O
insomnia	O
,	O
are	O
available	O
in	O
the	O
United	O
Kingdom	O
.	O

Trastuzumab	other-medical
or	O
Herceptin	other-medical
inhibits	O
downstream	O
signal	O
cascades	O
by	O
selectively	O
binding	O
to	O
the	O
extracellular	O
domain	O
of	O
ErbB-2	other-medical
receptors	other-medical
to	O
inhibit	O
it	O
.	O

While	O
one	O
of	O
the	O
main	O
rationales	O
for	O
the	O
use	O
of	O
this	O
class	O
is	O
the	O
avoidance	O
of	O
a	O
persistent	O
dry	O
cough	O
and/or	O
angioedema	O
associated	O
with	O
ACE	other-medical
inhibitor	other-medical
therapy	O
,	O
rarely	O
they	O
may	O
still	O
occur	O
.	O

Hence	O
tamoxifen	other-medical
's	O
tissue	O
selective	O
action	O
directly	O
led	O
to	O
the	O
formulation	O
of	O
the	O
concept	O
of	O
SERMs	other-medical
.	O

Desipramine	other-medical
has	O
the	O
weakest	O
antihistamine	O
and	O
anticholinergic	O
effects	O
of	O
the	O
TCAs	other-medical
.	O

Talley	O
's	O
research	O
interests	O
are	O
in	O
neurogastroenterology	other-medical
;	O
including	O
the	O
treatment	O
,	O
pathophysiology	O
and	O
epidemiology	O
of	O
functional	O
dyspepsia	O
and	O
irritable	O
bowel	O
syndrome	O
;	O
he	O
is	O
considered	O
an	O
international	O
authority	O
in	O
the	O
field	O
.	O

When	O
using	O
over-the-counter	O
drug	O
clotrimazole	other-medical
products	O
,	O
use	O
should	O
be	O
discontinued	O
if	O
condition	O
does	O
not	O
improve	O
after	O
treatment	O
for	O
2	O
weeks	O
for	O
jock	O
itch	O
or	O
after	O
4	O
weeks	O
for	O
athlete	O
's	O
foot	O
or	O
ringworm	O
.	O

There	O
are	O
fixed-dose	O
combination	O
drugs	O
,	O
such	O
as	O
ACE	other-medical
inhibitor	other-medical
and	O
thiazide	O
combinations	O
.	O

Chloral	other-medical
hydrate	other-medical
has	O
not	O
been	O
approved	O
by	O
the	O
FDA	O
in	O
the	O
United	O
States	O
or	O
the	O
EMA	O
in	O
the	O
European	O
Union	O
for	O
any	O
medical	O
indication	O
and	O
is	O
on	O
the	O
FDA	O
list	O
of	O
unapproved	O
drugs	O
that	O
are	O
still	O
prescribed	O
by	O
clinicians	O
.	O

The	O
discovery	O
and	O
development	O
of	O
this	O
first	O
sulfonamide	other-medical
drug	O
opened	O
a	O
new	O
era	O
in	O
medicine	O
.	O

Palliative	other-medical
care	other-medical
should	O
be	O
involved	O
earlier	O
,	O
rather	O
than	O
later	O
in	O
the	O
disease	O
course	O
.	O

AAV-DC-CTL	other-medical
:	O
A	O
clinical	O
trial	O
is	O
currently	O
in	O
Phase	O
I	O
investigation	O
of	O
Oncolytic	O
AAV	O
treatments	O
for	O
stage	O
IV	O
gastric	O
cancer	O
in	O
China	O
.	O

Couples	O
without	O
children	O
can	O
receive	O
funding	O
for	O
IVF	other-medical
for	O
up	O
to	O
two	O
children	O
.	O

Lisinopril	other-medical
/	O
amlodipine	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Lisonorm	O
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
high	O
blood	O
pressure	O
.	O

For	O
the	O
less	O
aggressive	O
allergic	O
bronchopulmonary	O
aspergillosis	O
,	O
findings	O
suggest	O
the	O
use	O
of	O
oral	O
steroids	other-medical
for	O
a	O
prolonged	O
period	O
of	O
time	O
,	O
preferably	O
for	O
6–9	O
months	O
in	O
allergic	O
aspergillosis	O
of	O
the	O
lungs	O
.	O

Cigarette	O
smokers	O
who	O
have	O
LET	O
may	O
not	O
respond	O
very	O
well	O
to	O
chloroquine	other-medical
.	O

Because	O
pruritus	O
is	O
due	O
to	O
excessive	O
serum	O
histamine	O
levels	O
,	O
antihistamines	other-medical
such	O
as	O
diphenhydramine	other-medical
(	O
Benadryl	other-medical
)	O
are	O
often	O
co-administered	O
.	O

The	O
acute	O
administration	O
of	O
stimulants	O
such	O
as	O
amphetamines	other-medical
typically	O
produces	O
hyperglycemia	O
;	O
chronic	O
use	O
,	O
however	O
,	O
produces	O
hypoglycemia	O
.	O

Subsequent	O
RhoA	O
expression	O
decrease	O
has	O
also	O
been	O
associated	O
with	O
increased	O
sensitivity	O
to	O
doxorubicin	other-medical
and	O
the	O
complete	O
reversion	O
of	O
doxorubicin	other-medical
resistance	O
in	O
certain	O
cells	O
;	O
this	O
shows	O
the	O
resilience	O
of	O
RhoA	O
as	O
a	O
consistent	O
indicator	O
anti-	O
cancer	O
activity	O
.	O

On	O
June	O
10	O
,	O
2014	O
the	O
UK	O
Advisory	O
Council	O
on	O
the	O
Misuse	O
of	O
Drugs	O
(	O
ACMD	O
)	O
recommended	O
that	O
LSZ	other-medical
be	O
specifically	O
named	O
in	O
the	O
UK	O
Misuse	O
of	O
Drugs	O
Act	O
as	O
a	O
class	O
A	O
drug	O
despite	O
not	O
identifying	O
any	O
harm	O
associated	O
with	O
its	O
use	O
.	O

Signs	O
and	O
symptoms	O
of	O
withdrawal	O
from	O
abrupt	O
cessation	O
of	O
an	O
SNRI	other-medical
include	O
dizziness	O
,	O
anxiety	O
,	O
insomnia	O
,	O
nausea	O
,	O
sweating	O
,	O
and	O
flu-like	O
symptoms	O
,	O
such	O
as	O
lethargy	O
and	O
malaise	O
.	O

Topical	other-medical
clotrimazole	other-medical
is	O
usually	O
not	O
effective	O
in	O
treatment	O
of	O
fungal	O
infections	O
of	O
the	O
scalp	O
or	O
nails	O
.	O

It	O
was	O
developed	O
in	O
the	O
late	O
1960s	O
and	O
has	O
since	O
been	O
used	O
in	O
France	O
and	O
several	O
other	O
European	O
countries	O
,	O
and	O
although	O
pyrovalerone	other-medical
is	O
still	O
occasionally	O
prescribed	O
,	O
it	O
is	O
used	O
infrequently	O
due	O
to	O
problems	O
with	O
abuse	O
and	O
dependence	O
.	O

In	O
1982	O
,	O
DeLong	O
became	O
involved	O
in	O
the	O
investigation	O
of	O
the	O
Chicago	O
Tylenol	other-medical
murders	O
,	O
in	O
which	O
seven	O
people	O
died	O
from	O
potassium	O
cyanide	O
-laced	O
Tylenol	other-medical
capsules	O
.	O

Feldene	other-medical
(	O
piroxicam	O
)	O
,	O
a	O
non-steroidal	O
anti-inflammatory	O
drug	O
developed	O
jointly	O
by	O
the	O
Sandwich	O
site	O
and	O
Pfizer	O
's	O
R	O
&	O
amp	O
;	O
D	O
facility	O
in	O
Groton	O
,	O
United	O
States	O
,	O
was	O
launched	O
in	O
1980	O
.	O

Metenolone	other-medical
acetate	O
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
number	O
of	O
brand	O
names	O
including	O
Primobolan	other-medical
,	O
Primobolan	other-medical
S	other-medical
,	O
Primonabol	other-medical
,	O
and	O
Nibal	other-medical
.	O

Anaphylactic	O
shock	O
requires	O
advanced	O
medical	O
care	O
immediately	O
;	O
but	O
other	O
first	O
aid	O
measures	O
include	O
rescue	O
breathing	O
(	O
part	O
of	O
CPR	other-medical
)	O
and	O
administration	O
of	O
epinephrine	other-medical
using	O
an	O
EpiPen	other-medical
for	O
immediate	O
administration	O
of	O
epinephrine	other-medical
(	O
adrenaline	other-medical
)	O
to	O
reverse	O
swelling	O
and	O
to	O
keep	O
the	O
respiratory	O
airway	O
(	O
trachea	O
)	O
open	O
.	O

Poisoning	O
is	O
treated	O
with	O
atropine	other-medical
and	O
simultaneously	O
with	O
oximes	O
such	O
as	O
pralidoxime	other-medical
.	O

In	O
Canada	O
,	O
2C-B	other-medical
is	O
classified	O
under	O
Controlled	O
Drugs	O
and	O
Substances	O
Act	O
as	O
Schedule	O
III	O
as	O
``	O
4-bromo-2,5-dimethoxybenzeneethanamine	O
and	O
any	O
salt	O
,	O
isomer	O
or	O
salt	O
of	O
isomer	O
thereof	O
''	O
.	O

In	O
the	O
United	O
States	O
,	O
Vytorin	other-medical
featured	O
a	O
television	O
advertising	O
campaign	O
showing	O
a	O
series	O
of	O
split-screen	O
images	O
of	O
a	O
person	O
and	O
a	O
food	O
item	O
to	O
make	O
the	O
point	O
that	O
cholesterol	O
comes	O
from	O
two	O
sources	O
and	O
can	O
be	O
absorbed	O
from	O
food	O
or	O
manufactured	O
by	O
the	O
body	O
,	O
and	O
that	O
heredity	O
plays	O
a	O
role	O
in	O
the	O
latter	O
.	O

In	O
May	O
2015	O
the	O
restaurant	O
manager	O
,	O
a	O
North	O
Korean	O
National	O
was	O
arrested	O
for	O
selling	O
illegal	O
Viagra	other-medical
and	O
Alcohol	O
out	O
of	O
the	O
restaurant	O
.	O

Possible	O
side	O
effects	O
of	O
olanzapine	other-medical
/	O
fluoxetine	other-medical
include	O
all	O
those	O
of	O
the	O
two	O
component	O
drugs	O
:	O
olanzapine	other-medical
(	O
side	O
effects	O
)	O
and	O
fluoxetine	other-medical
(	O
side	O
effects	O
)	O
.	O

As	O
such	O
,	O
levomethorphan	other-medical
has	O
similar	O
effects	O
to	O
levorphanol	other-medical
but	O
is	O
less	O
potent	O
as	O
it	O
must	O
be	O
demethylated	O
to	O
the	O
active	O
form	O
by	O
liver	O
enzymes	O
before	O
being	O
able	O
to	O
produce	O
its	O
effects	O
.	O

However	O
,	O
atropine	other-medical
does	O
not	O
affect	O
acetylcholine	O
at	O
nicotinic	O
receptors	O
and	O
thus	O
is	O
a	O
partial	O
treatment	O
.	O

Carboplatin	other-medical
has	O
also	O
been	O
used	O
for	O
adjuvant	O
therapy	O
of	O
stage	O
1	O
seminomatous	O
testicular	O
cancer	O
.	O

It	O
was	O
one	O
of	O
the	O
earlier	O
bacteria	O
in	O
which	O
penicillin	other-medical
resistance	O
was	O
found—in	O
1947	O
,	O
just	O
four	O
years	O
after	O
the	O
drug	O
started	O
being	O
mass-produced	O
.	O

Atypical	other-medical
antipsychotics	other-medical
can	O
be	O
used	O
to	O
stabilise	O
mood	O
and	O
control	O
aggression	O
,	O
especially	O
in	O
those	O
with	O
comorbid	O
ASD	O
.	O

A	O
study	O
done	O
in	O
wide	O
range	O
of	O
bacteria	O
and	O
different	O
classes	O
of	O
antibiotics	O
showed	O
that	O
``	O
Pseudomonas	O
aeruginosa	O
``	O
and	O
``	O
Stenotrophomonas	O
maltophilia	O
``	O
,	O
already	O
resistant	O
to	O
triclosan	other-medical
,	O
had	O
increased	O
resistance	O
against	O
antibiotics	O
tetracycline	O
and	O
norfloxacin	O
when	O
exposed	O
to	O
triclosan	O
.	O

The	O
effects	O
of	O
recreational	O
use	O
are	O
exhaustion	O
and	O
an	O
accumulation	O
of	O
“	O
sleep	O
debt.	O
”	O
Furthermore	O
,	O
frequent	O
use	O
of	O
adderall	other-medical
during	O
the	O
day	O
and	O
night	O
can	O
lead	O
to	O
sleep	O
deprivation	O
and	O
insomnia	O
.	O

Tamoxifen	other-medical
is	O
useful	O
in	O
the	O
treatment	O
of	O
peripheral	O
precocious	O
puberty	O
,	O
for	O
instance	O
due	O
to	O
McCune–Albright	O
syndrome	O
,	O
in	O
both	O
girls	O
and	O
boys	O
.	O

Compared	O
to	O
other	O
NSAIDs	other-medical
,	O
it	O
may	O
have	O
other	O
side	O
effects	O
such	O
as	O
gastrointestinal	O
bleeding	O
.	O

Morphine	other-medical
is	O
also	O
available	O
as	O
a	O
slow-release	O
formulation	O
for	O
opiate	other-medical
substitution	other-medical
therapy	other-medical
(	O
OST	other-medical
)	O
in	O
Austria	O
,	O
Germany	O
,	O
Bulgaria	O
,	O
Slovenia	O
,	O
and	O
Canada	O
for	O
addicts	O
who	O
can	O
not	O
tolerate	O
either	O
methadone	other-medical
or	O
buprenorphine	other-medical
.	O

Piracetam	other-medical
has	O
been	O
found	O
to	O
diminish	O
erythrocyte	O
adhesion	O
to	O
vascular	O
wall	O
endothelium	O
,	O
making	O
any	O
vasospasm	O
in	O
the	O
capillary	O
less	O
severe	O
.	O

In	O
1980	O
,	O
9.7	O
%	O
of	O
the	O
dialysis	O
population	O
was	O
on	O
home	other-medical
hemodialysis	other-medical
but	O
by	O
1987	O
the	O
proportion	O
had	O
dropped	O
to	O
3.6	O
%	O
.	O

Formulations	O
containing	O
high	O
concentrations	O
of	O
aspirin	other-medical
often	O
smell	O
like	O
vinegar	O
because	O
aspirin	other-medical
can	O
decompose	O
through	O
hydrolysis	O
in	O
moist	O
conditions	O
,	O
yielding	O
salicylic	O
and	O
acetic	O
acids	O
.	O

It	O
is	O
most	O
commonly	O
available	O
as	O
the	O
hydrochloride	other-medical
salt	other-medical
,	O
clenbuterol	other-medical
hydrochloride	other-medical
.	O

Other	O
tertiary	O
amine	O
TCAs	other-medical
include	O
amitriptyline	other-medical
,	O
imipramine	other-medical
,	O
clomipramine	other-medical
,	O
dosulepin	other-medical
(	O
dothiepin	other-medical
)	O
,	O
and	O
trimipramine	other-medical
.	O

Use	O
is	O
widespread	O
among	O
amphetamine	other-medical
users	O
,	O
with	O
those	O
that	O
use	O
amphetamines	other-medical
and	O
benzodiazepines	other-medical
having	O
greater	O
levels	O
of	O
mental	O
health	O
problems	O
and	O
social	O
deterioration	O
.	O

Benzodiazepine	other-medical
injectors	O
are	O
almost	O
four	O
times	O
more	O
likely	O
to	O
inject	O
using	O
a	O
shared	O
needle	O
than	O
non-	O
benzodiazepine	other-medical
-using	O
injectors	O
.	O

In	O
infants	O
,	O
the	O
Apt	other-medical
test	O
can	O
be	O
used	O
to	O
distinguish	O
fetal	O
hemoglobin	O
from	O
maternal	O
blood	O
based	O
on	O
the	O
differences	O
in	O
composition	O
of	O
fetal	O
hemoglobin	O
as	O
compared	O
to	O
the	O
hemoglobin	O
found	O
in	O
adults	O
.	O

Stereotactic	other-medical
radiation	other-medical
therapy	other-medical
,	O
also	O
called	O
stereotactic	other-medical
external-beam	other-medical
radiation	other-medical
therapy	other-medical
and	O
stereotaxic	other-medical
radiation	other-medical
therapy	other-medical
,	O
is	O
a	O
type	O
of	O
external	O
radiation	O
therapy	O
that	O
uses	O
special	O
equipment	O
to	O
position	O
the	O
patient	O
and	O
precisely	O
deliver	O
radiation	O
to	O
a	O
tumor	O
.	O

On	O
July	O
30	O
,	O
2009	O
the	O
FDA	O
approved	O
colchicine	other-medical
as	O
a	O
monotherapy	O
for	O
the	O
treatment	O
of	O
three	O
different	O
indications	O
(	O
familial	O
Mediterranean	O
fever	O
,	O
acute	O
gout	O
flares	O
,	O
and	O
for	O
the	O
prophylaxis	O
of	O
gout	O
flares	O
)	O
,	O
and	O
gave	O
URL	O
Pharma	O
a	O
three-year	O
marketing	O
exclusivity	O
agreement	O
in	O
exchange	O
for	O
URL	O
Pharma	O
doing	O
17	O
new	O
studies	O
and	O
investing	O
$	O
100	O
million	O
into	O
the	O
product	O
,	O
of	O
which	O
$	O
45	O
million	O
went	O
to	O
the	O
FDA	O
for	O
the	O
application	O
fee	O
.	O

More	O
than	O
three	O
hundred	O
people	O
tried	O
the	O
curry	O
before	O
Dr	O
.	O
Ian	O
Rothwell	O
became	O
the	O
first	O
person	O
to	O
finish	O
a	O
dish	O
,	O
taking	O
just	O
over	O
an	O
hour	O
,	O
including	O
10	O
minutes	O
spent	O
hallucinating	other-medical
due	O
to	O
the	O
endorphin	other-medical
rush	other-medical
.	O

In	O
four	O
clinical	O
trials	O
of	O
duloxetine	other-medical
for	O
the	O
treatment	O
of	O
MDD	O
,	O
sexual	O
dysfunction	O
occurred	O
significantly	O
more	O
frequently	O
in	O
patients	O
treated	O
with	O
duloxetine	other-medical
than	O
those	O
treated	O
with	O
placebo	other-medical
,	O
and	O
this	O
difference	O
occurred	O
only	O
in	O
men	O
.	O

This	O
lipodystrophy	O
is	O
colloquially	O
known	O
as	O
``	O
Crix	O
belly	O
''	O
,	O
after	O
indinavir	other-medical
(	O
Crixivan	other-medical
)	O
.	O

Furosemide	other-medical
should	O
be	O
used	O
with	O
caution	O
when	O
combined	O
with	O
corticosteroids	other-medical
(	O
as	O
this	O
increases	O
the	O
risk	O
of	O
electrolyte	O
imbalance	O
)	O
,	O
aminoglycoside	other-medical
antibiotics	other-medical
(	O
increases	O
risk	O
of	O
kidney	O
or	O
ear	O
damage	O
)	O
,	O
and	O
trimethoprim	other-medical
sulfa	other-medical
(	O
causes	O
decreased	O
platelet	O
count	O
)	O
.	O

In	O
some	O
cases	O
,	O
switching	O
from	O
venlafaxine	other-medical
to	O
fluoxetine	other-medical
,	O
a	O
long-acting	O
SSRI	other-medical
,	O
and	O
then	O
tapering	O
off	O
fluoxetine	other-medical
,	O
may	O
be	O
recommended	O
to	O
reduce	O
discontinuation	O
symptoms	O
.	O

Because	O
borage	O
oil	O
can	O
theoretically	O
lower	O
the	O
seizure	O
threshold	O
due	O
to	O
its	O
GLA	O
content	O
,	O
it	O
could	O
therefore	O
trigger	O
a	O
seizure	O
in	O
users	O
of	O
phenothiazines	other-medical
or	O
tricyclic	other-medical
antidepressants	other-medical
.	O

It	O
is	O
also	O
available	O
in	O
combination	O
with	O
pseudoephedrine	other-medical
,	O
a	O
decongestant	other-medical
,	O
known	O
as	O
loratadine	other-medical
/	O
pseudoephedrine	other-medical
.	O

Doxepin	other-medical
is	O
a	O
mixture	O
of	O
(	O
``	O
E	O
''	O
)	O
and	O
(	O
``	O
Z	O
''	O
)	O
stereoisomers	O
(	O
the	O
latter	O
being	O
known	O
as	O
``	O
cidoxepin	O
''	O
or	O
``	O
cis	O
''	O
-doxepin	O
)	O
and	O
is	O
used	O
commercially	O
in	O
a	O
ratio	O
of	O
approximately	O
85:15	O
.	O

Via	O
activation	O
of	O
the	O
KOR	O
,	O
levomethorphan	other-medical
can	O
produce	O
dysphoria	O
and	O
psychotomimetic	O
effects	O
such	O
as	O
dissociation	O
and	O
hallucinations	O
.	O

CHMP	O
had	O
concluded	O
that	O
the	O
marketing	O
authorizations	O
for	O
norfloxacin	other-medical
,	O
when	O
used	O
in	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	O
complicated	O
pyelonephritis	O
,	O
should	O
be	O
withdrawn	O
because	O
the	O
benefits	O
do	O
not	O
outweigh	O
their	O
risks	O
in	O
this	O
indication	O
.	O

Opioid	other-medical
medications	other-medical
are	O
not	O
utilized	O
to	O
treat	O
ETTH	other-medical
.	O

As	O
with	O
other	O
opioids	O
,	O
chronic	O
use	O
of	O
oxycodone	other-medical
(	O
particularly	O
with	O
higher	O
doses	O
)	O
often	O
causes	O
concurrent	O
hypogonadism	O
(	O
low	O
sex	O
hormone	O
levels	O
)	O
.	O

As	O
with	O
other	O
statins	other-medical
,	O
atorvastatin	other-medical
is	O
a	O
competitive	O
inhibitor	O
of	O
HMG-CoA	O
reductase	O
.	O

In	O
some	O
cases	O
,	O
Botox	other-medical
may	O
be	O
used	O
to	O
provide	O
temporary	O
decompression	O
of	O
the	O
nerve	O
.	O

Botulinum	other-medical
toxin	other-medical
A	other-medical
is	O
used	O
to	O
treat	O
involuntary	O
muscle	O
contraction	O
and	O
spasms	O
.	O

Some	O
research	O
suggests	O
that	O
lamivudine	other-medical
can	O
cross	O
the	O
blood–brain	O
barrier	O
.	O

It	O
,	O
along	O
with	O
WF-23	other-medical
the	O
other	O
``	O
2-naphthyl	other-medical
``	O
cocaine	other-medical
analogue	O
,	O
are	O
considered	O
the	O
more	O
potent	O
of	O
the	O
WF	other-medical
series	O
cocaine	other-medical
analogues	O
.	O

Percodan	other-medical
has	O
largely	O
been	O
replaced	O
by	O
Percocet	other-medical
(	O
which	O
is	O
oxycodone	other-medical
combined	O
with	O
paracetamol	other-medical
(	O
acetaminophen	other-medical
)	O
instead	O
of	O
Percodan	other-medical
's	O
aspirin	other-medical
)	O
and	O
other	O
oxycodone-containing	O
compounds	O
for	O
post-operative	O
pain	O
.	O

As	O
a	O
laxative	other-medical
syrup	other-medical
with	O
a	O
concentration	O
of	O
1.745	O
g	O
of	O
magnesium	O
citrate	O
per	O
fluid	O
ounce	O
,	O
a	O
typical	O
dose	O
for	O
adults	O
and	O
children	O
twelve	O
years	O
or	O
older	O
is	O
between	O
,	O
followed	O
immediately	O
with	O
a	O
full	O
glass	O
of	O
water	O
.	O

In	O
addition	O
to	O
coining	O
the	O
term	O
``	O
pediatric	other-medical
psychology	other-medical
``	O
,	O
Wright	O
wrote	O
several	O
conceptual	O
papers	O
related	O
to	O
the	O
field	O
.	O

This	O
block	O
of	O
nucleotide	O
biosynthesis	O
is	O
more	O
toxic	O
to	O
rapidly	O
growing	O
cells	O
than	O
non-dividing	O
cells	O
,	O
since	O
a	O
rapidly	O
growing	O
cell	O
has	O
to	O
carry	O
out	O
DNA	O
replication	O
,	O
therefore	O
methotrexate	O
is	O
often	O
used	O
in	O
cancer	other-medical
chemotherapy	other-medical
.	O

Cardiac	O
arrest	O
may	O
occur	O
in	O
propranolol	other-medical
overdose	O
due	O
to	O
sudden	O
ventricular	O
arrhythmias	O
,	O
or	O
cardiogenic	O
shock	O
which	O
may	O
ultimately	O
culminate	O
in	O
bradycardic	O
PEA	O
.	O

Protein	other-medical
C	other-medical
replacement	other-medical
is	O
often	O
in	O
combination	O
with	O
anticoagulation	other-medical
therapy	other-medical
of	O
injectable	O
low	O
molecular	other-medical
weight	other-medical
heparin	other-medical
or	O
oral	other-medical
warfarin	other-medical
.	O

Lamivudine	other-medical
is	O
often	O
given	O
in	O
combination	O
with	O
zidovudine	other-medical
,	O
with	O
which	O
it	O
is	O
highly	O
synergistic	O
.	O

Cryotherapy	other-medical
,	O
sometimes	O
known	O
as	O
cold	O
therapy	O
,	O
is	O
the	O
local	O
or	O
general	O
use	O
of	O
low	O
temperatures	O
in	O
medical	O
therapy	O
.	O

This	O
mechanism	O
also	O
explains	O
the	O
selection	O
of	O
HER2/neu	O
(	O
also	O
called	O
ERBB2	O
)	O
and	O
the	O
overexpressing	O
(	O
lineage-addicted	O
)	O
cancer	O
cells	O
during	O
the	O
process	O
of	O
carcinogenesis	O
,	O
and	O
the	O
efficacy	O
of	O
targeted	O
therapy	O
against	O
the	O
Her-2	O
receptor	O
with	O
trastuzumab	other-medical
(	O
Herceptin	other-medical
)	O
in	O
the	O
treatment	O
of	O
adenocarcinomas	O
at	O
the	O
gastroesophageal	O
junction	O
.	O

It	O
tends	O
to	O
be	O
slightly	O
activating/stimulating	O
rather	O
than	O
sedating	O
,	O
unlike	O
most	O
others	O
TCAs	other-medical
.	O

A	O
systematic	O
review	O
and	O
meta	O
analysis	O
conducted	O
in	O
2014	O
,	O
demonstrated	O
that	O
the	O
BCG	other-medical
vaccine	other-medical
reduced	O
infections	O
by	O
19–27	O
%	O
and	O
reduced	O
progression	O
to	O
active	O
TB	O
by	O
71	O
%	O
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
users	O
seeking	O
to	O
discontinue	O
an	O
SNRI	other-medical
slowly	O
taper	O
the	O
dose	O
under	O
the	O
supervision	O
of	O
a	O
professional	O
.	O

Taking	O
equal	O
doses	O
of	O
vitamin	other-medical
C	other-medical
and	O
aspirin	other-medical
may	O
decrease	O
the	O
amount	O
of	O
stomach	O
damage	O
that	O
occurs	O
compared	O
to	O
taking	O
aspirin	other-medical
alone	O
.	O

“	O
Mononeuropathy	O
refers	O
to	O
single	O
peripheral	O
nerve	O
involvement	O
and	O
usually	O
occurs	O
due	O
to	O
trauma	other-medical
,	O
compression	other-medical
or	O
entrapment	other-medical
”	O
.	O

Doxorubicin	other-medical
has	O
been	O
referred	O
to	O
frequently	O
as	O
a	O
highly-promising	O
anti-	O
cancer	O
drug	O
that	O
is	O
also	O
being	O
utilized	O
in	O
chemotherapy	other-medical
treatments	O
;	O
however	O
,	O
as	O
with	O
nearly	O
all	O
chemotherapeutics	other-medical
,	O
the	O
issue	O
of	O
drug	O
resistance	O
remains	O
.	O

Enzalutamide	O
was	O
the	O
first	O
new	O
AR	O
antagonist	O
to	O
be	O
approved	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer	O
in	O
over	O
15	O
years	O
,	O
following	O
the	O
introduction	O
of	O
the	O
first-generation	O
NSAA	other-medical
bicalutamide	other-medical
in	O
1995	O
.	O

In	O
both	O
young	O
and	O
old	O
people	O
with	O
hypoglycemia	other-medical
,	O
the	O
brain	O
may	O
habituate	O
to	O
low	O
glucose	O
levels	O
,	O
with	O
a	O
reduction	O
of	O
noticeable	O
symptoms	O
despite	O
neuroglycopenic	other-medical
impairment	other-medical
.	O

They	O
are	O
used	O
to	O
treat	O
estrogen	O
receptor-sensitive	O
or	O
progesterone	O
receptor-sensitive	O
breast	O
cancer	O
,	O
along	O
with	O
older	O
classes	O
of	O
drugs	O
like	O
selective	other-medical
estrogen	other-medical
receptor	other-medical
modulators	other-medical
(	O
SERMs	other-medical
)	O
and	O
aromatase	other-medical
inhibitors	other-medical
.	O

As	O
such	O
,	O
it	O
was	O
characterized	O
as	O
a	O
highly	O
potent	O
antimineralocorticoid	O
with	O
far	O
fewer	O
hormonal	O
side	O
effects	O
relative	O
to	O
spironolactone	other-medical
.	O

Despite	O
the	O
non-steroidal	O
nature	O
of	O
finerenone	other-medical
which	O
yields	O
a	O
different	O
lipophilicity	other-medical
and	O
polarity	O
profile	O
for	O
this	O
compound	O
,	O
finerenone	other-medical
's	O
affinity	O
toward	O
mineralocorticoid	other-medical
receptors	O
is	O
equal	O
to	O
that	O
of	O
spironolactone	other-medical
and	O
500	O
times	O
that	O
of	O
eplerenone	other-medical
,	O
hinting	O
that	O
the	O
steroidal	O
core	O
component	O
of	O
most	O
antimineralocorticoids	O
is	O
not	O
essential	O
for	O
mineralocorticoid	other-medical
receptor	O
affinity	O
.	O

Low	O
volume	O
hyponatremia	O
is	O
typically	O
treated	O
with	O
intravenous	O
normal	other-medical
saline	other-medical
.	O

In	O
some	O
cases	O
,	O
correction	O
of	O
a	O
dehydrated	O
state	O
is	O
accomplished	O
by	O
the	O
replenishment	O
of	O
necessary	O
water	O
and	O
electrolytes	O
(	O
through	O
oral	O
rehydration	other-medical
therapy	other-medical
or	O
fluid	O
replacement	O
by	O
i	O
ntravenous	other-medical
therapy	other-medical
)	O
.	O

To	O
demonstrate	O
,	O
the	O
serotonin	O
:	O
norepinephrine	O
ratios	O
of	O
SNRIs	other-medical
are	O
as	O
follows	O
:	O
venlafaxine	other-medical
=	O
30:1	O
,	O
duloxetine	other-medical
=	O
10:1	O
,	O
desvenlafaxine	other-medical
=	O
14:1	O
,	O
milnacipran	other-medical
=	O
1.6:1	O
,	O
and	O
levomilnacipran	other-medical
=	O
1:2	O
.	O

Nodular	O
vasculitis	O
is	O
a	O
skin	O
condition	O
characterized	O
by	O
crops	O
of	O
small	O
,	O
tender	O
,	O
erythematous	other-medical
nodules	other-medical
on	O
the	O
legs	O
,	O
mostly	O
on	O
the	O
calves	O
and	O
shins	O
.	O

Since	O
the	O
1960s	O
,	O
when	O
she	O
first	O
joined	O
the	O
university	O
,	O
Wohl	O
specialized	O
in	O
the	O
respiratory	other-medical
diseases	O
of	O
children	O
and	O
was	O
a	O
leader	O
in	O
the	O
field	O
of	O
clinical	O
research	O
on	O
Cystic	O
fibrosis	O
.	O

Dr	O
.	O
Lee	O
Suy	O
also	O
added	O
that	O
the	O
stocked	O
1.5	O
million	O
anti-viral	O
medicines	O
such	O
as	O
Tamiflu	other-medical
by	O
the	O
DOH	O
is	O
not	O
enough	O
for	O
possible	O
epidemic	O
since	O
most	O
of	O
them	O
are	O
given	O
free	O
to	O
discourage	O
uncontrolled	O
and	O
panic	O
buying	O
.	O

ABA	other-medical
-based	O
interventions	O
focus	O
on	O
teaching	O
tasks	O
one-on-one	O
using	O
the	O
behaviorist	O
principles	O
of	O
stimulus	O
,	O
response	O
and	O
reward	O
,	O
and	O
on	O
reliable	O
measurement	O
and	O
objective	O
evaluation	O
of	O
observed	O
behavior	O
.	O

Daunorubicin	other-medical
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
in	O
1979	O
.	O

Benzodiazepines	other-medical
are	O
not	O
without	O
their	O
drawbacks	O
;	O
substance	O
dependence	O
is	O
possible	O
,	O
and	O
deaths	O
from	O
overdoses	O
sometimes	O
occur	O
,	O
especially	O
in	O
combination	O
with	O
alcohol	O
and/or	O
other	O
depressants	O
.	O

Oxazepam	other-medical
when	O
taken	O
during	O
the	O
third	O
trimester	O
,	O
causes	O
a	O
definite	O
risk	O
to	O
the	O
neonate	O
including	O
a	O
severe	O
benzodiazepine	O
withdrawal	O
syndrome	O
including	O
hypotonia	other-medical
,	O
and	O
reluctance	O
to	O
suck	O
,	O
to	O
apnoeic	other-medical
spells	other-medical
,	O
cyanosis	other-medical
,	O
and	O
impaired	other-medical
metabolic	other-medical
responses	other-medical
to	O
cold	O
stress	O
.	O

This	O
can	O
be	O
done	O
through	O
a	O
CT	other-medical
or	O
MRI	other-medical
or	O
the	O
brain	O
;	O
these	O
are	O
the	O
first	O
imaging	O
modality	O
of	O
choice	O
.	O

The	O
result	O
is	O
high	O
glucose	other-medical
levels	O
in	O
the	O
blood	O
which	O
leave	O
the	O
individual	O
feeling	O
tired	O
and	O
weak	O
in	O
most	O
cases	O
.	O

There	O
are	O
commercially	O
available	O
immunohistochemical	O
tests	O
,	O
Dako	other-medical
HercepTest	other-medical
,	O
Leica	other-medical
Biosystems	other-medical
Oracle	other-medical
and	O
Ventana	other-medical
Pathway	other-medical
.	O

Applied	other-medical
Behavior	other-medical
Analysis	other-medical
is	O
the	O
only	O
empirically	O
proven	O
method	O
of	O
treatment	O
.	O

Pyrovalerone	other-medical
(	O
Centroton	other-medical
,	O
4-Methyl-β-keto-prolintane	other-medical
,	O
Thymergix	other-medical
,	O
O-2371	other-medical
)	O
is	O
a	O
psychoactive	O
drug	O
with	O
stimulant	O
effects	O
via	O
acting	O
as	O
a	O
norepinephrine-dopamine	other-medical
reuptake	other-medical
inhibitor	other-medical
(	O
NDRI	other-medical
)	O
,	O
and	O
is	O
used	O
for	O
the	O
clinical	O
treatment	O
of	O
chronic	O
fatigue	O
or	O
lethargy	O
and	O
as	O
an	O
anorectic	O
or	O
appetite	O
suppressant	O
for	O
weight	O
loss	O
purposes	O
.	O

Starting	O
with	O
linked	O
COX-2	other-medical
inhibitors	other-medical
,	O
such	O
as	O
Vioxx	other-medical
(	O
rofecoxib	other-medical
)	O
in	O
2001	O
,	O
Nissen	O
was	O
one	O
of	O
the	O
first	O
physicians	O
to	O
link	O
it	O
to	O
an	O
increased	O
risk	O
of	O
heart	O
attacks	O
and	O
strokes	O
.	O

A	O
gene	O
knockout	O
experiment	O
of	O
the	O
mouse	O
homologue	O
of	O
ZDHHC13	O
showed	O
hair	other-medical
loss	other-medical
,	O
severe	other-medical
osteoporosis	other-medical
,	O
and	O
systemic	other-medical
amyloidosis	other-medical
,	O
both	O
of	O
AL	O
and	O
AA	O
depositions	O
.	O

Acyclovir	other-medical
,	O
favipiravir	other-medical
,	O
and	O
remdesivir	other-medical
have	O
been	O
assessed	O
as	O
potential	O
antivirals	O
against	O
Nipah	O
virus	O
.	O

NIDA	O
has	O
drawn	O
criticism	O
for	O
continuing	O
to	O
provide	O
funding	O
to	O
George	O
Ricaurte	O
,	O
who	O
in	O
2002	O
conducted	O
a	O
study	O
that	O
was	O
widely	O
touted	O
as	O
proving	O
that	O
MDMA	other-medical
(	O
ecstasy	O
)	O
caused	O
dopaminergic	O
neurotoxicity	O
in	O
monkeys	O
.	O

If	O
pH	O
is	O
also	O
less	O
than	O
7.35	O
this	O
is	O
respiratory	other-medical
acidosis	other-medical
.	O

Several	O
internal	O
documents	O
,	O
which	O
were	O
released	O
by	O
the	O
British	O
Medical	O
Journal	O
,	O
indicated	O
a	O
link	O
between	O
use	O
of	O
Prozac	other-medical
and	O
suicidal	O
or	O
violent	O
behavior	O
.	O

Brand	O
names	O
of	O
MPA	other-medical
in	O
combination	O
with	O
estradiol	O
as	O
oral	O
tablets	O
include	O
Indivina	other-medical
and	O
Tridestra	other-medical
.	O

When	O
combined	O
with	O
antidepressants	O
of	O
the	O
MAOI	other-medical
or	O
SSRI	other-medical
class	O
,	O
very	O
high	O
parenteral	O
doses	O
of	O
5-HTP	O
can	O
cause	O
acute	O
serotonin	O
syndrome	O
in	O
rats	O
.	O

The	O
major	O
active	O
forms	O
of	O
spironolactone	other-medical
include	O
7α-thiomethylspironolactone	O
(	O
7α-TMS	O
)	O
and	O
canrenone	O
(	O
7α-desthioacetyl-δ6-spironolactone	O
)	O
,	O
while	O
more	O
minor	O
metabolites	O
of	O
spironolactone	other-medical
include	O
7α-thiospironolactone	O
(	O
7α-TS	O
)	O
,	O
6β-hydroxy-7α-thiomethylspironolactone	O
(	O
6β-OH-7α-TMS	O
)	O
,	O
and	O
a	O
number	O
of	O
others	O
.	O

Given	O
its	O
irritant	O
nature	O
to	O
mammal	O
tissues	O
,	O
capsaicin	O
is	O
widely	O
used	O
to	O
determine	O
the	O
cough	O
threshold	O
and	O
as	O
a	O
tussive	O
stimulant	O
in	O
clinical	O
research	O
of	O
cough	other-medical
suppressants	other-medical
.	O

Acetamiprid	other-medical
is	O
an	O
insecticide	O
belonging	O
to	O
the	O
chloropyridinyl	O
neonicotinoids	O
,	O
this	O
family	O
of	O
insecticides	O
was	O
introduced	O
in	O
the	O
early	O
1990s	O
.	O

Tyrosine	other-medical
kinase	other-medical
inhibitors	other-medical
(	O
such	O
as	O
sunitinib	other-medical
,	O
pazopanib	other-medical
,	O
and	O
dasatinib	other-medical
)	O
have	O
shown	O
some	O
effect	O
against	O
several	O
cancer	O
types	O
,	O
most	O
notably	O
Imatinib-mesylate	other-medical
in	O
gastrointestinal	other-medical
stromal	other-medical
tumors	other-medical
(	O
GISTs	other-medical
)	O
.	O

The	O
condition	O
can	O
be	O
prevented	O
by	O
using	O
chloramphenicol	other-medical
at	O
the	O
recommended	O
doses	O
and	O
monitoring	O
blood	O
levels	O
,	O
or	O
alternatively	O
,	O
third	O
generation	O
cephalosporins	other-medical
can	O
be	O
effectively	O
substituted	O
for	O
the	O
drug	O
,	O
without	O
the	O
associated	O
toxicity	O
.	O

Physicians	O
have	O
called	O
for	O
more	O
research	O
to	O
better	O
understand	O
the	O
potential	O
benefits	O
of	O
controlled	O
use	O
of	O
medical	other-medical
marijuana	other-medical
;	O
Sharon	O
Levy	O
,	O
director	O
of	O
the	O
Adolescent	O
Substance	O
Abuse	O
Program	O
at	O
Children	O
's	O
Hospital	O
Boston	O
said	O
:	O

GGPS	O
has	O
since	O
been	O
successfully	O
inhibited	O
by	O
a	O
novel	O
bisphosphonate	other-medical
compound	O
with	O
a	O
triazole	O
group	O
within	O
R2	O
and	O
a	O
methyl	O
group	O
in	O
R1	O
.	O

At	O
23	O
May	O
2007	O
,	O
during	O
the	O
2007	O
Giro	O
d'Italia	O
,	O
Alessandro	O
Petacchi	O
was	O
found	O
guilty	O
of	O
using	O
salbutamol	other-medical
after	O
a	O
doping	O
control	O
.	O

Biotron	O
's	O
lead	O
drug	O
,	O
BIT225	other-medical
,	O
is	O
in	O
clinical	O
development	O
for	O
treatment	O
of	O
both	O
HIV	O
and	O
Hepatitis	O
C	O
,	O
as	O
well	O
as	O
the	O
hard	O
to	O
treat	O
HIV	O
/	O
Hepatitis	O
C	O
co-infected	O
population	O
.	O

Patients	O
Out	O
of	O
Time	O
(	O
POT	O
)	O
is	O
an	O
American	O
medical	O
cannabis	other-medical
nonprofit	O
organization	O
and	O
patients	O
rights	O
group	O
,	O
established	O
in	O
1995	O
.	O

Anti-GM1	other-medical
antibodies	O
are	O
positive	O
in	O
around	O
80	O
%	O
of	O
cases	O
.	O

Common	O
symptoms	O
,	O
which	O
tend	O
to	O
be	O
vague	other-medical
,	O
include	O
fatigue	other-medical
(	O
unrelieved	O
by	O
sleep	O
;	O
occurs	O
in	O
66	O
%	O
of	O
cases	O
)	O
,	O
lack	other-medical
of	other-medical
energy	other-medical
,	O
weight	other-medical
loss	other-medical
,	O
joint	other-medical
aches	other-medical
and	other-medical
pains	other-medical
(	O
which	O
occur	O
in	O
about	O
70	O
%	O
of	O
cases	O
)	O
,	O
arthritis	other-medical
(	O
14–38	O
%	O
of	O
cases	O
)	O
,	O
dry	other-medical
eyes	other-medical
,	O
swelling	other-medical
of	other-medical
the	other-medical
knees	other-medical
,	O
blurry	other-medical
vision	other-medical
,	O
shortness	other-medical
of	other-medical
breath	other-medical
,	O
a	O
dry	O
,	O
hacking	other-medical
cough	other-medical
,	O
or	O
skin	other-medical
lesions	other-medical
.	O

It	O
has	O
less	O
activity	O
against	O
factor	O
IIa	O
(	O
thrombin	O
)	O
compared	O
to	O
unfractionated	other-medical
heparin	other-medical
(	O
UFH	other-medical
)	O
due	O
to	O
its	O
low	O
molecular	O
weight	O
.	O

Medical	other-medical
diagnosis	other-medical
(	O
abbreviated	O
Dx	other-medical
or	O
DS	other-medical
)	O
is	O
the	O
process	O
of	O
determining	O
which	O
disease	O
or	O
condition	O
explains	O
a	O
person	O
's	O
symptoms	O
and	O
signs	O
.	O

Pregabalin	other-medical
and	O
gabapentin	other-medical
may	O
reduce	O
pain	O
associated	O
with	O
diabetic	O
neuropathy	O
.	O

It	O
is	O
used	O
to	O
treat	O
fluid	other-medical
retention	other-medical
(	O
edema	other-medical
)	O
in	O
people	O
with	O
congestive	other-medical
heart	other-medical
failure	other-medical
,	O
liver	other-medical
disease	other-medical
,	O
or	O
a	O
kidney	other-medical
disorder	other-medical
such	O
as	O
nephritic	other-medical
syndrome	other-medical
.	O

By	O
the	O
mid-1980s	O
,	O
Tylenol	other-medical
had	O
rebounded	O
completely	O
.	O

In	O
Bangladesh	O
,	O
the	O
combination	O
of	O
triamcinolone	other-medical
acetonide	other-medical
and	O
econazole	other-medical
nitrate	other-medical
is	O
branded	O
as	O
Pevisone	other-medical
by	O
Janssen	O
Pharmaceutica	O
.	O

Scopolamine	other-medical
and	O
atropine	other-medical
have	O
similar	O
effects	O
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

They	O
recommend	O
that	O
it	O
be	O
used	O
only	O
when	O
artemisinins	other-medical
are	O
not	O
available	O
.	O

14.7	O
%	O
of	O
the	O
patients	O
(	O
n	O
=	O
44	O
)	O
on	O
fluoxetine	other-medical
had	O
suicidal	O
events	O
,	O
compared	O
to	O
6.3	O
%	O
in	O
the	O
psychotherapy	O
group	O
and	O
8.4	O
%	O
from	O
the	O
combined	O
treatment	O
group	O
.	O

The	O
FDA	O
stated	O
``	O
In	O
June	O
2018	O
,	O
FDA	O
was	O
informed	O
of	O
the	O
presence	O
of	O
an	O
impurity	O
,	O
identified	O
as	O
N-Nitrosodimethylamine	O
(	O
NDMA	O
)	O
,	O
from	O
one	O
valsartan	other-medical
API	other-medical
producer	O
.	O

In	O
children	O
,	O
hemodialysis	other-medical
must	O
be	O
individualized	O
and	O
viewed	O
as	O
an	O
``	O
integrated	O
therapy	O
''	O
that	O
considers	O
their	O
long-term	O
exposure	O
to	O
chronic	O
renal	O
failure	O
treatment	O
.	O

``	O
NSAIDs	other-medical
``	O
,	O
or	O
non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
may	O
help	O
improve	O
the	O
lameness	O
in	O
the	O
horse	O
.	O

Analgecine	other-medical
(	O
brand	O
name	O
AGC	other-medical
)	O
is	O
an	O
analgesic	O
extract	O
that	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
back	other-medical
pain	other-medical
and	O
neuralgia	other-medical
in	O
China	O
.	O

A	O
meta-analysis	O
of	O
53	O
clinical	O
trials	O
has	O
shown	O
that	O
all	O
triptans	other-medical
are	O
effective	O
for	O
treating	O
migraine	O
at	O
marketed	O
doses	O
and	O
that	O
naratriptan	other-medical
,	O
although	O
less	O
effective	O
than	O
sumatriptan	other-medical
and	O
rizatriptan	other-medical
was	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
migraine	O
symptoms	O
at	O
two	O
hours	O
and	O
efficacy	O
was	O
demonstrated	O
in	O
almost	O
two	O
thirds	O
of	O
subjects	O
after	O
four	O
hours	O
of	O
treatment	O
.	O

Naturally	O
infected	O
hens	O
were	O
dewormed	O
completely	O
in	O
24	O
hours	O
using	O
mebendazole	other-medical
orally	O
at	O
doses	O
25	O
mg/kg	O
body	O
weight	O
and	O
higher	O
,	O
without	O
apparent	O
sideeffect	O
.	O

First	O
made	O
in	O
1977	O
,	O
ketoconazole	other-medical
was	O
the	O
first	O
orally-active	O
azole	other-medical
antifungal	other-medical
medication	O
.	O

The	O
American	O
Dental	O
Association	O
(	O
ADA	O
)	O
recommends	O
antibiotic	other-medical
prophylaxis	other-medical
for	O
very	O
few	O
people	O
since	O
only	O
a	O
small	O
number	O
of	O
cases	O
of	O
endocarditis	O
might	O
be	O
caused	O
by	O
dental	O
procedures	O
.	O

Shakur-Still	O
ran	O
the	O
WOMAN	other-medical
Trial	other-medical
which	O
looked	O
the	O
blood	O
clot	O
stabilising	O
drug	O
tranexamic	other-medical
acid	other-medical
for	O
post-delivery	O
bleeding	O
,	O
which	O
is	O
the	O
largest	O
cause	O
of	O
maternal	O
mortality	O
around	O
the	O
world	O
.	O

While	O
Fisher	O
was	O
in	O
Chicago	O
filming	O
the	O
movie	O
,	O
she	O
choked	O
on	O
a	O
Brussels	O
sprout	O
;	O
Dan	O
Aykroyd	O
performed	O
the	O
Heimlich	other-medical
maneuver	other-medical
and	O
``	O
saved	O
my	O
life	O
''	O
.	O

Trebananib	other-medical
and	O
tasquinimod	other-medical
are	O
other	O
angiogenesis	O
inhibitors	O
being	O
investigated	O
.	O

Among	O
the	O
first	O
technology	O
to	O
be	O
added	O
to	O
the	O
institute	O
,	O
was	O
equipment	O
for	O
in	O
vivo	O
NMR	other-medical
studies	O
(	O
which	O
nowadays	O
is	O
mainly	O
known	O
as	O
MRI	other-medical
)	O
for	O
animal	O
studies	O
.	O

The	O
American	O
Sleep	O
Apnea	O
Association	O
(	O
ASAA	O
)	O
is	O
a	O
non-profit	O
organization	O
founded	O
in	O
1990	O
by	O
persons	O
with	O
sleep	other-medical
apnea	other-medical
,	O
health	O
care	O
providers	O
and	O
researchers	O
.	O

He	O
also	O
supported	O
the	O
idea	O
of	O
a	O
p24-	other-medical
vaccine	other-medical
without	O
gp120	other-medical
which	O
was	O
patented	O
by	O
Jonas	O
Salk	O
as	O
``	O
Remune	other-medical
``	O
.	O

However	O
,	O
as	O
no	O
material	O
had	O
been	O
offered	O
to	O
indicate	O
that	O
the	O
beta	O
crystalline	O
form	O
of	O
imatinib	other-medical
mesylate	O

He	O
wrote	O
seminal	O
papers	O
in	O
the	O
areas	O
of	O
hematology	other-medical
and	O
iron	other-medical
metabolism	other-medical
.	O

Potassium	other-medical
chloride	other-medical
is	O
the	O
last	O
of	O
the	O
three	O
drugs	O
administered	O
and	O
actually	O
causes	O
death	O
.	O

Counterfeit	O
drugs	O
such	O
as	O
Profetamine	other-medical
(	O
a	O
generic	O
form	O
of	O
amphetamine	other-medical
sulfate	other-medical
)	O
appeared	O
,	O
aiming	O
to	O
circumvent	O
Alles	O
'	O
'weak	O
'	O
patent	O
.	O

Montelukast	other-medical
has	O
been	O
tested	O
in	O
clinical	O
trials	O
under	O
different	O
conditions	O
to	O
observe	O
different	O
adverse	O
effects	O
.	O

Many	O
Psychostimulant	O
drugs	O
are	O
known	O
to	O
interact	O
with	O
VMAT	other-medical
,	O
including	O
Amphetamine	other-medical
analogs	O
such	O
as	O
Methamphetamine	other-medical
(	O
METH	other-medical
)	O
,	O
Cocaine	other-medical
,	O
and	O
Ecstasy	other-medical
(	O
MDMA	other-medical
)	O
.	O

Stents	other-medical
to	O
maintain	O
the	O
arterial	O
widening	O
are	O
often	O
used	O
at	O
the	O
same	O
time	O
.	O

Before	O
initiating	O
warfarin	other-medical
therapy	other-medical
,	O
a	O
few	O
days	O
of	O
therapeutic	other-medical
heparin	other-medical
may	O
be	O
administered	O
to	O
prevent	O
warfarin	O
necrosis	O
and	O
other	O
progressive	O
or	O
recurrent	O
thrombotic	O
complications	O
.	O

Nevertheless	O
,	O
if	O
the	O
mechanism	O
of	O
action	O
of	O
imatinib	other-medical
on	O
melanocyte	O
stem	O
cells	O
can	O
be	O
discovered	O
,	O
it	O
is	O
possible	O
that	O
a	O
safer	O
and	O
less	O
expensive	O
substitute	O
drug	O
might	O
someday	O
be	O
developed	O
.	O

He	O
also	O
completed	O
advanced	O
TMS	other-medical
Therapy	O
Fellowship	O
at	O
Duke	O
University	O
Medical	O
Center	O
in	O
2014	O
.	O

Weight	O
loss	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
pirfenidone	other-medical
.	O

Anticonvulsant	other-medical
medication	O
is	O
commonly	O
prescribed	O
for	O
migraine	O
prevention	O
,	O
because	O
they	O
have	O
been	O
shown	O
in	O
placebo-controlled	O
double-blind	O
trials	O
to	O
be	O
effective	O
in	O
some	O
migraine	O
sufferers	O
.	O

Most	O
formulations	O
of	O
tretinoin	other-medical
are	O
incompatible	O
for	O
use	O
with	O
benzoyl	other-medical
peroxide	other-medical
.	O

Melatonin	other-medical
receptor	other-medical
agonists	other-medical
were	O
developed	O
with	O
the	O
melatonin	O
structure	O
as	O
a	O
model	O
.	O

When	O
laparoscopy	O
is	O
used	O
for	O
diagnosis	O
,	O
the	O
most	O
common	O
cause	O
of	O
dysmenorrhea	other-medical
is	O
endometriosis	O
,	O
in	O
approximately	O
70	O
%	O
of	O
adolescents	O
.	O

Azithromycin	other-medical
appears	O
to	O
have	O
less	O
side	O
effects	O
than	O
either	O
high	O
dose	O
amoxicillin	other-medical
or	O
amoxicillin	other-medical
/	O
clavulanate	other-medical
.	O

Cardiac	other-medical
arrest	other-medical
can	O
also	O
occur	O
after	O
a	O
hard	O
blow	O
to	O
the	O
chest	O
at	O
a	O
precise	O
moment	O
in	O
the	O
cardiac	O
cycle	O
,	O
which	O
is	O
known	O
as	O
commotio	other-medical
cordis	other-medical
.	O

The	O
sale	O
of	O
dextromethorphan	other-medical
in	O
its	O
pure	O
powder	O
form	O
may	O
incur	O
penalties	O
,	O
although	O
no	O
explicit	O
law	O
exists	O
prohibiting	O
its	O
sale	O
or	O
possession	O
,	O
other	O
than	O
in	O
Illinois	O
.	O

The	O
Dutch	O
Pharmacogenetics	O
Working	O
Group	O
also	O
recommends	O
selecting	O
an	O
alternative	O
drug	O
or	O
monitoring	O
plasma	O
concentrations	O
of	O
amitriptyline	other-medical
in	O
patients	O
who	O
are	O
CYP2D6	O
poor	O
or	O
ultrarapid	O
metabolizers	O
,	O
and	O
selecting	O
an	O
alternative	O
drug	O
or	O
reducing	O
initial	O
dose	O
in	O
patients	O
who	O
are	O
CYP2D6	O
intermediate	O
metabolizers	O
.	O

25I-NBOH	other-medical
acts	O
as	O
a	O
potent	O
agonist	O
for	O
the	O
5HT2A	other-medical
receptor	other-medical
,	O
with	O
a	O
Ki	O
of	O
0.061	O
nM	O
at	O
the	O
human	O
5HT2A	other-medical
receptor	other-medical
,	O
similar	O
to	O
the	O
better-known	O
compound	O
25I-NBOMe	O
,	O
making	O
it	O
some	O
twelve	O
times	O
the	O
potency	O
of	O
2C-I	other-medical
itself	O
.	O

Howson	O
has	O
been	O
debilitated	O
,	O
at	O
times	O
,	O
by	O
Spasmodic	O
Dysphonia	O
which	O
affects	O
his	O
voice	O
;	O
it	O
is	O
periodically	O
mitigated	O
by	O
Botox	other-medical
injections	O
into	O
his	O
larynx	O
.	O

The	O
product	O
is	O
sold	O
globally	O
under	O
different	O
brand	O
names	O
such	O
as	O
Nicoderm	other-medical
in	O
the	O
US	O
,	O
Nicabate	other-medical
in	O
Australia	O
and	O
New	O
Zealand	O
and	O
NiQuitin	other-medical
CQ	other-medical
in	O
China	O
,	O
many	O
parts	O
of	O
Europe	O
and	O
South	O
America	O
.	O

Chemotherapy	other-medical
or	O
traditional	O
radiotherapy	other-medical
are	O
not	O
very	O
effective	O
for	O
most	O
chondrosarcomas	O
,	O
although	O
proton	other-medical
therapy	other-medical
is	O
showing	O
promise	O
with	O
local	O
tumor	O
control	O
at	O
over	O
80	O
%	O
.	O

In	O
Japan	O
,	O
Milnacipran	other-medical
is	O
used	O
in	O
the	O
treatment	O
of	O
Taijin	O
kyofusho	O
,	O
a	O
Japanese	O
variant	O
of	O
social	O
anxiety	O
disorder	O
.	O

Since	O
the	O
components	O
of	O
myelin	other-medical
are	O
stoichiometrically	O
set	O
,	O
any	O
irregular	O
expression	O
of	O
a	O
component	O
can	O
cause	O
destabilization	other-medical
of	other-medical
myelin	other-medical
and	O
neuropathic	other-medical
disorders	other-medical
.	O

Stereotactic	other-medical
radiation	other-medical
therapy	other-medical
is	O
used	O
to	O
treat	O
brain	O
tumors	O
and	O
other	O
brain	O
disorders	O
.	O

Triptans	other-medical
is	O
a	O
word	O
commonly	O
used	O
for	O
a	O
class	O
of	O
anti-migraine	O
drugs	O
that	O
are	O
selective	O
5-hydroxytryptamine/serotonin1B/1D	O
(	O
5-HT1B/1D	O
)	O
agonists	O
.	O

Antifungal	O
drugs	O
including	O
ketoconazole	other-medical
,	O
miconazole	other-medical
,	O
5-flucytosine	other-medical
and	O
pentamidine	other-medical
have	O
been	O
shown	O
to	O
be	O
effective	O
against	O
``	O
Acanthamoeba	O
``	O
``	O
in	O
vitro	O
''	O
.	O

Minocycline	other-medical
has	O
also	O
been	O
reported	O
to	O
very	O
rarely	O
cause	O
idiopathic	other-medical
intracranial	other-medical
hypertension	other-medical
(	O
pseudotumor	other-medical
cerebri	other-medical
)	O
,	O
a	O
side	O
effect	O
also	O
more	O
common	O
in	O
female	O
patients	O
,	O
potentially	O
leading	O
to	O
permanent	other-medical
vision	other-medical
damage	other-medical
if	O
not	O
recognized	O
early	O
and	O
treated	O
.	O